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African animal trypanosomiasis is a major threat to African agriculture causing a loss 
estimated to 4.5 billion US$ per annum. Trypanosoma congolense is the major causative agent 
in African animal trypanosomiasis and is transmitted by tsetse flies of the Glossina spp. 
Congopain, a major cathepsin L-like cysteine peptidase in T. congolense is associated with 
trypanotolerance in N‘Dama cattle and is a target for an anti-disease vaccine. It is suggested 
that trypanotolerant cattle control the disease by antibody mediated neutralisation of 
congopain, and that immunisation of cattle against congopain can mimic trypanotolerance 
resulting in minimised disease pathology. Susceptible cattle immunised with recombinant 
catalytic domain of congopain, C2, produced high levels of anti-congopain IgG specific 
antibodies against congopain, maintained weight and exhibited less severe anaemia. However, 
there was no effect on the establishment of T. congolense infection and acute anaemia 
development in trypanosusceptible cattle. It has been suggested that failure of congopain to 
give full protection of the host may be due to poor presentation to the immune system by 
conventional adjuvants used in previous studies.   
The aim of the present study was to improve the presentation of the catalytic domain of 
congopain (C2) to the immune system, by linking it to the proposed molecular adjuvant, BiP, 
an ER localised HSP70.  A further aim was to localise the domain(s) of BiP where the 
adjuvant properties reside. BiP consists of an ATPase domain (ATPD), a peptide binding 
domain (PBD) and a C-terminal domain (C-term). Consequently, BiP69, BiP69 lacking the C-
terminal domain (BiP60), BiP coding fragments (ATPD, PBD and C-term) and the C2 coding 
sequence were amplified by PCR from either genomic T. congolense DNA or plasmid DNA.  
The PCR products were each sub-cloned into a pTZ57RT vector, and C2 cloned into a pET-
28a expression vector. The BiP coding fragments were inserted into the recombinant pET-28a-
C2 vector, resulting in pET-28a-BiP69-C2, pET-28a-BiP60-C2, pET-28a-ATPD-C2, pET-
28a-PBD-C2 and pET-28a-C-term-C2 coding chimeras. The fusion proteins were expressed in 
an E. coli system as insoluble inclusion bodies at the expected sizes of 96 kDa (BiP69-C2), 88 
kDa (BiP60-C2), 47 kDa (PBD-C2), 34 kDa (C-term-C2) and 27 kDa (C2). However, the 
ATPD-C2 fusion protein was expressed at a larger and smaller size in different attempts. 
Protein expression was confirmed by western blots using anti-BiP antibodies and anti-
congopain N-terminal peptide antibodies. 
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Recombinantly expressed peptide binding domain (PBD)-C2, C-terminus-C2, BiP69-C2, 
BiP60-C2 chimeras and a BiP69 fusion protein were purified and refolded by a Ni-NTA based 
one-step on-column refolding method.  Bacterial proteins co-purifying with BiP69-C2 and 
BiP60-C2 chimeras were removed by incubation with 5 mM ATP in the dissociation buffer, 
but poor yields resulted in using these chimeras as non-pure proteins. Immunisation of Balb/c 
mice with the BiP69-C2 fusion protein chimera induced a higher antibody response to C2 
compared to immunisation with the BiP69/C2 mixture or with C2 in Adjuphos/Quil A.  
BiP69-C2 and PBD-C2 chimeras and BiP69/C2 mixture induced a robust antibody response to 
BiP69, but no correlation could be made with the contribution to control of parasitemia and 
disease induced pathology. Mice immunised with BiP69-C2 and PBD-C2 chimeras showed a 
better booster effect of T. congolense infection with higher anti-C2 antibody stimulation 
compared to control groups. Immunisation did not change the establishment of T. congolense 
infection and anaemia development in most immunised groups. However, mice immunised 
with the BiP69/C2 mixture and with the PBD-C2 chimera produced anti-C2 antibodies 
possible contributing to clearing parasites 10 days and 16 days earlier respectively, than mice 
immunised with BiP69-C2, C-term-C2 and BiP60-C2 chimeras and PBS, C2 and C2 in 
Adjuphos/Quil A control groups and showed no clinical symptoms of the disease. There was 
no significant difference in percentage mice survival between BiP-C2 chimera immunised 
mice and control groups immunised with C2 alone or with a mixture of Adjuphos/Quil A or 
immunised with PBS. 
In the present study, it was shown that BiP69 has adjuvant effects when linked to C2 and that 
its peptide binding domain acts as an adjuvant. It is possible that the removal of the C-terminal 
domain reduced the adjuvant potency of the peptide binding domain suggesting a prominent 
role in the adjuvant effect of the BiP molecule. Finding the exact role of the C-terminal 
domain in the adjuvant effect of BiP would be of utmost interest, and would involve 
comparing anti-C2 antibody response produced by immunisation with C2 linked to the peptide 
binding domain with or without the C-terminal domain. Future work includes repeating this 
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African trypanosomiasis is a devastating disease in sub-Saharan Africa caused by parasites of 
the genus Trypanosoma (Sakurai et al., 2008).  It is transmitted via tsetse flies of the Glossina 
species from one mammalian host to another (Roditi and Lehane, 2008; Schofield and 
Kabayo, 2008). Current control strategies of the disease include chemotherapy and vector 
control, which have proven thus far to be unsatisfactory (Delespaux and de Koning, 2007; 
Schofield and Kabayo, 2008; Molyneux et al., 2010).  There is an urgent need for the 
development of a safe, effective solution. Antigenic variation is a result of the expression of 
different variable surface glycoproteins (VSGs) (Morrison et al., 2009). These VSGs cover the 
surface of the parasite, enabling them to escape the immune system, and therefore it is difficult 
to develop a VSG based vaccine against trypanosomiasis (Kabayo, 2002; Barry and 
McCulloch, 2009). The concept of an ―anti-disease vaccine‖ was developed, which targets the 
disease rather than the parasite (Playfair et al., 1990). Congopain is a major cysteine peptidase 
and a pathogenic factor of T. congolense, and has consequently been identified as an anti-
disease vaccine candidate (Authié, 1994; Authié et al., 2001). The catalytic domain of 
congopain (C2) has poor immunogenicity and hence provides a good model for adjuvant 
assessment (Authié et al., 2001; Boulangé et al., 2001; Boulangé et al., 2011).  Adjuvants play 
a vital role in antigen presentation and in enhancing an immune response. Aside from 
conventional adjuvants, some biological molecules have been described more recently, that 
can target the antigen directly to the effector cells of the immune system (Kornbluth and 
Stone, 2006). Heat shock proteins are chaperones, that bind to nascent and misfolded proteins, 
and have recently been shown to have adjuvant properties when complexed to antigens (Li et 
al., 2007a; Li et al., 2009). Heat shock protein 70 is the best studied of the HSP family and 
activates monocytes, induces cytokine production and up-regulates co-stimulatory molecules 
(Wang et al., 2002; Lehner et al., 2004; Tobian et al., 2005; Ge et al., 2006; Li et al., 2006). 
Immunoglobulin binding protein (BiP) is a member of the HSP70 family, residing in the 
endoplasmic reticulum (ER) (Munro and Pelham, 1986; Boulangé and Authié, 1994), and just 
like other HSP70 family members is expected to have adjuvant properties. It consists of an 




(Robert, 2003; Lehner et al., 2004). It is unclear as to which domain of the BiP molecule has 
adjuvant properties (Wang et al., 2002; Ge et al., 2006; Li et al., 2006). The objective of this 
study is to establish which of the T. congolense BiP domains bear adjuvant effects when 
complexed to C2, a model antigen. Constructs were prepared in which the three BiP domains, 
BiP60 devoid of the C-terminal region and full length BiP69 were individually linked to C2 
and expressed as His-tagged fusion protein chimeras in a bacterial system. The purified fusion 
protein chimeras were used in immunisation experiments and the antibody response to C2 was 
evaluated before and after infection with trypanosomes. 
1.2 TRYPANOSOMIASIS 
African trypanosomes are insect-borne haemoflagellate protozoan parasites, that cause 
‗sleeping sickness‘ in humans, and ‗nagana‘ in domesticated animals in sub-Saharan Africa 
(Molyneux et al., 1996; Kabayo, 2002; Roditi and Lehane, 2008; Sakurai et al., 2008). 
Sleeping sickness is endemic to approximately 36 countries in sub-Saharan Africa and it is 
estimated that about 60 million people are at risk of infection with approximately 300 to 
500 000 people suffering from human African trypanosomiasis (Fèvre et al., 2008; Welburn et 
al., 2009). Nagana affects more than 50 million cattle each year, with more than 10 million 
km
2
 of potential grazing land in 37 countries not utilisable for farming (Shaw, 2004).  
African trypanosomes are transmitted to the mammalian host by blood feeding tsetse flies of 
the Glossina spp (Akoda et al., 2008; Masumu et al., 2010). Trypanosoma brucei gambiense 
and T. b. rhodeisiense are causative agents of human African trypanosomiasis while T. 
congolense, T. vivax, T. b brucei and T. simiae are causative agents of nagana (Taylor, 1998; 
Sakurai et al., 2008). Other vectors identified in transmitting trypanosomes are Tabanus, 
Haematopoda, Chrysops and Stomoxys spp., which transmit T. evansi in Asia, Central and 
South America, the Middle East and Africa via their faeces, and T. cruzi and Leishmania in 
South America (Hargrove, 2004; Luckins and Dwinger, 2004; Miles et al., 2004; Rogers and 
Robinson, 2004; Baral, 2010). Rarely, transmission can also be through breastfeeding and 
contaminated foods (Hargrove, 2004; Miles et al., 2004). In cattle, trypanosomiasis is 
characterised by high fever, chronic anaemia, enlarged liver and spleen, loss of appetite that 
results in weight loss, reduced fertility and increased abortions (Murray et al., 1982; Authié et 




is common, and these animals often die of congestive heart failure (Tabel et al., 2000; 
Naessens, 2006; Baral, 2010). 
African trypanosomiasis is therefore a major threat to both animal based agriculture and 
human health. It is estimated that more than 4.5 billion US$ per annum is lost to African 
agriculture as a result of trypanosomiasis (Kristjanson et al., 1999; Antoine-Moussiaux et al., 
2009). Furthermore, this hinders socio-economic development in the continent as a whole 
(Bhalla, 2002; Shaw, 2004; Salifu et al., 2010). 
1.3 BIOLOGY OF AFRICAN TRYPANOSOMES 
1.3.1 Life cycle   
The life cycle of T. congolense, T. brucei and T. vivax (Fig 1.1) is spent within an insect vector 
(the tsetse fly), and the bloodstream of a host mammal (Vickerman, 1985). Parasites undergo 
many changes during transmission from the mammal host to the tsetse fly and these changes 
are crucial for adaptation to the different environmental conditions they encounter (Sharma et 
al., 2009). Adaptations include morphological, biochemical and motility changes, e.g. 
parasites change from a slender to a stumpy form, and change their energy source from 
proline, the main source of energy in the insect midgut, to glucose in the host bloodstream 
(Hendriks et al., 2000; Hill, 2003; Sharma et al., 2009).  
After ingestion by the tsetse fly, the quiescent blood stream forms differentiate into actively 
dividing procyclic forms inside the tsetse midgut. The procyclic, elongated forms have high 
mobility and migrate to the tsetse proboscis, hypopharynx and finally to the lumen of the 
salivary glands.  In the salivary glands, cell division is completed by differentiation into short 
metacyclic, stumpy forms suitable for mammalian infection. The metacyclic stumpy forms, or 
epimastigotes, attach to the salivary glands by a flagellar membrane and cytoskeletal 
connections (Fig. 1.1) (Vickerman et al., 1988; Hill, 2003; Matthews, 2005; Sakurai et al., 
2008). The adherent metacyclic forms differentiate into non-adherent, metacyclic infective 
forms by a process known as ‗metacyclogenesis‘ (Sakurai et al., 2008; Sharma et al., 2009). 
Variant surface glycoproteins are expressed at this stage to prepare for bloodstream invasion 




Upon biting of the mammalian host by the infected tsetse, the metacyclic infective forms are 
injected intradermally, where it causes skin lesions or ‗chancre‘ (Tabel et al., 2000). They then 
further differentiate and proliferate quickly into slender bloodstream forms. Eventually they 
enter the blood stream via lymphatic vessels and spread throughout the circulatory system 
(Tabel et al., 2000; Matthews, 2005). The blood stream slender forms are slowly replaced by 
the non-proliferative stumpy forms, ensuring longer survival within the host and improving 
chance of transmission (Hendriks et al., 2000; Matthews, 2005).  
1.3.2 Morphology 
The trypanosome cell body (Fig. 1.2) is elongated and consists of a well organised 
arrangement of microtubules (Vickerman, 1985; Woods et al., 1989; Matthews, 2005). The 
microtubule skeleton is inter-connected and fixed to the membrane via cross-bridges 
(Vickerman et al., 1988). The cell shape is held together by the microtubule cytoskeleton 
which remains intact throughout the trypanosomal cell cycle (Matthews, 2005). The single 
copy organelles like the flagellum, flagellar pocket, kinetoplast, mitochondrion and nucleus 
are positioned within the cytoskeleton and are concentrated at the posterior and central regions 
of the trypanosome cell. The flagellum, which runs to the anterior cell edge, is attached to the 
posterior mouth of the flagellar pocket. The flagellum is responsible for cell motility and 
consists of the microtubule ‗axoneme‘, trypanin, and a paraflagellar rod, which all have been 
shown to contribute to motility (Woods et al., 1989; Hutchings et al., 2002; Hill, 2003; 
Vaughan and Gull, 2003). The flagellum is connected to the cell body in a region called the 
‗Flagellum Attachment Zone‘ (FAZ) by trypanin, a microtubule binding domain (Woods et 
al., 1989; Hutchings et al., 2002; Matthews, 2005). Trypanin has been shown to be important 
in giving direction during mobility (Hutchings et al., 2002; Hill, 2003).  
 
The mitochondrion is a single elongated structure running from the posterior to the anterior of 
the cell. The mitochondrion is active in the procyclic forms and generates energy through the 
mitochondrion based respiratory system, whereas it is less active and tubular in the 
bloodstream forms and lacks cristea (Matthews, 2005). The position of the kinetoplast depends 
on the stage in the life cycle of the trypanosome. In the bloodstream forms they are in the 




the posterior membrane, and in epimastogotes they are anterior to the central nucleus. The 
reasons for trypanosome shape change remain unclear, but it has been shown to be necessary 
for cell division in different life cycle stages (Matthews, 2005). 
 









Figure 1.2: General structure of Trypanosoma congolense in bloodstream form 
(http://www.icp.ucl.ac.be/opperd/parasites/images/dia17 10.06.2009). 
1.3.3 Host invasion  
African trypanosomes are covered by variant surface glycoproteins which constitutes a highly 
antigenic surface coat.  Trypanosomes have developed an efficient and complicated defence 
mechanism against the host immune response called ‗antigenic variation‘ (Vickerman, 1969b; 
Donelson, 2003; Barry, 2004). ‗Antigenic variation‘ is the phenomenon whereby a 
trypanosomal population spontaneously switches to expressing a new surface coat and 
continues to proliferate without being recognised by antibodies specific to the previous 
trypanosome population (Barry et al., 1985; Barry, 1997). Each variant is distinct and is 
known as the ‗Variant Antigen Type (VAT)‘. It is the variation of these different VATs which 
provides protection against a specific host immune response (Vickerman, 1969b; Borst et al., 
1998; Barry et al., 2003; Donelson, 2003). 
1.3.4 Classification of trypanosomes  
Trypanosome species have been classified on the basis of morphology, pathogenicity, host 
range, distribution and development cycle in the tsetse vector (Stevens and Brisse, 2004; 
Gibson, 2007). There have been many disputes over taxonomy of known trypanosome species, 
which has resulted in the demotion of some species to sub-species and the discarding of others 




in classification of tsetse transmitted trypanosome parasites (Stevens and Brisse, 2004; Njiru 
et al., 2008b; Hide and Tait, 2009) Development of isoenzyme electrophoresis has enabled 
further and clearer characterisation of the trypanosome genus based on genetic variation of the 
18S ribosomal RNA (Allsopp et al., 1985; Hide et al., 1990; Malele et al., 2003). Levels of 
genetic divergence have been found in subgenera Nannomonas and Duttonella, while no clear 
boundaries are available in Trypanozoon subgenera. The taxonomy of trypanosomes is shown 
in Fig. 1.3. Trypanosomes belong to the phylum protozoa, family Trypanosomatidae, class 
Zoomastigophora, order Kinetoplastida, and genus Trypanosoma (Stevens and Brisse, 2004; 
Baral, 2010).   
Trypanosomes are further sub-divided into two sections, Stercoraria and Salivaria based on the 
mode of transmission of metacyclic forms from vector to mammalian host. In Stercoraria, the 
metacyclic stage develops within the intestinal tract of the insect vector and is transferred 
through faeces. However, in the Salivaria, the metacyclic form is deposited in the proboscis of 
the vector and transmission occurs via saliva when the insect vector bites the mammalian host 
(Stevens and Brisse, 2004). 
1.4 DIAGNOSIS OF AFRICAN TRYPANOSOMIASIS  
Diagnosis of African trypanosomiasis has improved significantly in the past four decades. 
Currently, there are multiple diagnostic techniques for detecting African trypanosome 
infection (Eisler et al., 2004; Chappuis et al., 2005; Hide and Tait, 2009; Deborggraeve and 
Büscher, 2010). These techniques include clinical, parasitological, serological, and molecular 
methods (Eisler et al., 2004). Early detection of trypanosomiasis allows for more effective 
control measures and is useful in studies of disease distribution, drug resistance, vector 
migration and eradication (Eisler et al., 2004; Simarro et al., 2008; Hide and Tait, 2009). 
Clinical diagnosis is still regarded as the best available diagnostic method because of its 
simplicity and no requirement of specialist equipment, but is limited and requires verification 
by other diagnostic techniques.  In parasitological detection methods, parasites can be directly 
detected in the host blood by microscopy, however this test is limited by low sensitivity at low 
parasitaemia levels (Uilenberg, 1998; Eisler et al., 2004). In serological detection methods, 




antigens (Rebeski et al., 1999) are detected using tests such as indirect fluorescent antibody 
(IFA), enzyme linked immunosorbent assay (ELISA), and card agglutination test (CATT) 
(Eisler et al., 1998; Hide and Tait, 2009; Radwanska, 2010). False positives and negatives, 
poor specificity, cross reactivity, lack of recombinant antigens and low sensitivity have been 
reported in tests for T. congolense, T. vivax and T. brucei (Masake and Vinand, 1991; Eisler et 
al., 1998; Bossard et al., 2010). 
Molecular diagnosis methods by PCR have been useful where serological and parasitological 
diagnosis methods have failed, and have been shown to increase detection sensitivity by using 
DNA probes (Desquesnes and Dávila, 2002; Magona et al., 2003; Njiru et al., 2008a; Njiru et 
al., 2008b; Deborggraeve and Büscher, 2010). This method identifies stable parasite genetic 
markers, which are present in all life cycle stages of trypanosomes, for example the internal 
transcribed spacer-1 (ITS-1) of highly conserved trypanosome ribosomal RNA (Masake et al., 
2002; Thumbi et al., 2008). A more accurate trypanosomiasis diagnosis method is required if 
complete eradication or control of the disease is to be achieved. Although clinical and 
parasitological diagnosis methods are considered acceptable in field diagnosis, their low 
respective specificity and sensitivity, disqualify them as gold standard diagnostic methods. 
Single step ITS PCR is a promising alternative diagnostic method for animal trypanosomiasis, 
and in the near future may become the gold standard in epidemiology studies (Desquesnes and 






Figure 1.3: Classification of protozoan parasites belonging to the Trypanosoma genus. Adapted from Stevens 
and Brisse (2004). 
 
 




















Duttonella Nannomonas Trypanozoon Pycnomonas 
T. (D.) vivax T. (N.) congolense 
Herpetosoma Schizotrypanum 
T. (H.) lewisi T. (S.) cruzi 
T. (T.) evansi T. (T.) brucei 
T. b. gambiense 
Section 
STERCORARIA 
T. (M.) theileri 
Megatrypanum 
T. b. rhodesiense 
T. (T.) equiperdum 




1.5 CONTROL OF TRYPANOSOMIASIS 
There have been various attempts to control trypanosome infection in Africa. Currently there 
are three control strategies: trypanocidal drugs (chemotherapy and chemoprophylaxis), 
breeding trypanotolerant cattle, and tsetse population control (McDermott and Coleman, 2001; 
Seed, 2001; Kgori et al., 2006; Delespaux and de Koning, 2007; Molyneux et al., 2010).   
1.5.1 Vector control 
Tsetse eradication attempts have included: clearing vegetation where tsetse flies rest, reducing 
host quantity (mostly wild mammals), development of odour baited tsetse fly traps, 
insecticides and sterilising male tsetse flies (Vreysen et al., 2000; Aksoy, 2003; Welburn et 
al., 2009). Initially insecticides proved to be successful due to the low population variability 
amongst tsetse and non-resistance. Unfortunately, non-selectivity of insecticide spraying, their 
toxicity and environmental contamination raised considerable safety concerns (Kgori et al., 
2006; Torr et al., 2007). Fly traps and bait technology are manageable by small rural 
communities, but require commitment and integrated systems throughout the whole affected 
region (Eisler et al., 2004; Vale and Torr, 2004; Van den Bossche and De Deken, 2004; 
Welburn et al., 2009). The technique of sterilising male tsetse reduced the frequency of 
successful fertilisation of female flies and resulted in complete removal of tsetse flies from 
Zanzibar island (Vreysen et al., 2000; Schofield and Maudlin, 2001; Aksoy, 2003). Limits to 
sustainability and monitoring allow re-infestation due to the rapid movement of tsetse 
communities from one place to the other. Tsetse eradication would require an integrated 
system throughout the sub-Saharan continent (Eisler et al., 2004; Welburn et al., 2009). 
1.5.2 Trypanocidal drugs 
Prophylactic and therapeutic trypanocidal drugs are the only effective methods used in the 
treatment and control of trypanosomiasis. In sub-Saharan Africa alone expenditure on 
trypanocidal drugs has been estimated at 13-35 million US$ per annum, and approximately 
25-30 million drug doses are administered annually (Kristjanson et al., 1999; Torr et al., 
2007). Currently there are three common trypanocidal drugs on the market: ‗Isometamidium‘, 
‗Homidium‘ and ‗Diminazene‘. The former two have prophylactic and therapeutic effects, 




drugs have been on the market for more than 50 years (Priotto et al., 2006; Welburn et al., 
2009; Delespaux et al., 2010; Molyneux et al., 2010), and because of the slow progress in 
developing new drugs or alternative control strategies, this has led to monotherapy drug 
resistance and in some cases multi-drug resistance (Delespaux and de Koning, 2007; 
Delespaux et al., 2008).  Drug resistance has been reported in more than 17 African countries, 
and surveys conducted by the International Livestock Research Institute (ILRI) showed high 
incidence in East and West African countries (Delespaux et al., 2008). Multi-drug resistance 
has been reported in Kenya and eastern Zambia (Mulugeta et al., 1997; Delespaux and de 
Koning, 2007). The decentralisation of drugs to farmers and high cost of trypanocidal drugs 
has allowed suboptimal use by resource poor farmers, resulting in drug resistance (Anene, 
2001; Geerts et al., 2001; Welburn et al., 2009). Mechanisms of trypanocidal drug resistance 
are not fully understood, but it is suspected that some animals are resistant to drugs simply  
because of a natural immunity (innate) or they are resistant due to prolonged exposure 
(acquired) (Holmes et al., 2004). Cross-resistance and mutagenesis have not been excluded as 
mechanisms of resistance (Bray et al., 2003; Delespaux et al., 2010; Stewart et al., 2010). 
Cross resistance may be due to the similarity between compound structures of drugs, so 
acquiring resistance to one may make the host resistant to multiple therapies (Delespaux et al., 
2010). Increasing drug dose and repeating treatments at short intervals are theoretical ways of 
dealing with drug and multi-drug resistance, however, this is limited by drug toxicity related 
side effects (Barrett et al., 2004; Holmes et al., 2004; Delespaux and de Koning, 2007). 
Combination therapy has huge potential in bringing synergistic therapeutic effects, which may 
result in reduced drug dosage, increased efficacy, reduced resistance and minimised adverse 
effects (Anene, 2001; Delespaux and de Koning, 2007; Delespaux et al., 2010). 
With no sign of a successful anti-trypanosomiasis vaccine, and alarming levels of resistance to 
available drugs, there is an urgent need for the development of less host-toxic 
chemotherapeutic agents to fight the disease. 
 
In this regard, proteins with prominent roles in the parasite life cycle e.g. major cysteine 
peptidases have been targeted for chemotherapeutic intervention (McGrath et al., 1995; 




inhibitors have been investigated in multiple protozoan parasites. Studies have shown that 
these inhibitors are capable of killing parasites or inhibiting specific active cysteine peptidases 
in vivo and/or in vitro e.g T. cruzi (Engel et al., 1998), T. congolense (Mbawa et al., 1992), T. 
b brucei (Troeberg et al., 1999; Troeberg et al., 2000), P. falciparum (Rosenthal et al., 1996). 
Irreversible vinyl sulfones, peptidyl methylketones (CMK), fluoromethylketones (FMK) and 
chalcones have been shown to be lethal to bloodstream forms of T. b brucei parasites in 
culture at low concentrations (Troeberg et al., 1999; Troeberg et al., 2000). 
Mice infected with T. b brucei and treated with micromolar amounts of vinyl sulfones, its 
derivatives or with small inhibitory molecules (Z-Phe-Ala-CNH2), survived longer and cleared 
parasitaemia better than the untreated mice control group. Furthermore, chemotherapy altered 
trypanosomal cell division and morphology resulting in poor degradation of host proteins 
(Scory et al., 2007; O'Brien et al., 2008). Interestingly, some cysteine peptidase inhibitors 
have shown desirable pharmacokinetic and safety profiles in rodents, dogs and primates 
(Engel et al., 1998; McKerrow, 1999; Keiser et al., 2001; McKerrow et al., 2008). These 
studies show cysteine peptidase inhibitors to have significant potential as chemotherapeutic 
agents in the treatment of diseases such as malaria, human and animal trypanosomiasis, 
leishmaniasis, schistosomiasis and Chagasis (Rosenthal et al., 1996; McKerrow, 1999; 
Abdulla et al., 2007; McKerrow et al., 2008). 
However, inhibition of host cysteine peptidases and the proteasome, and toxicity of 
fluoromethyl ketone derivatised peptidomimotopes have been a cause of concern in drug 
development. This has resulted in some irreversible inhibitors being withdrawn from drug 
development research/trials. It is still not understood, why some inhibitors are potentially 
lethal to livestock and humans, but have shown no toxic effects in rodents (McKerrow et al., 
2008).    
 
Biochemical kinetics using specific inhibitors has paved a way of designing new synthetic 
drugs, which target and inhibit major cysteine peptidases of protozoan parasites.  The crystal 
structures of cruzipain (McGrath et al., 1995; Ljunggren et al., 2007), rhodesain (Kerr et al., 
2009a; Kerr et al., 2010), falcipain-2 (Kerr et al., 2009b), and cathepsin B (Kerr et al., 2010), 




substrate binding sites of targeted peptidases. This has become the structural basis of 
designing new peptidomimotopes for use as chemotherapeutic agents.  
1.5.3 Trypanotolerance 
West African N‘Dama cattle (Bos taurus) were introduced in Africa in 6000BC and through 
natural selection in the tsetse belt they have managed to attain a certain degree of tolerance 
against trypanosomal infection (Akol et al., 1986; Naessens, 2006). This breed of cattle is able 
to survive without the aid of drug treatment in the humid and semi-humid areas of West and 
East Africa which have the highest incidence of trypanosomal infection (d'Ieteren et al., 1998; 
Murray, 2004). Hence, trypanotolerance is described as the capacity to survive, and to remain 
productive after trypanosome infection (Murray et al., 1982). Trypanotolerant N‘Dama 
continues to gain weight, remain productive and develops a lesser severity of anaemia 
compared to the trypanosusceptible Zebu (Bos indicus), which often become weak, with high 
incidence of abortion and death (Authié et al., 2001; Black et al., 2001; Murray, 2004; Taylor 
and Authié, 2004; Naessens, 2006). Studies aimed at identifying the genetic markers 
responsible for trypanotolerance may bring new insights as to how resistance is induced 
(Naessens et al., 2002; Naessens, 2006). 
1.5.4 Vaccine against trypanosomiasis 
Vaccination against trypanosomiasis is arguably the most desirable control method, with great 
potential impact. However, the antigenic variation of VSG coating the parasite has hampered 
attempts at producing an effective VSG based vaccine (Barry et al., 1998; Donelson et al., 
1998; Donelson, 2003; Barry et al., 2005). Vaccine development against disease remains an 
attractive approach to control with the increase in demand for safer and environmentally 
friendly control strategies (Authié, 1994; Taylor, 1998). An anti-disease vaccine strategy was 
developed as an alternative approach compared to methods mentioned in Section 1.5 for 
control of the disease (Playfair et al., 1990; Authié, 1994). This strategy aims at inhibiting 
proteins implicated in pathogenesis, thereby halting disease progression. Invariant antigens are 
under research for their possible use in vaccine design. Invariable antigens expressed on the 
parasite surface and during the infection phase are often recognised by trypanotolerant cattle, 
and vaccination with these dominant proteins has been thought to be the optimal method for 




2001). Partial protection has been obtained when cattle were vaccinated with flagellar pocket 
antigen fractions (Mkunza et al., 1995) and purified tubulin (Lubega et al., 2002; Li et al., 
2007b). Trypanosomal peptidases are also under investigation as anti-disease vaccine 
candidates, and there is promising evidence showing that immunisation with cysteine 
peptidases can confer significant protection against trypanosomiasis (Authié et al., 2001), 
Chagasis (Schnapp et al., 2002; Cazorla et al., 2008a; Cazorla et al., 2008b) and 
Leishmaniasis (Rafati et al., 2006; Khoshgoo et al., 2008). 
1.6 KINETOPLASTID PAPAIN LIKE CYSTEINE PEPTIDASES  
Peptidases are very important in protein catabolism, and are involved in many processes of 
living organisms. There are seven mechanistic classes of peptidases including aspartic, 
cysteine, glutamic, metallo, serine, threonine and mixed (Sajid and McKerrow, 2002; Caffrey 
and Steverding, 2009). Kinetoplastid cysteine peptidases are most important for survival, 
immunoevasion, enzyme activation, virulence, tissue and cellular invasion, hatching, 
development and moulting (Sajid and McKerrow, 2002; Mottram et al., 2004; Caffrey and 
Steverding, 2009).  Clan CA, family C1 cysteine peptidases are the most widely distributed 
among living organisms and are present in helminths (Robinson et al., 2008; Smooker et al., 
2010), nematodes (Malagon et al., 2010),  bacteria (Shao et al., 2002), protozoa (Sajid and 
McKerrow, 2002; Mottram et al., 2004; Rosenthal, 2004; Ruszczyk et al., 2008; Rodrigues et 
al., 2010), plants (Solomon et al., 1999) and mammals (Fernandes-Alnemri et al., 1995). 
Kinetoplastid cysteine peptidases include cathepsin L-like and cathepsin B-like subfamilies, 
due to sequence identities with their mammalian homologues (Sajid and McKerrow, 2002). 
The main members of clan CA are lysosomal peptidases, optimally active in a weakly acidic 
and a reducing environment, and are sensitive to E-64 (Barrett et al., 1982; Turk et al., 2000; 
Lalmanach et al., 2002; Serveau et al., 2003). Lysosomal cysteine peptidases share similar 
amino acid sequences, structural folds and catalytic mechanisms. Their molecular weights 





1.6.1 Congopain, a major cysteine peptidase of Trypanosoma congolense 
Congopain is the major cysteine peptidase in T. congolense and belongs to the papain family 
(Authié et al., 1992; Mbawa et al., 1992; Lalmanach et al., 2002).  The 33 kDa peptidase is 
released in the bloodstream of the mammalian host.  It has been implicated in host invasion, 
parasite development and differentiation, and plays a prominent role in mitigating the disease, 
producing a prominent antibody response in trypanotolerant cattle and also in susceptible 
cattle upon infection with T. congolense parasites (Authié et al., 1993a; Authié, 1994; Authié 
et al., 2001). 
Two genes coding for T. congolense cathepsin L-like cysteine peptidase have been identified 
thus far. These genes are closely related and were named ‗CP1‘ (Fish et al. 1995, EMBL 
accession number Z25813), and ‗CP2‘ (Jaye et al. 1994, EMBL accession number L25130). 
Several polymorphic copies of the T. congolense cysteine peptidase gene are arranged in a 
tandem repeated array like those of L. mexicana (Souza et al., 1992; Mottram et al., 1997), L. 
donovani (Mundodi et al., 2002; Hide and Bañuls, 2008) and T. cruzi (Lima et al., 1994). 
There is emerging evidence for the existence of multiple variant genes, coding for cysteine 
peptidases in T. congolense (Kakundi, 2008; Mendoza-Palomares et al., 2008; Pillay et al., 
2010).   
More than 13 different genes have been identified coding for T. congolense cathepsin B-like 
peptidases and they have been grouped into clusters based on their catalytic triads (Mendoza-
Palomares et al., 2008). Some clusters have shown an unusual catalytic triad of Cys, Xaa and 
Asn. Two variants of congopain have been identified with substitutions in their catalytic triad 
where Cys is replaced by Ser and Asn is replaced by Tyr (Pillay et al., 2010). These variants 
differ slightly in their substrate preferences, pH profiles and inhibitor kinetics compared to C2. 
It is likely that there are more cathepsin L-like peptidase gene copies embedded in this 
multiple tandem repeat array. There is 90% identity between the CP1 and CP2 gene, based on 
their amino acid sequences, although the N-terminal amino acid sequence and the catalytic 
domain residues differ (Boulangé et al., 2001; Lalmanach et al., 2002). The negative charge of 
CP2 relative to CP1 also accounts for their differences in kinetic parameters and pH activity 




Congopain has a similar sequence identity to cruzipain, a major cysteine peptidase in T. cruzi, 
sharing 54% ORF sequence identity (McKerrow et al., 1995). The catalytic domain of 
congopain shares 68% sequence identity with that of cruzipain (Chagas et al., 1997). A 
congopain 3-dimensional model has been constructed based on a cruzipain model and 
superimposition shows restricted specificity of congopain, with its catalytic domain buried 
inside a cleft between the R and L domains (McGrath et al., 1995; Lecaille et al., 2001). The 
structure of congopain is similar to that of cathepsin L-like enzymes and consists of two 
domains: the α-helical L-domain and the β-antiparallel sheet-containing R domain (Fig 1.4). 
The active site region is located in the V-shaped cleft between the R and L-domains and 






 (papain numbering). These 
residues are highly conserved among cathepsin L-like enzymes. The catalytic triad, together 
with other substrate binding sites, determine substrate specificity (Turk et al., 1998; Lecaille et 
al., 2001; Lalmanach et al., 2002; Akoda et al., 2008).  
 
Figure 1.4: Predicted structure of the catalytic domain of congopain based on the sequence identity with 
cruzipain (Ndlovu, 2009). The 3-D model was coloured according to the secondary structure The green ribbon 
being congopain and yellow ribbon being cruzipain. The structure also shows α-helix L- domain and β-sheets R-
domain. The v-shaped active site with the catalytic residues located between the R and L domains.  
Congopain specificity is determined by the P2/S2 interaction (nomenclature according to 
Schechter and Berger (1967) and is shown to have preference towards bulky hydrophobic or 
aromatic residues in the P2 site (Mbawa et al., 1992; Turk et al., 1998). The structure of 







congopain is composed of a pre-domain, a pro-domain, central catalytic domain and a C-
terminal extension (Authié, 1994). The catalytic domain (215 residues) is similar to 
mammalian cathepsin L, and differs from cruzipain in its enzymatic specificity, due to the 
presence of a Leu instead of Glu at position 205 in the S2 subsite (McGrath et al., 1995; Turk 
et al., 1998; Caffrey and Steverding, 2009). The highly immunogenic C-terminal domain (105 
residues) is linked to the catalytic domain by a poly-proline sequence, susceptible to 
proteolytic cleavage (Fig. 1.5). It has no effect on enzyme activity and its function is unknown 
(Chagas et al., 1997; Boulangé et al., 2001), although the L. pifanoi cathepsin L-like C-
terminal extension has been linked to macrophage infection inside the host (Marin-Villa et al., 
2008). The pro-domain is involved in trafficking, secretion, and chaperoning the mature 
enzyme (Lalmanach et al., 2002). The pro-domain contains the ERFNIN peptide embedded in 
the ER(F/W)N(I/V)N motif, specific to cathepsin L-like enzymes, and acts as a reversible 
competitive inhibitor of its mature enzyme (Lalmanach et al., 1998). Synthetic peptides based 
on the pro-domain of cathepsin L-like enzymes, containing a common YHNGA sequence, 
inhibited purified congopain and cruzipan but did not inhibit lysosomal cathepsins L and B 
(Lalmanach et al., 1998).  
Congopain has been enzymatically characterised using conventional synthetic fluorogenic 
substrates (Authié et al., 1992; Mbawa et al., 1992; Chagas et al., 1997). It shows proteolytic 
properties towards endopeptidyl substrates, preference to substrates with Arg or Lys in P1 (Z-
Arg-Arg-AMC), and hydrophobic amino acids in the P2 site (Z-Phe-Arg-AMC) (Mbawa et al., 
1992; Chagas et al., 1997; Gillmor et al., 1997). Congopain is activated by reducing agents 
like DTT, L-cysteine and β-mercaptoethanol, irreversibly inhibited by E-64 and leupeptin, and 
reversibly inhibited by its natural inhibitors, cystatins and kininogens (Lalmanach et al., 
2002). Inhibition by natural inhibitors is similar to that observed in cruzipain, but congopain 
retains some of its activity in the host (Serveau et al., 2003). Like mammalian cysteine 
peptidases, congopain is synthesised as an inactive zymogen that is activated into a mature 
form by autocatalytical cleavage and release of the pro-domain at acidic pH (pH<5.0) 
(Lalmanach et al., 1998; Boulangé et al., 2001; Lalmanach et al., 2002; Serveau et al., 2003). 
Congopain has been shown to be active at basic and neutral pH (8 and 6.5) (Boulangé et al., 





Figure 1.5: Schematic representation of Trypanosoma congolense cysteine peptidase (congopain). The 
structure is composed of the pre-domain, pro-domain, central catalytic domain, the poly-proline region and the C-
terminal region according to the deduced amino acid sequence from Fish et al. (1995). 
1.6.1.1 Congopain as a vaccine target 
Trypanosomal peptidases are being investigated as possible anti-disease vaccine candidates 
(Authié, 1994). There is increasing evidence implicating congopain, a major cysteine 
peptidase of T. congolense, in the pathogenesis in trypanosomiasis (Authié, 1994; Authié et 
al., 2001; Lalmanach et al., 2002). Congopain has been shown to retain most of its activity at 
basic and neutral pH, suggesting its possible role in extracellular activities (Serveau et al., 
2003; Boulangé et al., 2011). Trypanotolerant cattle produce a predominantly IgG response 
and proliferative response of lymph node cells to congopain, resulting in inhibition of enzyme 
activity, and thus neutralising its pathogenic effects (Authié, 1994; Lutje et al., 1995a; Taylor, 
1998). These findings imply that congopain is associated with trypanotolerance in cattle, and 
therefore, is an attractive target for an anti-disease vaccine strategy against bovine 
trypanosomiasis. It was proposed that an immune response targeting the catalytic domain of 
congopain (C2), produced through immunisation, could lead to the catalytic activity of 
congopain (C2) being completely inhibited by anti-congopain antibodies. A study using C2 as 
an antigen, expressed in the Baculovirus system (Boulangé et al., 2001), showed that cattle 
were partially protected and mounted a highly specific IgG response to congopain. This 
suggests that antibody mediated inhibition of congopain activity could result in increased 
resistance to trypanosomiasis in susceptible cattle (Authié et al., 2001). Studies have also 
shown that congopain has poor immunogenicity which results in only partial protection of 
cattle (Authié et al., 2001; Boulangé et al., 2001). Poor immunogenicity may be attributed to 
poor presentation of protective dimeric epitopes of congopain,  poor delivery by the adjuvant 
and/or failure of the adjuvant to protect these protective dimeric epitopes within the host 





Vaccines would not be successful without the co-injection of adjuvants with the antigen to 
enhance humoral and/or cell mediated immune responses (Stills, 2005). All poorly 
immunogenic subunit and inactivated vaccines require immunostimulators or adjuvants to 
induce the desired type (cellular or humoral) and increased immune response (O'Hagan, 2001; 
O'Hagan et al., 2001; Jansen et al., 2006; Linghua et al., 2006). The concept and use of 
adjuvants was discovered more than 90 years ago, and found to enhance the immune response 
of the host to the antigen (Schijns, 2001; Stills, 2005). Adjuvants are described as agents that 
stimulate the immune system response without acting as antigens (Singh and O'Hagan, 2003; 
Wilson-Welder et al., 2008). Adjuvants increase the vaccine potency and reduce the amount of 
vaccine material required for disease protection; thereby decreasing toxicity, improving 
solubility and protecting conformation of the antigenic epitope (O'Hagan, 2001; Chamberlain 
and Gronvall, 2007). Adjuvants have five major mechanisms of action, which include, a depot 
effect, targeting of the antigen to immune stimulating cells, protection of the conformation of 
the antigen, presentation of the antigen to antigen presenting cells (APCs) and modulation of 
the type of immune response (Stills, 2005). 
The depot effect protects the antigen from degradation, dilution and elimination by the host. It 
describes a process whereby the adjuvant localises and slowly releases an intact antigen, 
resulting in longer exposure of small amounts of antigen to the immune system. This results in 
host production of high levels of antibodies against the particular antigen (Stills, 2005). 
Adjuvants have specific features easily recognisable by the immune system, enhancing 
recognition and distribution of the antigen within the lymphatic system and spleen, resulting in 
stimulation of specific B- and T-cells (Janeway, 2001). Protection of the conformation of the 
antigenic epitope by the adjuvant is essential for proper immune induction (Chamberlain and 
Gronvall, 2007). Adjuvants have specific receptors on the APC surface and enhance 
presentation of the antigen to major histocompatibilty complex (MHC) molecules. Good 
adjuvants, used in therapeutic vaccines, induce protective immunity with minimal side effects, 
and protection is via humoral and/ or cell-mediated specific immune response (Stills, 2005). 




1.7.1 Conventional adjuvants 
Conventional adjuvants have been used effectively in traditional vaccines for years to enhance 
humoral and cell-mediated immunity adequate to confer protection.  One of the first 
conventional adjuvants used successfully was an oil emulsigen with Salmonella typhimurium 
back in 1916. Later Freund‘s adjuvants were developed that included heat killed 
Mycobacterium (Jansen et al., 2006).  Conventional adjuvants are mostly chemically 
synthesised and include water-in-oil emulsions and oil-in-water emulsions. These two types 
differ slightly in oil content, antigen interaction and presentation, and viscosity (Jansen et al., 
2006). Some of the widely used water-in-oil emulsions include Freund‘s complete adjuvant 
and incomplete, Specol
® 
(Prionics AG, Switzerland), RIBI
®
 (Ribi ImmunoChem Research, 
Inc., Hamilton, MT, USA), Titermax
®
 (CytRx Corp., Norcross, USA) which all stimulate the 
immune system in different ways. Currently, there are many water-in-oil adjuvants being 
tested in clinical trials as potential candidates in veterinary vaccines. The commonly known 
and probably most widely used conventional adjuvants are oil-in-water emulsigens. They 
include aluminium salts (Alum
®
) (Accurate Chemical & Scientific Co., USA), Syntex
®
 
(Chiron Corporation, USA) and Gerbu
®
 (Biotechnik GmbH, Germany). Alum is the only 
conventional adjuvant that is permitted for use in both human and veterinary vaccines 
(O'Hagan et al., 2001; Stills, 2005; Jansen et al., 2006; Kornbluth and Stone, 2006). Though it 
is considered the safest and most desirable adjuvant so far, some studies have shown that it has 
poor adjuvanticity when co-administered with certain antigens and fails to induce cell-
mediated, Th1 type and IgE mediated immune responses (Gupta, 1998). 
Conventional adjuvants have been used effectively in traditional vaccines to enhance humoral 
and cell-mediated immunity adequate to confer protection, but the undesirable adverse side 
effects preclude their use in commercial vaccines (Gupta, 1998; Stills, 2005; Kornbluth and 
Stone, 2006; Linghua et al., 2006). Most adjuvants lack good antigen presentation and 
distribution abilities and so there is poor recognition by the immune system. Furthermore, they 
induce side effects at the injection site including inflammation, lesions, granulomas, pain and 
late hypersensitivity, and thus are unsuitable for use in human and veterinary vaccines 
(Kornbluth and Stone, 2006). Therefore, there is an urgent need for much safer adjuvants 




1.7.2 Molecular adjuvants 
There has been a great interest in the use of molecular adjuvants in vaccination. Molecular 
adjuvants include proteins, lipids, nucleic acids, carbohydrates and chemical compounds. They 
have specific receptors on the surface of APCs including dendritic cells (DCs) and 
macrophages (Stills, 2005). Molecular adjuvants maintain the antigen conformation, ensuring 
presentation of immunogenic epitopes to the immune system, resulting in improved magnitude 
and quality of the immune response (Kornbluth and Stone, 2006). They induce fewer side 
effects whilst prolonging antigen presentation to immune cells (Wilson-Welder et al., 2008). 
This has brought about significant interest in identifying possible molecular adjuvants. One 
superfamily currently being investigated to this end is the heat shock proteins (Lindquist and 
Craig, 1988; Segal et al., 2006). 
1.8 HEAT SHOCK PROTEINS 
Heat shock proteins (HSPs) are present in eukaryotes and prokaryotes and show a high degree 
of sequence phylogenetic conservation homology (Lindquist, 1986; Boulangé and Authié, 
1994). Heat shock proteins are chaperones, binding to misfolded, non-native and nascent 
proteins, mediating their proper folding, trafficking, antigen processing and presentation 
(Lindquist and Craig, 1988; Hartl, 1996; Rico et al., 1999; Nishikawa et al., 2008). They are 
mainly released during periods of elevated stress (e.g. temperature change, UV light and 
chemical exposure) in order to protect cells from lethal damage (Hartl and Hayer-Hartl, 2002; 
Calderwood et al., 2007). Furthermore, heat shock proteins have been shown to play a major 
role in stimulating the immune response directed towards tumour cell antigens, acting as 
adjuvants (Srivastava, 1994; Srivastava et al., 1994; Udono et al., 1994; Enomoto et al., 
2006). The heat shock protein family together with the grp family fall under the stress protein 
superfamily and are classified according to molecular weight, location and function (Lindquist 
and Craig, 1988). The heat shock protein family includes HSP27 (16-24 kDa), HSP60, HSP70 
(68-73 kDa), HSP90 (85-90 kDa) and HSP110 (Pockley et al., 2008), whereas the grp family 
includes gp96, GRP78, gp 170 and calreticulin (Table 1). These two families differ slightly in 




1.8.1 Heat shock protein 70  
Heat shock protein 70 is the major and most studied of the HSP molecular chaperone family. 
The heat shock protein 70 sub-family includes ‗Heat Shock Cognate‘ (HSC70), released under 
normal conditions, HSP70 induced under stressful conditions, and the endoplasmic reticulum 
(ER)-localised ‗BiP‘ mainly responsible for housekeeping chaperoning functions (Munro and 
Pelham, 1986; Bangs et al., 1993; Pidoux and Armstrong, 1993; Boulangé and Authié, 1994). 
Heat Shock Protein 70 has helped reveal characteristics of receptor mediated uptake by cells 
(e.g dendritic cells, macrophages) (Pockley et al., 2008). HSP70 has both peptide dependent 
and independent immuno-stimulatory activities as it can be linked with antigens or injected 
along with antigens individually.  It affects the adaptive immune system by direct presentation 
of antigenic peptides to APCs, or by stimulating antigen uptake via cross-presentation 
(Srivastava et al., 1994; Nishikawa et al., 2008). HSP70 activates monocytes, induces 
cytokines and up-regulates co-stimulatory molecules (Asea et al., 2000; Moroi et al., 2000; 
Wang et al., 2001; Asea et al., 2002; Mambula et al., 2007). 
Table 1: The location and function of molecular stress proteins (adapted from Calderwood et 
al., 2007 and Pockley et al., 2008). 
Family               Location                         Major Function (intracellular and extracellular) 
HSP27* Cytoplasm/ nucleus Chaperone, anti-death and anti-inflammatory  
HSP60* Mitochondria  Chaperone, anti- and pro-inflammatory             
HSP70*
#
 Cytoplasm/nucleus Chaperone, pro-inflammatory, immunoregulatory 
HSP90  Cytosol            Stabilise non-native, pro-immune 
HSP110 Cytosol            Co-chaperone, pro-immune 
Gp96/grp94 ER lumen       Substrate folding and stabilisation, pro-immune            
GRP78/BiP ER lumen       Chaperone, anti-inflammatory  
Calreticulin ER lumen  Chaperone, pro-inflammatory 
* can be released under normal conditions 






1.8.1.1 HSP70 structure and function 
The structure of HSP70 consists of three functional domains (Fig. 1.6A): an N-terminal 
ATPase (44 kDa) domain, followed by a peptide binding domain (18 kDa) and a C-terminal 
(10 kDa) domain (Bukau and Horwich, 1998; Li et al., 2006; Daugaard et al., 2007). The 
structure of eukaryotic HSP70 is based on DnaK (Fig. 1.6B), an E. coli homolog of HSP70, 
the different domains of which have been crystallised independently (Bukau and Horwich, 
1998; Hartl and Hayer-Hartl, 2002). The ATPase domain has two lobes and a deep cleft 
binding ATP (Robert, 2003; Lehner et al., 2004). Most substrate binding takes place in the 
ATP bound state, allowing opening of the peptide binding pocket. The substrate is stably 
bound to hydrolysed ATP (i.e. ADP plus free phosphate), which allows closing of the 
substrate binding pocket (Bukau et al., 2000; Hartl and Hayer-Hartl, 2002; Bukau et al., 
2006).  
The peptide/substrate binding domain is made up of a lower and upper, four stranded, anti-
parallel β-sheet and a single α-helical sub-domain.  The loops on the substrate binding site are 
positioned on the upper β-sheet, interacting with the substrate. The α-helical sub-domain has 
αA and βB helices which form hydrophobic side chains and interact with the β-sandwich 
(Robert, 2003; Lehner et al., 2004).  
The C-terminal domain of HSP70 is Gly/Pro rich, highly immunogenic and contains a 
localisation signal EEVD motif for cystosolic and nucleic HSPs. The motif enables binding to 
co-chaperones and other HSPs. The ER localised HSP70 members, like BiP/grp78, have an 
ER retention/retrieval signal or ‗KDEL motif‘, which is highly conserved among ER resident 
proteins (Daugaard et al., 2007). The variation/low degree of identity of the C-terminal region 
of the HSP70 sequence in different species has proved to be advantageous in vaccine 
development and has reduced the potential risk of autoimmune responses (Li et al., 2006). The 
mechanism of how these three domains stimulate monocytes and dendritic cells is not clear. 
The C-terminal substrate binding domain has been shown to stimulate production of high 
concentrations of IgG2a and IgG3 subclasses of antibodies, and to attract immunological 
repertoires which enhance chemotactic cytokines (CC), chemokines, IL-2, TNF-α, nitric oxide 
and dendritic cell maturation (Wang et al., 2002; Lehner et al., 2004; Ge et al., 2006; Li et al., 




The ATPase domain has a stimulatory factor in antigen specific cytotoxic T cell induction, via 
the CD4
+
 T cell independent pathway (Rico et al., 1999; Nishikawa et al., 2008; Pockley et 
al., 2008; Zitzler et al., 2008).   
 
Figure 1.6: The structure of heat shock protein 70. A. The protein is composed of an N-terminal ATP binding 
domain, a peptide binding domain, a C-terminal variable region and the MDDL amino acid sequence adapted 
from Daugaard et al. (2007). B.  Structures of the E. coli DnaK (HSP70) showing ATPase domain (green), and 
the peptide binding domain (yellow with green) and the α-helical latch of the peptide binding domain showing 
bound peptide (pink ball and stick model). ATP indicates the position of the ATP binding site (Hartl and Hayer-
Hartl, 2002).  
1.8.1.2 HSP70 binding receptors on Antigen Presenting Cells (APCs) 
Heat shock protein 70 binds to antigenic peptides and the resulting HSP70 antigen-peptide 
complex is efficiently taken up by APCs possessing HSP70 receptors on their surfaces. These 
receptors include CD91 and ‗lectin like-low density lipoprotein receptors 1 (LOX-1)‘ (Fig. 
1.7) (Binder et al., 2004; Massa et al., 2005; Takemoto et al., 2005; Calderwood et al., 2007; 
Nishikawa et al., 2008; Pockley et al., 2008).  CD91 is a member of the lipoprotein receptor 
family. It is expressed on fibroblasts, smooth muscle, macrophages and hepatocytes and is 
involved in HSP–antigenic peptide binding (Basu et al., 2001). It has been suggested that 
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calreticulin (Basu et al., 2001). LOX-1 belongs to a scavenger receptor family, and recognises 
polyanions and HSP70 (Nishikawa et al., 2008; Pockley et al., 2008). It is expressed on 
endothelial cells, smooth muscle cells, fibroblasts, macrophages, and dendritic cells 
(Calderwood et al., 2007). LOX-1 forms large complexes on the cell surface, and activation by 
lipopolysaccharides (LPS) can lead to secondary activation of Toll Like Receptor-2 (TLR-2) 
which signals multiple events of APC–T cell interaction (Asea et al., 2002; Delneste et al., 
2002).  
 
Figure 1.7: Heat shock protein 70-antigen complex uptake mechanism. HSP70-antigen complex is 
recognised by two receptors ‗CD91‘ and ‗LOX-1‘ and endocytosed for processing and presentation to MHC 
molecules. The internalised HSP70-antigen complex is processed by two pathways: the endosomal pathway and 
the TAP dependent pathway. HSP70 is recognised by co-stimulatory receptors such as CD40, TLR-2 and TLR-4 
which signal activation of NF-κB, which induce cytokine and chemokine secretion (Nishikawa et al., 2008). 
1.8.1.3 Mechanisms of HSP70-antigen presentation 
HSP70 binds to antigenic peptides through its C-terminal polypeptide-binding domain (Bukau 
and Horwich, 1998). HSP70-peptide complexes bind to APCs by binding to surface receptors 
such as CD91/LPR, LOX-1 and co-stimulatory receptors TLR (Moroi et al., 2000; Basu et al., 
2001; Delneste et al., 2002; Wang et al., 2002; Nishikawa et al., 2008). The HSP70-peptide 
complexes are internalised and processed within the APC endosomes (Fig. 1.7). The processed 
peptides are mainly loaded into MHC class II molecules for presentation to CD4
+
 (helper) T-
cells which stimulate and regulate the humoral immune response, i.e. antibody production 
(Udono et al., 2001; Tobian et al., 2005).  It has been suggested that HSP70-peptide 




presentation‖ by MHC class I molecules to CD8
+
 (effector) T-cells (Robert, 2003; Nishikawa 
et al., 2008). In the cytoplasm the HSP70-antigen complex is processed by the proteosome and 
the resulting peptide is transported by the transport associated protein (TAP) to the MHC class 
I molecule in the endoplasmic reticulum (Robert, 2003; Wang et al., 2006b). The MHC-
peptide complex molecule is trafficked to the cell surface of the APC for presentation. Cross-
presented antigens are recognised by specific and CD8
+
 (effector) T-cells which, when 
activated, elicit specific cell lysis (Blachere et al., 1997; Massa et al., 2005; Tobian et al., 
2005; Nishikawa et al., 2008; Pockley et al., 2008). 
1.8.1.4 Adjuvant potential of HSP70 
Heat shock proteins have been used successfully as adjuvants to improve the immune response 
in rodent trials against various antigens e.g. oncogenic peptides in a cancer vaccine 
(Srivastava, 1994; Udono et al., 1994; Tamura et al., 1997; Segal et al., 2006; Zhang et al., 
2006), Plasmodium falciparum antigen in a malarial vaccine (Qazi et al., 2005), viral proteins 
in Japanese Encephalitis virus, Foot and Mouth disease virus, Hantavirus, Hepatitis B virus, 
and HIV vaccines (Bogers et al., 2004; Ge et al., 2006; Li et al., 2006; Wang et al., 2006a; Li 
et al., 2007a; Su et al., 2007; Li et al., 2009) and Chagas disease vaccine (Rico et al., 1999; 
Planelles et al., 2001; Morell et al., 2006). In these studies heat shock proteins were co-
injected with antigens, or as recombinant fusion proteins linked with the antigen. A more 
marked adjuvant effect was observed when HSP was covalently linked to the respective 
antigens. 
A study was conducted to  identify the domain of Mycobacterium tuberculosis HSP70 acting 
as adjuvant, and its role in enhancing the immune response when mixed or genetically linked 
to the major antigenic segment of Japanese Encephalitis Virus (JEV) ―E protein‖ (Ge et al., 
2006). They also attempted to determine whether the truncated form of HSP70, i.e. peptide 
binding domain or (PBD), can act alone as efficiently as an adjuvant, as the whole HSP70 
molecule. Results showed that linking E protein with PBD or HSP70 enhanced 
immunogenicity and elicited better humoral and cellular responses against E protein. Increased 
antigenicity was demonstrated with increased antibody titres, neutralising antibodies, 
increased lymphocyte proliferation, high levels of mIL-2 and mIFN-γ with E-PBD and E-




Although, these fusion proteins were less effective compared to E protein administered with 
Freund‘s adjuvant, the significant adjuvant potential of M. tuberculosis HSP70 was clearly 
demonstrated. 
It has also been thought that immunisation of mice with T. cruzi genes coding for KMP11 
protein linked to HSP70, confers some degree of protection against late-stage Chagas disease 
in the absence of adjuvant (Planelles et al., 2001).  To confirm these findings Morell et al. 
(2006) conducted a study where T. cruzi paraflagellar rod proteins 2 and 3 (PFR-2 and PFR-
3), a major component in the paraxial structure of the flagellum used for mobility and 
attachment to the host, were fused to the T. cruzi HSP70 gene. The resulting DNA plasmids 
were used in genetic immunisation of BALB/c and transgenic C57BL/6 mice.  
Mice immunised with PFR-HSP70 fused genes had a significantly higher percentage of 
splenic cells expressing Th type 1 cytokines, IL-2 and IFN-γ, when compared to mice 
immunised with PFRs, HSP70 or vector alone.  The presence of cytotoxic T lymphocytes 
(CTL) was measured as a marker indicating cellular lysis of target spleen cells (Jurkart-A2/k
d
). 
Spleen cells in mice immunised with PFRs-HSP70 genes had the highest over-expression of 
PFRs and thus, highest CTL levels and cellular lysis. BALB/c mice immunised with PRFs and 
PFRs-HSP70 genes were infected with attenuated trypomastigote forms 10 weeks after their 
last immunisation. Mice immunised with PFRs and PFRs-HSP70 were able to control 
infection 21 to 28 days post-infection, whereas 25% of control mice immunised with vector 
alone or saline solution died at day 26. 
1.8.2 Immunoglobulin Binding Protein (BiP).  
Immunoglobulin binding protein (BiP) formerly known as grp78 (glucose regulatory protein 
78) is a member of the HSP70 family of protein chaperones, and it resides in the cell ER. BiP 
is involved in translocation and trafficking of nascent secreted and membrane bound 
polypeptides from the cytoplasm into the ER, and also helps with their folding. BiP is an 
abundant protein that is expressed at increased levels in response to glucose deprivation, high 
levels of stress and is normally heat induced (Jensen et al., 2002; Labriola et al., 2011). BiP 
binds to newly synthesised polypeptides through cycles of binding ATP and releasing low 




Hartl, 2002). In vitro BiP prefers heptapeptides with aliphatic residues, and normally binds to 
slow folding and multi-subunit proteins (Hellman et al., 1999). BiP has been identified to be 
present in eukaryotes including rats (Munro and Pelham, 1986), humans (Panayi and 
Corrigall, 2006), nematodes (Heschl and Baillie, 1990), yeast (Vogel et al., 1990; Pidoux and 
Armstrong, 1993), plants (Anderson et al., 1994) and protozoan parasites including P. 
falciparum (Kumar et al., 1991; Kumar and Zheng, 1992), L. donovani (Jensen et al., 2002), 
Babesia caballi (Ikadai et al., 2005), T. brucei (Bangs et al., 1993), T. cruzi (Tibbetts et al., 
1994; Labriola et al., 2011), and T. congolense (Boulangé and Authié, 1994). BiP of T. 
congolense, just like other HSP70 family proteins, has chaperone properties, binding to 
nascent polypeptides and being involved in their proper folding.  
Trypanosoma congolense BiP is one the most abundant proteins expressed in all life cycle 
stages of the parasite (Authié et al., 1993b; Boulangé and Authié, 1994; Grébaut et al., 2009). 
A 69 kDa BiP was identified by blotting T. congolense lysates with sera from infected and 
uninfected cattle (Authié et al., 1993b). Trypanotolerant and susceptible cattle showed 
differing antibody isotypes against 69 kDa BiP. This brought interest in  identifying BiP as a 
possible antigen for use in both immunodiagnostics and an anti-disease vaccine strategy 
(Boulangé and Authié, 1994). The cDNA of BiP was immunoscreened and sequenced. It was 
found to be homologous to mammalian immunoglobulin binding protein, part of the heat 
shock protein 70 family, and named ―R69BiP‖ (Boulangé and Authié, 1994). Its open reading 
frame of 2.35 kb, coding for 653 amino acid residues was identified and cloned in a pMAL 
expression vector system (Boulangé and Authié, 1994). The 69 kDa BiP was evaluated for its 
immunodiagnostic potential by cloning different fragments of its ORF and subsequently 
expressing them (Boulangé et al., 2002).  The different fragments of BiP were tested by dot 
blot technique, using anti-BiP antibodies raised in rabbits, and sera from infected and 
uninfected cattle. It was found that most antibodies recognised the species specific, variable C-
terminal extension and had poor detection of primary infections of trypanosomiasis (Boulangé 
et al., 2002). This diminished potential of BiP as an immunodiagnostic target was exacerbated 
by the highly conserved sequence identity of its ATPase and peptide binding domains to 
mammalian BiP (Boulangé and Authié, 1994). Development of an inhibition ELISA based on 
full length BiP, using a specific monoclonal antibody has shown improved sensitivity in 




differentiate between species, uses low cost reagents and is likely to be used in large scale 
screening of cattle (Bossard et al., 2010). 
BiP is also thought to have protective capabilities when mice are immunised with either 
recombinant BiP or a DNA coding for BiP (Jensen et al., 2002). The protective efficiency of 
recombinant BiP co-administered with Freund‘s adjuvant and L. donovani DNA coding for 
BiP/Grp78 was tested separately in mice (Jensen et al., 2002).  Following immunisation, mice 
were infected with L. donovani promastigotes. Protective ability was measured by the number 
of skin lesions formed in each group and the time taken for healing. Mice immunised with 
recombinant BiP had significantly fewer lesions compared to controls, immunised with either 
GST or PBS. Only one BiP immunised mouse developed lesions, which healed after six 
weeks, whereas in control experiments six mice out of seven developed lesions requiring 7-10 
weeks to heal. The parasitaemia burden in lymph nodes was cleared six weeks post-infection 
in vaccinated mice, except for one mouse which had a parasitaemia burden comparable to that 
of control mice at week ten. DNA vaccination showed similar results. Recombinant BiP and 
DNA coding for BiP were almost 100% protective against development of skin lesions 
suggesting that memory B- and T-cells developed, which elicited a rapid, strong immune 
response upon infection. 
The present study was aimed at finding whether T. congolense BiP has adjuvant effects, and if 
so, which domain(s) would possess adjuvant properties. Congopain catalytic domain showing 
poor presentation to the immune system by conventional adjuvants, was to be used as a model 





1.9 OBJECTIVES OF THE STUDY  
Previous studies in our laboratory, aimed at improving the immunogenicity of congopain, 
focussed on complexing  bovine or rabbit α2-macroglobulin (α2M) with C2 (Huson et al., 
2009) or immunisation of C2 with different conventional adjuvants (Kateregga et al, In 
preparation
1
). Antibodies against C2 produced in rabbits immunised with a C2:α2M complex 
consistently inhibited approximately 65% of C2 and congopain activity. However, antibodies 
against C2, produced in rabbits immunised with C2 alone, showed no inhibition of C2 or 
congopain. Although immunisation of cattle and mice with C2 co-administered with a 
conventional adjuvant (Quil A), gave a robust immune response inhibiting C2 and congopain 
activity, these antibodies failed to give full protection of the mammalian host upon infection 
with live parasites (Authié et al., 2001; Kateregga et al., In preparation).  These findings show 
that there is an urgent need for a better delivery system, with improved targeting and 
presentation of C2 to immune cells, resulting in enhancement of the immune response and full 
protection of the host against trypanosomiasis.  
The present study aimed to improve the delivery and presentation of C2 to the immune system 
by genetically linking C2 to BiP, a proposed molecular adjuvant. The first part of this study 
involved cloning of the congopain catalytic domain, C2, in a pET-28 expression vector, and 
subsequent sub-cloning each of the BiP fragments: ATPase domain, peptide binding domain 
(PBD), C-terminus as well as BiP69 and BiP60 into the same vector. The resulting His-tagged 
BiP-C2 fusion protein chimeras were expressed in an E. coli bacterial system (Chapter 2). The 
second part of this study focussed on purification of His-tagged BiP-C2 fusion protein 
chimeras and BiP69 followed by immunisation of BALB/c mice with the purified proteins, to 
assess the adjuvant potential of the BiP fragments when linked to C2 (Chapter 3). The anti-C2 
antibody production, anaemia development, parasitemia levels, and percentage mice survival 
were compared between mice immunised with the BiP-C2 chimeras and mice immunised with 
C2 admixed with BiP69 or Adjuphos/Quil A. These results are finally discussed and possible 
future work proposed (Chapter 4). 
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ABSTRACT 
Trypanosoma congolense is the major causative agent of African animal trypanosomiasis. The 
disease costs African agriculture an estimated 4.5 billion US$ per annum. Current control 
strategies are not effective and there is no vaccine against the disease. Congopain, a major 
cathepsin L-like cysteine protease of T. congolense is a target for an anti-disease vaccine, and 
showed partial protection in cattle. To improve the immunogenicity of C2, BiP, a 69 kDa 
HSP70 chaperone member, was considered as a molecular adjuvant. BiP comprises an ATPase 
domain (ATPD), a peptide binding domain (PBD) and a C-terminal domain (C-term). The aim 
of this study was to produce BiP-C2 fusion protein chimeras to identify the specific domain(s) 
of BiP bearing adjuvant effects. To this end BiP69, BiP69 lacking the C-terminal domain 
(BiP60),  BiP coding fragments (ATPD, PBD and C-term) and congopain catalytic domain 
coding sequence (C2) were amplified by PCR from either genomic T. congolense DNA or 
plasmid DNA.  The PCR products were each sub-cloned into a pTZ57RT vector, and C2 
cloned into a pET-28a expression vector. The BiP coding fragments were inserted into the 
recombinant pET-28a-C2 vector, resulting in pET-28a-BiP69-C2, pET-28a-BiP60-C2, pET-
28a-ATPD-C2, pET-28a-PBD-C2 and pET-28a-C-term-C2 coding chimeras. The fusion 
proteins were expressed in an E. coli system as insoluble inclusion bodies at the expected sizes 
of 96 kDa (BiP69-C2), 88 kDa (BiP60-C2), 47 kDa (PBD-C2), 34 kDa (C-term-C2) and 27 
kDa (C2). However, the ATPD-C2 fusion protein was expressed at a larger and smaller size in 
different attempts. Protein expression was confirmed by western blots using anti-BiP 
antibodies and anti-congopain N-terminal peptide antibodies. 
2.1 INTRODUCTION 
Trypanosomiasis is a devastating disease affecting both man and animals mainly in Sub-
Saharan Africa, South America and to a lesser extent Asia (Rogers and Robinson, 2004; 




brucei gambiense and T. b rhodeisiense, while nagana is caused by T. congolense, T. vivax and 
to a lesser extent T. b. brucei (Hide, 1999; Cox, 2004; Stevens and Brisse, 2004).  Nagana 
remains a major constraint to livestock-based agriculture and has significant impact on 
millions of people in developing African countries (Fèvre et al., 2008; Hide and Tait, 2009) 
Current control strategies including trypanocidal drugs, tsetse control and trypanotolerant 
cattle are inefficient, due to drug resistance, environmental concerns and reduced economic 
production (Kabayo, 2002; Kgori et al., 2006; Delespaux and de Koning, 2007; Torr et al., 
2007).  One control strategy that remains most attractive with significant potential impact, if it 
could be developed, is vaccination (Welburn et al., 2009; Baral, 2010). However, variable 
surface glycoproteins coating parasites hamper vaccine development (Barry and McCulloch, 
2009; Morrison et al., 2009; Baral, 2010). Alternative anti-disease strategies are being pursued 
where pathogenic factors are targeted for chemotherapy and/or vaccine development, to halt 
disease progression rather than killing the parasite (Playfair et al., 1990; Playfair, 1991; 
Authié, 1994; Antoine-Moussiaux et al., 2009; Baral, 2010). 
In this context, kinetoplastid cysteine proteases are being considered as possible anti-disease 
vaccine candidates (Authié et al., 2001; Rafati et al., 2006; Cazorla et al., 2008b). There is 
increasing evidence implicating congopain, a major cysteine proteinase of T. congolense, in 
the pathogenesis of trypanosomiasis (Authié, 1994; Authié et al., 2001; Lalmanach et al., 
2002). Trypanotolerant N‘Dama cattle produce prominent IgG responses against congopain 
(Authié, 1994; Taylor, 1998). This suggests that trypanotolerant cattle control the disease by 
antibody mediated neutralisation of congopain, and that immunisation of cattle with congopain 
can mimic trypanotolerance resulting in minimised disease pathology (Authié, 1994). 
Susceptible cattle immunised with recombinant catalytic domain of congopain (C2) produced 
high levels of anti-congopain IgG, maintained weight and exhibited less severe anaemia 
(Authié et al., 2001). However, there was no effect on the establishment of T. congolense 
infection and acute anaemia development in trypanosusceptible cattle (Authié et al., 2001). 
This study, also suggested that congopain is poorly presented by conventional adjuvants 
resulting in partial protection of cattle against trypanosome infection (Authié et al., 2001; 




Attempts to improve the effectiveness of congopain inhibition by antibodies have been made 
where bovine and rabbit α2-macroglobulin were complexed with C2 in separate experiments 
(Huson et al., 2009). Antibodies from rabbits immunised with a C2-α2-macroglobulin complex 
inhibited approximately 65% of congopain activity whereas antibodies against C2 raised in 
rabbits immunised with C2 alone showed no significant inhibition of C2 or congopain activity 
(Huson et al., 2009). Rabbit and bovine α2-macroglobulin gave the same results. Immunisation 
of cattle with C2 co-administered in different conventional adjuvants mounted high antibody 
responses, but failed to mitigate disease progression (Kateregga et al. In preparation). These 
findings show that there is a need for an agent to improve delivery of C2 to the immune 
system resulting in enhanced immune response and full protection of the host against 
trypanosomiasis.  
Adjuvants increase the vaccine potency and reduce the amount of vaccine material required 
for disease protection; thereby decreasing toxicity, improving solubility, and protecting 
immunogenic epitopes. Good adjuvants, used in therapeutic vaccines, induce protective 
immunity with minimal side effects, and protection is via humoral and/ or cell-mediated 
specific immune responses (O'Hagan et al., 2001; Stills, 2005; Chamberlain and Gronvall, 
2007). There is a demand for much safer, cheaper, efficient adjuvants, giving robust immune 
responses (O'Hagan, 2001; O'Hagan et al., 2001; Singh and O'Hagan, 2003). Molecular 
adjuvants have recently gained popularity in eradication of diseases compared to conventional 
adjuvants due to their efficiency, safety and reasonably ease to produce (Kornbluth and Stone, 
2006; Wilson-Welder et al., 2008). 
Heat Shock Proteins (HSPs) are highly conserved chaperones involved in protein trafficking 
and proper folding of misfolded and nascent peptides (Lindquist and Craig, 1988; Hartl, 1996; 
Hartl and Hayer-Hartl, 2002).  They have also been shown to play a major role in stimulating 
the immune system towards complexed antigens or when co-injected with antigens without 
adjuvants (Qazi et al., 2005; Li et al., 2006; Li et al., 2007a; Karyampudi and Ghosh, 2008). 
The best studied class of HSPs is HSP70 and it is classified according to its localisation i.e. in 
the endoplasmic reticulum (ER), cytosol or membrane bound, and its secretion during stressful 
or non-stressful conditions (Calderwood et al., 2007; Pockley et al., 2008; Määttänen et al., 




(44 kDa), a peptide binding domain (18 kDa) and a variable C-terminal domain (10 kDa) 
which is species specific (Hartl and Hayer-Hartl, 2002; Robert, 2003; Lehner et al., 2004; 
Daugaard et al., 2007).  
Immunoglobulin binding protein (BiP) is a member of the HSP70 family of chaperones, and 
resides in the ER (Vogel et al., 1990; Panayi and Corrigall, 2006; Määttänen et al., 2010). 
Trypanosoma congolense BiP is one the most dominant proteins expressed in all life cycle 
stages of the parasite (Boulangé and Authié, 1994; Grébaut et al., 2009). A 69 kDa BiP was 
identified by blotting T. congolense lysates with sera from infected and uninfected cattle 
(Authié et al., 1993b). Trypanotolerant and trypanosusceptible cattle showed differing 
antibody isotypes against the 69 kDa BiP, which brought interest in evaluating BiP as a 
possible antigen to be used in both immunodiagnostics and anti-disease vaccine strategies 
(Boulangé and Authié, 1994; Boulangé et al., 2002; Bossard et al., 2010). 
The present study is aimed at producing recombinant BiP domain-C2 chimeras for evaluating 
the adjuvant potential of T. congolense BiP to enhance the immune response against 
congopain for improved disease control by the host. The catalytic domain of congopain has 
been shown to express in high amounts in the eukaryotic P. pastoris system from where it is 
easy to purify (Boulangé et al., 2011). Efforts to express C2 in a bacterial system have proved 
difficult as the protease expresses as inclusion bodies, making it difficult to renature 
(Boulangé et al., 2001). BiP has been expressed in a bacterial system as a soluble fusion 
protein with maltose binding protein, MBP, (Boulangé et al., 2002). Expression of constructs 
of T. congolense BiP linked to C2 have been attempted in both bacterial and yeast systems 
(Ndlovu, 2009). BiP-C2 chimera-MBP fusion proteins were expressed as inclusion bodies in a 
bacterial system and proved difficult to purify and renature, while expression of the same 
chimeras in a yeast system was very poor (Ndlovu, 2009). The inclusion of the pro-domain of 
congopain in most constructs led to maturation of congopain into its catalytic active form 
during purification and this resulted in complete proteolysis of chimeras. In the present study 
the pro-domain of congopain was consequently omitted from all constructs. Since the C-
terminal region of congopain is highly immunogenic, is unlikely to produce antibodies that 
can contribute to the inhibition of congopain activity and can misdirect the immune response 




Different domains of BiP i.e. the ATPase domain, the peptide binding domain, the C-terminal 
domain, full length BiP69 and BiP60 (BiP69 devoid of its C-terminal domain) were separately 
linked to the N-terminus of C2.  Here the cloning of these constructs in a pET-28a expression 
vector and their expression as His-tagged fusion chimeras in a bacterial system is reported. 
2.2 MATERIALS AND METHODS 
Materials 
Buffer salts and other commonly used chemicals were obtained from Merck (Johannesburg, 
South Africa) and Sigma-Aldrich (Munich, Germany) and were of the highest purity available. 
Coomassie blue R-250, 4-chloro-1-naphthol, L-trans-epoxysuccinyl-leucylamido(4-
guanidino)butane (E-64),  ampicillin and kanamycin were purchased from Sigma (Munich, 
Germany). DNA markers: O‘Gene
®
 1 kb mix, FastRuler
®
 High range and Middle range 
molecular mass markers, EcoRI, NotI, NdeI, shrimp alkaline phosphatase (SAP), T4 DNA 
ligase, DNA dilution buffer, GeneJet
®
  Plasmid Miniprep Kit, TranformAid
® 
Bacterial 
Transformation kit, X-gal, IPTG and the pTZ57RT vector were obtained from Fermentas 
(Vilnius, Lithuania). The E.Z.N.A
®
 gel extraction kit was purchased from peQLab (Enlangen, 
Germany) and the DNA clean and concentrator kit
®
 from ZymoReseach (Orange, CA, USA). 
Competent Escherichia coli JM109, JM109 DE3 and BL21 DE3 were obtained from New 
England Biolabs (Ipswitch, MA, USA). The pET-28a expression vector was purchased from 
Novagen (Madison,WI, USA). Taq polymerase, 10 x PCR reaction buffer, 10 mM dNTP mix, 
and MgCl2 were obtained from Solis Biodyne (Tartu, Estonia). Horse radish peroxidase- 
(HRPO) labelled horse anti-mouse IgG and HPRO-labelled rabbit anti-chicken IgY were 
obtained from Sigma. Leupeptin and 4-(2-aminoethyl)benzenesulfonylfluoride (AEBSF) were 
purchased from Roche (Germany). Biosciences Low molecular weight marker was obtained 
from GE Healthcare (South Africa). The pPic9-proC2 and pMAL-BiP69 (R69) plasmids were 
provided by Dr Alain Boulangé (University of KwaZulu-Natal). Chicken anti-congopain N-
terminal peptide antibodies (Mkhize, 2003) and chicken anti-BiP antibodies were in house 
preparations. Mouse anti-BiP N-terminal monoclonal antibodies (M1D4) and mouse anti-BiP 





2.2.1  Isolation of plasmid DNA 
A glycerol stock of pPic9-proC2 was three-way streaked on a 2x YT plate [tryptone (16 g/L), 
yeast extract (10 g/L), NaCl (5 g/L), bacterial agar (15 g/L)] containing ampicillin (50 µg/ml) 
and the plate was incubated overnight at 37
o
C. A single colony was selected from the plate 
and cultured overnight while shaken in liquid 2x YT medium [tryptone (16 g/L), yeast extract 
(10 g/L), NaCl (5 g/L)] containing ampicillin (50 µg/ml) at 37
o
C. The plasmid DNA was 
isolated using GeneJet
®
 plasmid DNA isolation kit (Fermentas) in accordance with the 
manufacturers‘ instructions. The plasmid DNA was analysed by electrophoresis on a 1% (w/v) 
agarose gel in TAE buffer [40 mM Tris-Cl, 1 mM Na2EDTA, 0.06 % (v/v) glacial acetic acid, 
pH 7.4]. 
2.2.1  Agarose gel for DNA analysis  
Agarose gel electrophoresis was used to separate and analyse DNA samples before 
visualisation under UV light. Agarose (1 g) was dissolved in 100 ml of 1 x TAE buffer [40 
mM Tris-Cl, 1 mM Na2EDTA, 0.06 % (v/v) glacial acetic acid, pH 7.4] and dissolved by 
heating in a microwave oven. Once cooled, ethidium bromide (0.5µg/ml) was added, and the 
solution poured into a casting tray. When the gel was set, it was placed in a tank filled with 
TAE buffer. DNA samples were mixed with loading solution [30 % (v/v) glycerol, 0.25 % 
(v/v) xylene, 0.25 % (w/v) bromophenol blue) and loaded in the wells. Electrophoresis was 
conducted at 80V for 35 min and the gel viewed and photographed under UV light using a 
Versadoc
®
 imaging system (BioRad) using the Quantity one software from BioRad. 
The molecular size of DNA bands were determined using a calibration curve prepared by 






Figure 2.1: Standard curve of relative mobility of DNA size markers against the log of their molecular 
weight to determine size of DNA bands of unknown size. DNA Ladder O‘Gene
®
 Mix containing 10, 4, 2, 1, 
0.5, 0.25 and 0.08 kb fragments (Fermentas) was used as a standard to plot the standard curve. The equation of 
the slope is y = -0.352x + 1.4666 with a correlation co-efficient of 0.965. 
 
2.2.2  Amplification of C2 ORF using PCR 
The plasmid DNA of pPic9-C2 (Fig. 2.2) was used as a template to amplify the gene coding 
for C2 using specific primers. Primers for C2 were designed in such a way that the sense 
primer would introduce an EcoRI restriction site (Roberts et al., 2003) and the anti-sense 
primer would introduce a NotI restriction site with a stop codon (Fig 2.3; Table 2.1). The PCR 
reaction was carried out in a 20 µl reaction volume containing 25 mM MgCl2, 1 x Taq 
polymerase buffer [80 mM Tris-Cl buffer, pH 9.4, 20 mM (NH4)2SO4, 0.02% (v/v) Tween 20] 
(Solis Biodyne), 10 μM C2 Fw primer, 10 μM C2 Rv primer, 25 U Taq FirePol
®
 DNA 
polymerase (Solis Biodyne), 20 mM dNTPs (Solis Biodyne). Amplification conditions for 25 
cycles were as follows: initial denaturation (94
o
C, 5 min), activation of Taq polymerase (94
o
C, 
30 s), primer annealing (56
o
C, 30 s), extension (72
o
































Figure 2.2: pPic9 expression vector map.  ColE1 origin of replication (pBR322), 5‘ AOX1 fragment 
(5‘AOX), multiple cloning sites, α-factor secretion signal (S), c-myc epitope (TT), ampicillin resistance gene, 
and the his4 gene for the selection by complementation in the his4 yeast strain (Invitrogen system manual). 
 
Table 2.1: Sequences of primers used for amplification of C2 ORF by PCR.  
Primer       Sequence                                                                                   Restriction site                                                                                                                           
C2 Fw       CTGAATTCGCACCTGAGGCAGTTGACTGG         EcoRI 
C2Rv       CCGCGGCCGCTTACGGAGTCGGGGGTGGAGGC         NotI 
 
2.2.3 Cloning of C2 PCR product into pTZ57RT sub-cloning vector  
A PCR product of 600 bp was amplified from a pPic9-proC2 template, as a single band and 
was cleaned using ZymoResearch
®
DNA clean and concentrator kit. The purified PCR product 
was ligated into the pTZ57RT sub-cloning vector (Fig 2.4) using DNA ligase, overnight at 
4
o
C. The ligated plasmid was transformed into E. coli JM109 cells using Bacterial 
TransformAid
®
 kit (according to the manufacturers‘ instructions). The transformed cells were 
plated on 2xYT plates containing 50 µg/ml of ampicillin, 20 µg/ml of X-gal and 10 µg/ml of 








Figure 2.3: Scheme showing construction of His-tagged BiP-C2 fusion chimeras. Amplification of the catalytic domain of congopain (C2) from the pPic9-
proC2 plasmid using catalytic domain primers. The amplicon (C2) was subsequently sub-cloned into a T-vector, recombination confirmed by restriction 
enzyme digestion and cloned into pET-28a. The BiP fragments were also amplified by PCR from T. congolense or pMAL-BiP69 plasmid, cloned into a T-
vector, recombination confirmed by restriction digest and subsequently sub-cloned into recombinant pET-28a-C2 plasmid. The vertical arrows represent 

























Figure 2.4: pTZ57RT sub-cloning vector map showing features of cloning efficiency.  Multiple cloning sites, 
5‘ and 3‘ dTT over hangs, lacZ gene (coding for blue and white colony screening), f1 (IG) region (for 
replication), ampicillin resistant gene [bla Ap
R
] (selection of recombinants) and T7 promoter (Fermentas user‘s 
guide).  
White colonies were selected for further screening to identify recombinants by colony PCR, 
using C2 specific primers (Table 2.1). The colony PCR was carried out in a 20 µl reaction 
volume using thermostable Taq polymerase. A template colony was picked and inoculated in 
the PCR mix, amplified using conditions as per Section 2.2.2. Recombinant colonies were 
grown at 37
o
C overnight in 2xYT media containing ampicillin (50 µg/ml). Plasmid DNA of 
recombinant pTZ57RT-C2 was isolated using GeneJet
®
 miniprep kit (Fermentas), and 
electrophoresed through a 1% (w/v) agarose gel. The pTZ57RT-C2 plasmid DNA was cut 
with EcoRI and NotI in Orange buffer to confirm recombinants (shown by the presence of the 
excised C2 insert of the expected size on an agarose gel). The dropped out C2 insert was 
excised from the agarose gel and purified using E.Z.N.A
®
 pQEL gel extraction kit. The 
purified C2 product was ligated into the pET-28a vector. The pET-28a vector (Fig. 2.5) had 
previously been cut with EcoRI and NotI, dephosphorylated with 1U of shrimp alkaline 
phosphatase (SAP) (activated at 37
o
C, 1 h and deactivated at 65
o
C, 15 min) to circumvent re-
circulisation or re-ligation, and purified with Zymoresearch
®





Figure 2.5: pET-28a expression vector map. The vector has a kanamycin resistance coding sequence, f1 origin 
of replication, T7 inducible promoter, T7 transcription start codon, multiple cloning site, lac1 coding sequence, 
T7 terminator and N-terminal and C-terminal His-tag coding sequences, enabling easy purification by divalent 
ion affinity resins.  
 
The ligated pET-28a-C2 plasmid DNA (50 ng) was transformed in E. cloni
®
 cells (Lucigen) 
by heat shock (in accordance with manufacturers‘ instructions) (see Section 2.2.4). 
2.2.4 Transformation of ligated pET-28a-C2 plasmid DNA into E. cloni® EXPRESS 
chemically competent cells using heat shock 
Sterile culture tubes and the ligation mix (pET-28a-C2) were chilled on ice for 15 min. The E. 
cloni
®
 EXPRESS cells (stored at -80
o
C) were thawed completely on wet ice (10-20 min) and 
15 μl added into a pre-chilled microfuge tube containing 50 ng of ligation mix. The microfuge 
tube was finger tapped briefly to mix the contents. The cells were incubated on ice for 30 min, 
heat shocked in a 42
o
C water bath for 45 s and incubated on ice for 2 min before 985 μl of 
Expression Recovery Medium (Lucigen) was added at RT. The microfuge tubes with cells 
were shaken in a 37
o
C incubator at 250 rpm for 1 hour before the cells were centrifuged (12 




in 200 µl of the remaining recovery medium and cells plated on 2xYT plates containing 
kanamycin (33 μg/ml) and incubated overnight at 37
o
C. Recombinant colonies were selected 
and screened by colony PCR using both C2 primers (Table 2.1) and pET vector universal 
primers (Table 2.2). Two recombinant colonies were selected and grown overnight in 2xYT 
media containing kanamycin (33 μg/ml) before plasmid DNA was isolated as described in 
Section 2.2.1. 
Table 2.2: Sequences of primers used for screening of pET-28a recombinant colonies by PCR. The primers 
were designed based on the coding sequence of  the 5‘ T7 promoter (pET Forward) and 3‘ T7 terminator (pET 
Reverse) flanking multiple cloning sites. 
Primer Tm (
o
C) Sequence (5‘-3‘) 
pET Fw 54 TAATACGACTCACTATAGGG 
pET Rv 57 GCTAGTTATTGCTCAGCGG 
 
The pET-28a-C2 plasmids were restricted with EcoRI and NotI in Orange buffer (Fermentas) 
to confirm recombinants. Successful restriction digest was analysed on 1 % (w/v) agarose gel 
and recombinants shown by the presence of the excised C2 insert of the expected size when 
viewed under UV light. Positive clones were further digested with NdeI and EcoRI in Orange 
buffer, dephosphorylated with SAP and purified using ZymoResearch
®
 DNA clean and 
concentrator kit, for insertion/cloning of BiP fragments. 
2.2.5 Cloning and expression of His-tagged BiP-C2 fusion protein chimeras 
2.2.5.1  Isolation of genomic DNA from T. congolense IL1800 lysates and pMAL-R69 BiP 
plasmid DNA 
Procyclic T. congolense parasites were cultured in 10 ml minimum essential medium (MEM) 
[25 mM HEPES Acid, 0.1 mM hypoxanthine, 2 mM glutamine, 10 mM proline, 3 mM cis-
aconitate; 3 mM citrate] and containing 10% (w/v) foetal calf serum and were grown to 1 x 
10
7 
parasites/ml.  The medium containing parasites was centrifuged (1 600 x g, 10 min, RT) 
and the supernatant removed by decanting. The pellet was resuspended in 1 ml PBS and 
transferred to 4 x 1.5 ml microfuge tubes, and further diluted to 4 ml with PBS. Microfuge 
tubes were centrifuged (1 600 x g, 10 min, RT) and the supernatant removed. The pellet was 




(v/v) Triton X-100, pH 7.4), followed by incubation for 5 min on ice. A phenol:chloroform 
[150 µl, 1:1 (v/v)] mixture was added and incubated at RT for 5 min before the mixture was 
centrifuged (6 800 x g, 5 min) to separate nucleic acids from supernatant. The pellet was 
washed with 300 µl of 100% (v/v) ethanol and incubated for 5 min at RT followed by 
centrifugation (6 800 x g, 10 min) and the supernatant decanted carefully. The pellet was 
washed again with 100% (v/v) ethanol (1 ml) followed by centrifugation (6 800 x g, 5 min), 
the supernatant decanted again and the pellet incubated for 10 min at 37
o
C and left to dry. The 
pellet was resuspended in 100 µl of TE buffer (100 mM Tris-Cl buffer, pH 7.4, 10 mM 
EDTA) with RNAse (20 µg/ml) followed by incubation for 45 min at 37
o
C. The genomic 
DNA was stored at -20
o
C until further use. 
The pMAL-R69 BiP plasmid DNA was isolated from an overnight culture using the GeneJet
®
 
miniprep isolation kit (in accordance with the manufacturers‘ instructions). The pMAL-R69 
BiP plasmid DNA or T. congolense genomic DNA (1 µl) was used as a template for 
amplification of different BiP fragments by PCR (Fig. 2.3). Primers for BiP fragments (BiP69, 
BiP60, ATPD, PBD and C-term) were designed in such a way that the forward primer would 
introduce an NdeI restriction site (CATATG) and the reverse primer introduce an EcoRI 
restriction site (GAATTC) (Table 2.3). 
 
Table 2.3: Sequences of primers used for amplification of BiP fragments by PCR using T. congolense 
genomic DNA and pMAL-R69 BiP plasmid DNA as templates. The genomic DNA was isolated from T. 
congolense procyclic lysates, and plasmid DNA from pMAL- R69 BiP. The restriction enzyme sites are 
underlined. 
Primer Direction Tm (
o
C)       Sequence (5‘ -3‘) 
BiP NdeI Fw     70        CCCATATGGCGCCCGAGAGCGGCGGGAAG 
BiP69 EcoR1 Rv     61        CTGAATTCAAGGTCATCCATGGGCTGCGG 
BiP60 EcoRI Rv 46               GAGGAATTCCCGCGCCTCCACACGCTCCCC 
ATPD EcoRI Rv 73        AAAGAATTCCACGCCCGCCAACCTCACTCT 
PBD NdeI Fw  72        AAACATATGGTGCTGACCGGTGAGAGTGAG 







2.2.5.2 Sub-cloning of BiP fragments into pTZ57RT vector 
The PCR products of BiP fragments: BiP69 (2 kb), BiP60 (1.8 kb), ATPD (1.2 kb), PBD (0.55 
kb) and C-term (0.23 kb), were purified and concentrated using ZymoResearch
®
 DNA clean 
and concentrator kit. The purified BiP fragments were ligated into sub-cloning vector 
pTZ57RT (Fig. 2.4) using T4 DNA ligase
®
 (Fermentas) at 4
o
C, overnight.  
The ligated plasmids (pTZ57RT-BiP69, pTZ57RT-BiP60, pTZ57RT-ATPD, pTZ57RT-PBD, 
and pTZ57RT-C-term) were transformed separately into E. coli JM109 cells using Bacterial 
TransformAid
®
 kit (in accordance with the manufacturers‘ protocol). The cells were plated on 
2xYT plates in the presence of ampicillin (50 µg/ml), X-gal (20 µg/ml) and IPTG (10 µg/ml), 
for blue and white colony screening. 
White colonies from each transformed ligated plasmid, were selected and screened by colony 
PCR for recombinants using insert specific primers (Table 2.3). The colony PCR reaction was 
carried out as shown in Tables 2.4 and 2.5. Recombinant colonies were grown overnight in the 
appropriate media with antibiotic present. The plasmid DNA was isolated using GeneJet
®
 
plasmid DNA isolation kit and analysed by 1% (w/v) agarose gel electrophoresis. 
Recombinant plasmids were digested with NdeI in Orange buffer (Fermentas) overnight at 
RT. The plasmids restricted were analysed by 1% (w/v) agarose gel and plasmids that showed 
linearisation with NdeI on the gel were further restricted with EcoRI restriction enzyme. The 
restricted plasmids with both restriction enzymes were analysed by 1% (w/v) agarose gel 
electrophoresis and recombinants shown by the presence of the excised BiP fragment insert of 





Table 2.4: PCR reaction components used for amplification of products from plasmid DNA templates. 
PCR component Volume (μl) Final concentration  
MgCl2 (25 mM) 2 2.5 mM 
PCR Buffer (10 x) 2 1 x 
Fw primer (10 μM) 0.5 0.25 μM 
Rev primer (10 μM) 0.5 0.25 μM 
Taq  0.25 1U 
dNTPs (20 μM) 0.5 0.5 μM 
Sterile distilled H2O 14.5  
Total volume 20  
 
Table 2.5: PCR reaction conditions for amplification of BiP fragments. A master mix containing PCR 
components (Table 2.4) was amplified in a 20 µl volume for 25 cycles. The conditions for initial denaturation 
(95
o
C, 5 min) and final extension (72
o
C, 7 min) were constant. 
PCR conditions                 Primer 
                                    BiPFw/            BiPFw/            BiPFw/        PBDFw/          C-termFw/ 
                                BiP69Rv         BiP60Rv          ATPDRv      BiP60Rv         BiP69Rv 
Denaturation  95
o
C, 30 s       95
o
C, 30 s       95
o
C, 30 s     95
o
C, 30 s      95
o
C, 30 s 
Annealing  56
o
C, 1 min     58
o
C,  1 min   65
o
C, 1 min   65
o
C, 30 s      55
o
C, 1 min 
Elongation   72
o
C, 2 min     72
o
C, 2 min    72
o
C, 2 min   72
o
C, 1 min   72
o
C, 1 min 
2.2.5.3 Cloning of BiP fragment into recombinant expression vector pET-28a-C2 
The inserts dropped out by double digestion of the recombinant pTZ57RT vector plasmids 
were excised from the gel and purified using the E.Z.N.A
®
 pQEL gel extraction kit and 
analysed on a 1% (w/v) agarose gel. The BiP fragments were ligated into pET-28a-C2 using a 
3:1 insert to vector ratio. The vector was prepared as described in Section 2.2.4. 
The ligated plasmids, pET-28a-BiP69-C2, pET-28a-BiP60-C2, pET-28a-ATPD-C2, pET-28a-
PBD-C2 and pET-28a-C-term-C2, were transformed into E. cloni
®
 cells as per Section 2.2.4. 
The recombinant colonies were screened by colony PCR using pET universal primers (Table 
2.2) for C-term-C2 and PBD-C2, and BiP fragment insert specific primers for BiP69-C2, 
BiP60-C2 and ATPD-C2 (Table 2.3). Recombinant colonies were grown over-night in culture 
medium and plasmid DNA isolated. Recombinants were confirmed by digestion with NdeI 
and EcoRI in Orange buffer (to drop out BiP fragment insert) and digested with NdeI and NotI 




transformed into E. coli BL21DE3 cells or E. coli JM109DE3 cells by electroporation (Section 
2.2.5.4). 
2.2.5.4  Transformation of pET-28a-BiP-C2 plasmids into E. coli BL21DE3 or JM109DE3 
cells by electroporation 
The recombinant plasmid DNA (2 μl) of pET-28a-BiP69-C2, pET-28a-BiP60-C2, pET-28a-
ATPD-C2, pET-28a-PBD-C2, pET-28a-C-term-C2 and pET-28a-BiP69 were separately 
mixed with E. coli BL21DE3/JM109DE3 cells (50 μl), pre-chilled on ice. Each mixture was 
pipetted into an ice cold 1 mm Electroporator cuvette
®
 and electroporated using the 
GenePulser
®
 (BioRad) (settings: 2.5 kV, 25 μF, 200Ω). The cells were immediately resuspended 
in 2xYT medium (1 ml) without antibiotics and grown in culture tubes, in a shaking incubator at 
250 rpm, for 1 hour at 37oC.  The cultures were centrifuged (12 000 x g, 1 min) and 800 μl 
supernatant discarded. Pelleted cells were re-suspended in the remaining 200 μl supernatant 
and plated on 2xYT plates containing kanamycin (33 μg/ml) and incubated overnight at 37
o
C. 
Transformants in E. coli BL21DE3 or JM109DE3 strains were screened for recombinants by 
colony PCR (Section 2.2.3) Recombinant colonies were expressed in Terrific Broth with 
appropriate antibiotic (Section 2.2.5.5). 
2.2.5.5  Expression of recombinant clones as His-tagged fusion proteins in Terrific Broth® 
Recombinant clones in E. coli BL21DE3 or JM109DE3 strains were expressed in Terrific 
Broth
®
 by auto-induction (Tartof and Hobbs, 1987; Studier, 2005) at 37
o
C, overnight. 
Following expression, the culture was centrifuged (6 000 x g, 10 min, RT) and the pellet lysed 
in lysis buffer [100 mM NaCl, 50 mM Tris-Cl, 0.5% (v/v) Triton X-100, lysozyme 20 µg/ml, 
pH 8.2] in a volume 1/20 of the initial culture volume. The lysate was left at RT for 15 min 
and a protease inhibitor cocktail was added prior to freezing. The lysate was thawed and 
sonicated (3 x 1 min) to break down nucleic acids and centrifuged (5 000 x g, 15 min, RT). 
The supernatant and pellet were separated and kept for SDS-PAGE analysis (Section 2.2.6). 
The bacterial pellet was resuspended in PBS, in a volume 1/40 of the initial culture volume. 
2.2.6 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
analysis of proteins 
Protein sample analysis was carried out in a 10% SDS-PAGE gel using a discontinuous Tris-




g per g of protein and gives the protein a negative charge. When protein-SDS complexes are 
subjected to electrophoresis, they all have the same charge and therefore separate based only 
on differences in molecular weight (Dennison, 1999). Proteins were separated through a large 
pore stacking gel, pH 6.8 and a small pore running gel at pH 8.8, allowing clear separation of 
proteins of different sizes. A mini-PROTEAN 3
® 
gel system (BioRad) was used to separate 
proteins. Samples from expression media containing BiP-C2 chimeras, BiP69 and C2 protein 
samples (pellets and supernatants) were mixed with reducing treatment buffer [125 mM Tris-
Cl buffer, pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol, 10% (v/v) β-mercaptoethanol] in a 1:1 
ratio and boiled for 5 min before loading. Low molecular weight marker (Amersham) were 
used to construct a calibration curve (Fig. 2.6). Electrophoresis was conducted in Tank buffer 
[250 mM Tris-Cl buffer, 192 mM glycine, 0.1% (w/v) SDS, pH 8.3] at 18mA per gel. The 
proteins were stained with Coomassie brilliant blue R-250 [0.125 g (w/v) Coomassie blue R-
250, 50% (v/v) methanol, 10% (v/v) glacial acetic acid].  
The molecular size of protein bands were determined using a calibration curve prepared by 
plotting the relative mobility of protein molecular weight standards against the log of their 
molecular weight (Fig. 2.6) (Dennison, 1999). 
 
 
Figure 2.6: Standard curve of relative mobility of standard proteins against their log Mr, utilised to 
determine molecular weights of proteins of unknown size. Amersham Biosciences low molecular weight 
marker contains: phosphorylase b (97 kDa), BSA (66 kDa), ovalbumin (45 kDa), carbonic anhydrase (30 kDa), 
soybean trypsin inhibitor (20 kDa) and lysozyme (14 kDa). The equation of the slope is y = -0.9203x + 1.9394 





























2.2.7 Western blot using anti-BiP antibodies and anti-congopain N-terminal peptide 
antibodies 
The proteins separated by SDS-PAGE (Section 2.2.6) were transferred to a nitrocellulose 
membrane for 1 h using a semi-dry blotter (Sigma Chemical Co., St. Louis, USA). Efficiency 
of blotting was confirmed by staining the gel with Ponceau S [0.1% (w/v) Ponceau S in 1% 
(v/v) glacial acetic acid]. The unoccupied sites on the nitrocellulose membrane were blocked 
for 1 h with 5% (w/v) low fat milk powder in TBS (20 mM Tris-Cl buffer, 200 mM NaCl, pH 
7.4), followed by washing (3 x 5 min) with TBS. This was followed by incubation for 2 h with 
primary antibody [(affinity purified chicken anti-congopain N-terminal peptide antibody (1 
µg/ml)] (for C2) or [(mouse anti-BiP M1D4 monoclonal antibody (1: 2000) or chicken anti-
BiP antibody (1 µg/ml)] (for BiP), diluted in 0.5% (w/v) BSA in TBS. Following washing in 
TBS (3 x 5 min) nitrocellulose was incubated for 1 h at RT with HRPO-linked secondary 
antibody [(rabbit anti-chicken IgY 1:12 000 (Sigma) or rabbit anti-mouse IgG 1:10 000 
(Sigma)], diluted in 0.5% (w/v) BSA in TBS. Following washing in TBS (3 x 5 min) the 
nitrocellulose membrane was immersed in 4-chloro-1-naphthol/H2O2 substrate solution 
[0.006% (w/v) 4-chloro-1-naphthol, 0.1% (v/v) methanol, and 0.0015% (v/v) H2O2]. This was 
incubated in the dark and the reaction was terminated by rinsing the membrane in distilled 





2.3  RESULTS 
2.3.1  Amplification of BiP fragments and congopain catalytic domain (C2) by PCR  
The pMAL-BiPR69 plasmid DNA (Boulangé and Authié, 1994) and T. congolense genomic 
DNA were isolated and analysed on an agarose gel (Fig. 2.7). Plasmid DNA of pMAL-
BiPR69 migrated above 10 kb and genomic DNA migrated above 5 kb. Isolated plasmid DNA 
or genomic DNA was used as the template in a PCR reaction to amplify BiP fragments.  
 
Figure 2.7: Isolation of genomic DNA from procyclic T. congolense and plasmid DNA from pMAL-BiPR69 
culture. Genomic T. congolense DNA isolated using the phenol:methanol precipitation method (A), and R69BiP 
plasmid DNA isolated using GeneJet
®
 miniprep kit (B) were electrophoresed on a 1% (w/v) agarose gel in 1 x 
TAE buffer. A: lane 1, DNA Ladder FastRuler
®
 Middle range (Fermentas); lane 2, genomic T. congolense DNA. 
B: Lane 1, DNA Ladder O‘Gene
®
 1kb mix (Fermentas); lane 2, pMAL-BiPR69 plasmid DNA. 
Different BiP coding fragments were amplified using specific primers (Table 2.3) and 
analysed on a 1% (w/v) agarose gel (Fig. 2.8). BiP69 coding fragment was amplified as a 2 kb 
amplicon using BiP NdeI Forward and BiP69 EcoRI Reverse primers (Fig. 2.8, lane 2). BiP60 
coding fragment amplified as a 1.8 kb product using BiP NdeI Forward and BiP60 EcoRI 
Reverse primers (Fig. 2.8, lane 3). ATPase Domain coding fragments was amplified as a 1.2 
kb PCR product using BiP NdeI Forward and ATPD EcoRI Reverse primers (Fig. 2.8, lane 4). 
The peptide binding domain coding fragment was amplified as a 0.55 kb product using PBD 






















coding fragment was amplified as a 0.23 kb PCR product using C-term NdeI Forward and 




Figure 2.8: Amplification of BiP fragments by PCR using specific primers. BiP69 plasmid was used as a 
template to amplify BiP69, BiP60, ATPD, PBD and C-term fragments and the PCR products were cleaned with 
DNA clean and concentrator kit. PCR products were electrophoresed on a 1% (w/v) agarose gel. Lane 1, DNA 
Ladder FastRuler
®
, High Range (Fermentas); lane 2, BiP69; lane 3, BiP60; lane 4, ATPD; lane 5, PBD; lane 6, 
C-term. 
The pPic9-proC2 construct had been cloned and expressed previously  in a P. pastoris system 
(Boulangé et al., 2011). Plasmid DNA of pPic9-proC2 was isolated and used as a template to 
amplify the catalytic domain of congopain, C2. A single band at 600 bp was observed by 
electrophoresis on a 1% (w/v) agarose gel (Fig. 2.9, lane 2), corresponding to the expected 
size of the catalytic domain coding fragment of congopain (C2). 
 
 










Figure 2.9: Amplification of C2 by PCR using specific primers. pPic9-ProC2 plasmid was used as a template 
to amplify C2, and the PCR product was cleaned with DNA clean and concentrator kit and analysed by 
electrophoresis on a 1% (w/v) agarose gel in 1 x TAE buffer. Lane 1, DNA Ladder FastRuler
®
, High Range 
(Fermentas); lane 2, C2. 
2.3.2 Cloning of BiP fragments and the catalytic domain of congopain (C2) into a 
pTZ57RT vector  
The amplified PCR products of BiP coding fragments, (namely BiP69, BiP60, ATPD, PBD, 
and C-terminus) together with that of C2 were purified and ligated into a pTZ57R/T vector 
and transformed into E. coli JM109 cells. Following blue-white colony selection, recombinant 
clones were screened by colony PCR (results not shown). Two recombinant clones (indicated 
as 1 and 2 in figure legend of Fig. 2.10) from each ligation mix were grown in appropriate 
media, plasmid DNA isolated and double restricted: plasmid DNA of pTZ57RT-BiP69, 
pTZ57RT-BiP60, pTZ57RT-ATPD, pTZ57RT-PBD, and pTZ57RT-C-term with NdeI and 
EcoRI, and C2 plasmid DNA with EcoRI and NotI. Double digestion of BiP coding fragments 
inserted in the pTZ57RT vector, showed the pTZ57RT vector at 3 kb and BiP coding 
fragments at 2 kb for BiP69 (Fig. 2.10, Panel A, lanes 3 and 5), 1.8 kb for BiP60 (Fig. 2.10, 
Panel A, lanes 7 and 9), 1.2 kb for ATPD (Fig. 2.10, Panel B, lanes 3 and 5), 0.55 kb for PBD 
(Fig. 2.10, Panel B, lanes 7 and 9), 0.23 kb for C-term (Fig. 2.10, Panel B, lanes 11 and 13). 
Some plasmids were not completely digested after incubation overnight at 25
o
C and this was 
shown by triple bands representing no digestion, partial digestion and complete digestion 











Figure 2.10: Restriction digests of BiP-coding domains in T-vector. All BiP fragments in pTZ57R/T were 
double digested with NdeI and EcoRI (or EcoRI and NotI for C2) overnight at RT. The plasmid DNA was 
electrophoresed on a 1% (w/v) agarose gel. A: Lane 1, DNA ladder FastRuler
®
 (High range, Fermentas); lane 2, 
BiP69 1 uncut; lane 3, BiP69 1 cut; lane 4: BiP69 2 uncut; lane 5: BiP69 2 cut; lane 6, BiP60 1 uncut; lane 7, 
BiP60 1 cut; lane 8: BiP60 2 uncut; lane 9: BiP60 2 cut. B: Lane 1, DNA Ladder (O‘Gene
®
 Mix, Fermentas); 
lane 2, ATPD 1 uncut; lane 3: ATPD 1 cut; lane 4: ATPD 2 uncut; lane 5: ATPD 2 cut; lane 6: PBD 1 uncut; lane 
7: PBD 1 cut; lane 8, PBD 2 uncut; lane 9: PBD 2 cut; lane 10: C-term 1 uncut; lane 11: C-term 1cut; lane 12: C-
term 2 uncut; lane 13: C-term 2 cut; lane 14, C2 uncut; lane 15: C2 cut; lane 16, C2 uncut and lane 17, C2 cut.  
 
Double digestion of pTZ57RT-C2 plasmids with EcoRI and NotI showed the C2 insert at the 
expected size of 0.6 kb (Fig. 2.10, Panel B, lanes 15 and 17) and pTZ57RT vector at the 
expected size of 3 kb. This confirmed successful sub-cloning of all BiP coding fragments and 
C2 coding fragment into the pTZ57RT vector. The recombinant plasmids were sent for 
sequencing (SegoliLab Unit, ILRI, Kenya), to verify that no unwanted mutations had been 
introduced by the Taq polymerase enzyme that is not a high fidelity DNA polymerase enzyme 
and is likely to introduce mutations [estimated at a rate of 1 nucleotide per cycle of 




















2.3.3  Cloning of C2 coding sequence into a His-tagged pET-28a expression vector  
The pET-28a expression vector (Fig. 2.11, Panel A, lane 2) and recombinant catalytic domain 
(C2) coding sequence in a pTZ57RT vector (Fig. 2.11, Panel A, lane 4) were digested with 
EcoRI and NotI. The digested plasmids of both pET-28a (Fig. 2.11, Panel A, lane 3) and C2 
(Fig. 2.11, Panel A, lane 5) were analysed by 1% (w/v) agarose gel electrophoresis, and DNA 
bands corresponding to the expected sizes cut out and purified. The C2 coding sequence had 
an expected size of 0.6 kb (Fig. 2.11, Panel B, lane 2) and the pET-28a expression vector an 
expected size of 5.39 kb (Fig. 2.11, Panel B, lane 3). 
 
Figure 2.11: Restriction digests of C2 coding sequence in a pTZ57RT vector and pET-28a expression 
vector and their purification. The plasmids were double digested with EcoRI and NotI, electrophoresed on a 
1% (w/v) agarose gel (A), and then gel purified for ligation (B). A: lane 1, DNA Ladder FastRuler
®
, High range 
(Fermentas); lane 2, pET-28a vector uncut; lane 3, pET-28a cut; lane 4, C2 coding sequence in pTZ57RT vector 
uncut; lane 5, C2 coding sequence in pTZ57RT vector cut. B: lane 1, DNA Ladder Fast Ruler
®
, High range 
(Fermentas); lane 2, C2 coding sequence purified; lane 3, pET-28a purified. 
 
The purified insert (C2) and vector (pET-28a) were ligated and transformed into chemically 
competent E. cloni
®
 cells. The recombinant colonies were screened by colony PCR using pET 
universal forward and reverse primers. The resulting PCR products, migrated higher than the 
expected size of 0.6 kb (Fig. 2.12, lanes 2, 3 and 5), due to the extra 200 bases amplified by 
pET primers on the 5‘ and 3‘ ends of the pET-28a vector. Two recombinant colonies were 




















Figure 2.12: Screening of the pET-28-C2 recombinant colonies by colony PCR using pET universal 
primers. The reaction mix was analysed on a 1% (w/v) agarose gel in 1 x TAE buffer. Lane 1, DNA Ladder, 
FastRuler
®
 High range (Fermentas); lanes 2-6, colonies 1-5; lane 7, positive control pET-28a plasmid DNA. 
Neither single restriction digest of pET-28a-C2 plasmid DNA EcoRI and NotI (Fig. 2.13, 
lanes 4 and 5 respectively) nor double digest with NdeI and EcoRI (Fig. 2.13, lane, 6), 
released the C2 insert, although EcoRI completely linearised the plasmid. However, restriction 
digest with EcoRI and NotI released the C2 insert at the expected size of 600 base pairs (Fig 
2.13, lane 7).  
 
Figure 2.13: Single and double restriction digest of recombinant pET-28-C2 with various restriction 
enzymes. The recombinant pET-28a-C2 plasmid was either single digested with EcoRI or NotI, or double 
digested with a combination of NdeI and EcoRI, or EcoRI and NotI. The digested plasmid was analysed by 1% 
agarose gel electrophoresis. Lane 1, DNA Ladder FastRuler
®
 High range (Fermentas); lane 2, pET-28a plasmid; 
lane 3, pET-28-C2 plasmid; lane 4, pET-28-C2 cut with EcoRI; lane 5, pET-28-C2 cut with NotI; lane 6, pET-28-
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The NdeI and EcoRI double digested recombinant pET-28a-C2 plasmid was dephosphorylated 
and purified. BiP fragments, previously cut with NdeI and EcoRI and purified, were ligated 




Recombinant clones were screened by colony PCR (results not shown). Resulting positive 
clones were grown in appropriate media and plasmid DNA was isolated. The plasmid DNA of 
each construct (BiP69-C2, BiP60-C2, ATPD-C2, PBD-C2 or C-term-C2) was confirmed by 
restriction digest with NdeI and EcoRI to release BiP inserts (Fig. 2.14, lanes 3, 6, 9, 12 and 
15), and also with NdeI and NotI to release BiP-C2 fragment (Fig 2.14, lanes 4, 7, 10, 13 and 
16). The sizes of inserts were confirmed by comparison with results of previous restriction 
digests (Fig. 2.10). Uncut plasmids migrate slower in an agarose gel and so different 
conformations of plasmids can be seen as a faint band above the major band (Fig. 2.14, lanes 
8, 11 and 14). Some of the plasmids were not completely digested by restriction enzymes 
when left overnight at 25
o
C. This is shown by double bands between 5 kb and 8 kb, and they 
differ in size depending on the construct (Fig 2.14, lanes 6, 7, 9, 10 and 13).  
 
Figure 2.14: Restriction digest of recombinant plasmids of BiP-C2 coding fragments in a pET-28a vector. 
Recombinant plasmid DNA of BiP69-C2, BiP60-C2, ATPD-C2, PBD-C2 and C-term-C2 were double digested 
with NdeI and EcoRI, or NdeI and NotI overnight at RT. The plasmids were analysed by 1% agarose gel 
electrophoresis. Lane 1, DNA ladder O‘Gene
®
 Mix Mass Ruler (Fermentas); lane 2, BiP69-C2 uncut; lane 3, 
BiP69-C2 cut NdeI & EcoRI; lane 4,  BiP69-C2 cut NdeI & NotI; lane 5, BiP60-C2 uncut; lane 6,  BiP60-C2 cut 
NdeI & EcoRI; lane 7, BiP60-C2 cut NdeI & NotI; lane 8, ATPD-C2 uncut; lane 9:  ATPD-C2 cut NdeI & 
EcoRI;  lane 10, ATPD-C2 cut NdeI & NotI; lane 11,  PBD-C2 uncut, lane 12, PBD-C2 cut NdeI & EcoRI;  lane 
13,  PBD-C2 cut NdeI & NotI; lane 14, C-term-C2 uncut; lane 15, C-term-C2 cut NdeI & EcoRI; lane 16, C-
term-C2 cut NdeI & NotI. 
















The recombinant plasmids of pET-28a-BiP69-C2, pET-28a-BiP60-C2, pET-28a-ATPD-C2, 
pET-28a-PBD-C2 and pET-28a-C-term-C2 were transformed into E. coli BL21DE3 or 
JM109DE3 cells by electroporation and expression conducted in Terriffic Broth. The cells 
were lysed and the pellet separated from the supernatant to determine the solubility of the 
expressed protein (Fig 2.15). 
His-tagged BiP-C2 fusion chimeras were expressed as insoluble proteins at the expected sizes 
(Fig. 2.15): BiP69-C2, 96 kDa (lane 2), BiP60-C2, 88 kDa (lane 4), PBD-C2, 47 kDa (lane 8) 
and C-term-C2, 34 kDa (lane 11). The His-tagged ATPD-C2 fusion protein chimera was 
expressed at a higher molecular weight than expected: i.e 88 kDa (lane 6). BiP69 was 
expressed as an insoluble 73 kDa fusion protein (lane 13) and C2 was expressed as an 
insoluble 27 kDa fusion protein (lane 14). 
 
Figure 2.15: Expression of His-tagged BiP-C2 fusion protein chimeras in Terrific Broth overnight at 37
o
C. 
A single colony of transformed E. coli BL21DE3 strain was inoculated in Terrific Broth, and allowed to express 
overnight. Lane 1 and 10, Biosciences low molecular weight markers; lane 2, BiP69-C2 pellet; lane 3, BiP69-C2 
supernatant; lane 4, BiP60-C2 pellet; lane 5, BiP60-C2 supernatant; lane 6, ATPD-C2 pellet; lane 7, ATPD-C2 
supernatant; lane 8, PBD-C2 pellet; lane 9, PBD-C2 supernatant; lane 11, C-term-C2 pellet; lane 12, C-term-C2 
supernatant; lane 13, BiP69 pellet; lane 14, C2 pellet; lane 15, E. coli BL21DE3 cells. Lysate samples (PBS 
resuspended pellet and supernatant) were mixed with equal volumes of reducing treatment buffer before boiling 
for 5 min. Protein expression was analysed using reducing 10% SDS-PAGE and staining with Coomassie blue R-
250. 
Expression of soluble proteins has been achieved when culturing temperatures were lowered, 
allowing slow expression of target protein and proper folding by the E. coli chaperone 
machinery (Baneyx, 1999; Joseph and Andreotti, 2008). Overexpression of His-tagged BiP-C2 
fusion protein chimeras when cultured at 37
o
C resulted in protein aggregation, forming 
inclusion bodies. Inclusion bodies are very difficult to work with as they require solubilisation 














usually result in the loss of some of the target protein. To avoid this scenario, His-tagged BiP-
C2 fusion protein chimeras‘ expression was attempted at lower temperatures. Expression of 
His-tagged BiP-C2 chimeras at 16
o
C for 24 h had no effect on protein solubility (Fig. 2.16). 
Expression at 22
o
C did not improve solubility for most protein chimeras either (Fig. 2.17), 
except for BiP69 which had partially soluble protein (Fig. 2.17 Panel B, lane 2).  
 
Figure 2.16: Expression of His-tagged BiP-C2 fusion protein chimeras in Terrific Broth at 16
o
C for 24 h. A 
single colony from BiP69-C2, BiP60-C2, PBD-C2 or BiP69 recombinant E. coli BL21DE3 clones was picked 
from a plate and inoculated in Terrific Broth. The colony was cultured at 37
o
C overnight and the culture diluted 
(1:50) in new Terrific Broth, before being further cultured for 24 h at 16
o
C. Protein expression and solubility was 
analysed on a 10% SDS-PAGE gel, followed by staining in Coomassie blue R-250. Lane 1, Biosciences low 
molecular weight marker (Amersham); lane 2, BiP69-C2 pellet; lane 3, BiP69-C2 supernatant; lane 4, BiP60-C2 
pellet; lane 5, BiP60-C2 supernatant; lane 6, PBD-C2 pellet; lane 7: PBD-C2 supernatant; lane 8, BiP69 pellet; 
lane 9, BiP69 supernatant; lane 10, non-recombinant E. coli BL21DE3cells. 
 
Figure 2.17: Expression of His-tagged BiP-C2 fusion protein chimeras in Terrific Broth at 22
o
C for 18 h. A 
single colony selected from His-tagged BiP69-C2 and BiP60-C2 recombinant E. coli BL21DE3 clones (A) and 
BiP69 recombinant E. coli BL21DE3 clones (B) were inoculated in Terrific Broth media and grown for 18 h at 
22
o
C. Protein expression and solubility was analysed on a 10% SDS-PAGE gel followed by staining in 
Coomassie blue R-250. A: lane 1, Biosciences molecular weight marker (Amersham); lane 2, BiP69-C2 pellet; 
lane 3, BiP69-C2 supernatant; lane 4, BiP60-C2 pellet; lane 5, BiP60-C2 supernatant. B: Lane 1, Biosciences low 
molecular weight marker; lane 2, BiP69 pellet; lane 3, BiP69 supernatant; lane 4, E. coli BL21DE3 cells.  
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Failure to express soluble His-tagged BiP-C2 fusion protein chimeras at lower temperatures, 
meant that proteins required purification under denaturing conditions, and refolding of 
denatured proteins to their native form for immunisation experiments. The expression of His-
tagged BiP-C2 fusion protein chimeras was confirmed by western blot. Proteins separated on a 
SDS-PAGE gel were transferred onto a nitrocellulose membrane and probed with chicken 
anti-BiP IgY antibodies and chicken anti-congopain N-terminal peptide antibodies, to confirm 
that both BiP and C2 were present in each of the chimeras (Fig 2.18).  
 
Figure 2.18: Western blot analysis of expressed BiP-C2 chimeras using chicken anti-congopain N-terminal 
peptide and chicken anti-BiP antibodies. Expressed His-tagged BiP-C2 chimeras were probed with anti-BiP 
(A) and anti-congopain N-terminal peptide (B) antibodies (1 µg/ml) and HRPO linked rabbit anti-chicken 
antibodies (1:10 000) used as a secondary antibody. A & B: M, Biosciences molecular weight marker; lane 1, 
BiP69-C2 pellet; lane 2, BiP60-C2 pellet; lane 3, ATPD-C2 pellet; lane 4, PBD-C2 pellet; lane 5, C-term-C2 
pellet; lane 6: BiP69 pellet; lane 7, C2 pellet; lane 8, E. coli BL21DE3 cells. 
 
Anti-BiP antibodies (Fig. 2.18, Panel A) were able to detect BiP69-C2 (lane 1), BiP60-C2 
(lane 2), ATPD-C2 (lane 3) and BiP69 (lane 6) but could not detect PBD-C2 and C-term-C2 
(lanes 4 and 5). This can be explained by the fact that the anti-BiP antibodies recognise N-
terminal epitopes of BiP, and thus cannot detect the variable C-terminal and conserved peptide 
binding domains. Anti-congopain N-terminal peptide antibodies detected expression of all 
His-tagged BiP-C2 fusion protein chimeras (Fig. 2.18, Panel B). Non-specific interaction is 
observed for both anti-BiP and anti-congopain N-terminal peptide antibodies, as bands at 
smaller sizes were detected. Some of these bands are attributable to the degradation of fusion 


















Efforts to re-clone ATPD-C2 to obtain a chimera of the expected size using new ATPD clones 
were unsuccessful, as some clones either did not express or expressed at 50 kDa, a much 
smaller size than expected (Fig 2.19, Panel A, lanes 2-5). Probing of His-tagged ATPD-C2 
fusion protein chimera by western blot confirmed that only the ATPD part of the ATPD-C2 
chimera was being expressed at 50 kDa (Fig. 2.19, Panel B, lanes 7 and 8). Probing with anti-
congopain N-terminal peptide antibodies did not detect C2 as a fused chimera at 70 kDa as 
expected but only C2 at 27 kDa (Fig 2.19, Panel C, lane 13). Sequencing of the pET-28a-
ATPD-C2 plasmid DNA did not show any mutations or insertion of a stop codon causing 
incomplete expression of the chimera. 
 
Figure 2.19: Expression of ATPD-C2 in Terrific Broth and analysis with western blotting using anti-BiP 
and anti-congopain N-terminal peptide antibodies. Recombinant clones of ATPD-C2 were expressed in 
Terrific Broth and analysed using 10% SDS-PAGE and staining with Coomassie R-250 dye (Panel A). Expressed 
ATPD-C2 chimeras were probed with mouse anti-BiP M1D2 monoclonal antibody at 1:2 000 dilution (Panel B) 
and chicken anti-congopain N-terminal peptide antibodies at 1 µg/ml (Panel C). Goat anti-mouse IgG HRPO 
conjugated (1:10 000) and rabbit anti-chicken IgY-HRPO (1:10 000) were used as secondary antibodies. A: lane 
1, Biosciences molecular weight marker (Amersham); lane 2, ATPD-C2 pellet in PBS clone 1; lane 3, ATPD-C2 
supernatant clone 1; lane 4, ATPD-C2 pellet in PBS clone 2; lane 5, ATPD-C2 supernatant clone 2. B: Western 
blot analysis of ATPD-C2 chimera using anti-BiP M1D2 antibodies; lane 6, Biosciences molecular weight 
marker (Amersham); lane 7, ATPD-C2 pellet in PBS; lane 8, ATPD-C2 supernatant; lane 9, BiP69 pellet control. 
C: lane 10, Biosciences molecular weight marker (Amersham); lane 11, BiP69-C2 control; lane 12, ATPD-C2 
supernatant; lane 13, ATPD-C2 pellet in PBS. The arrows show the respective proteins of interest. 
 
Cloning of all BiP fragments, namely BiP69, BiP60, ATPD, PBD and C-terminus as well as 
congopain catalytic domain (C2) into the pTZ57RT vector was successful. All constructs were 
sent for sequencing, and confirmed to be the expected sizes with no mutations. C2 was 
successfully sub-cloned into a pET-28a expression vector, followed by cloning of BiP 





















tagged C2 and BiP69 fusion proteins were successfully expressed in auto-inducing, glucose 
rich media (Terrific Broth) as insoluble inclusion bodies. Over- expression was observed at E. 
coli optimum growing temperature (37
o
C) and attempts to express these His-tagged fusion 
proteins at lower temperatures as soluble proteins were unsuccessful. The expressed proteins 
were confirmed to have both BiP and C2 segments, by western blot using chicken anti-BiP 
and anti-congopain N-terminal peptide antibodies.  
2.4 DISCUSSION 
African trypanosomiasis still remains a major problem in Sub-Saharan Africa (Simarro et al., 
2008; Hide and Tait, 2009; Welburn et al., 2009; Molyneux et al., 2010). The emergence of 
drug- and multi-drug resistance threatens livestock production and has already caused a 
decline in productivity (Bray et al., 2003; Shaw, 2004; Delespaux and de Koning, 2007; 
Delespaux et al., 2008). With no sign of new drugs on the market and delays in finding 
alternative and safe control methods such as vaccination, trypanosomiasis eradication remains 
difficult (Bhalla, 2002; Vale and Torr, 2004; Welburn et al., 2009). The concept of an anti-
disease vaccine strategy, targeting the disease rather than the parasite, was developed aiming 
to inhibit invariant antigens implicated in pathogenesis (Playfair et al., 1990; Authié, 1994; 
Antoine-Moussiaux et al., 2009). Congopain, implicated in the development of anaemia in the 
host (Authié, 1994) and recognised by sera from trypanotolerant cattle, is one of the invariant 
antigens under investigation for the development of an anti-disease vaccine (Authié et al., 
2001). The catalytic domain of congopain expressed in Baculovirus, has been used in 
immunisation studies in cattle (using RWL proprietary adjuvant from SmithKline-Beecham) 
(Authié et al., 2001). Although this adjuvant induced higher and more sustained antibody titres 
in cattle against congopain and reduced host symptoms were observed (e.g. cattle maintained 
weight with milder anaemia) upon infection with T. congolense IL 3000 parasites, there was 
no difference in the development of infection when compared to non-immunised cattle (Authié 
et al., 2001). 
The objective of the present study was to improve the immune response against C2/congopain 
by using a chaperone BiP as a molecular adjuvant, with the hope of raising robust humoral or 
cell mediated immune response capable of completely inhibiting C2 activity and reducing 




proprietary adjuvant (Authié et al., 2001), α2-macroglobulin (Huson et al., 2009), Adjuphos 
and Quil A (Bizaaré, 2008; Kateregga et al.  In preparation), ISA206 oil-in-water (Alain 
Boulangé pers. comm.), all with a hope of improving the immunogenicity of C2 and ideally 
attaining full protection of the host upon trypanosome infection. Antibodies from mice 
immunised with C2, co-administered with alum, or combination of Adjuphos and Quil A, and 
rabbits immunised with a C2-α2-macroglobulin complex, inhibited between 65-100% of 
C2/congopain activity (Bizaaré, 2008; Huson et al., 2009). However, only partial protection 
was provided when the animals were challenged with T. congolense (Bizaaré, 2008; Kateregga 
et al.  In preparation). 
In the present study, the results of construction of congopain catalytic domain (C2) fused to 
various domains of BiP, and their subsequent expression in a bacterial system is reported. In 
the design of these constructs, a truncated form of congopain, i.e. the catalytic domain (C2) 
was chosen, because it was found that chimeras containing the pro-domain of congopain have 
a propensity to cleave the chimeras while expressing in P. pastoris (Ndlovu, 2009). Although, 
it has been shown that the pro-domain is vital in the proper folding of the protease and 
maintenance of the inactive zymogen state (Lalmanach et al., 1998; Korde et al., 2008; 
Lanfranco et al., 2008), its proteolytic activity during protein expression and purification 
(Ndlovu, 2009), resulted in its removal from all constructs. T. congolense BiP, like other 
HSP70 members, has three functionally distinct domains: an N-terminal ATPase domain, the 
C-terminal peptide binding domain and a C-terminal domain. How these different domains 
stimulate the immune response is not fully understood (Robert, 2003; Lehner et al., 2004). 
However, Wang and co-workers (2002) and Li et al. (2006) have shown that truncated 
Mycobacterium HSP70 C-terminal peptide binding domain can stimulate C-C chemokine and 
cytokine production, tumor necrosis factor, IL-12, NO and dendritic cell maturation.  
To identify which domain of BiP has adjuvant potential, these domains of T. congolense BiP 
were fused to C2 in frame on the N-terminus, and expressed as recombinant fusion protein 
chimeras in a His-tagged pET-28a vector. It has been shown that antigens genetically fused to 
HSP70 are better delivered and presented to APCs, resulting in increased immune response 
when compared to antigens complexed to HSP70 or co-administered along with HSP70 (Ge et 




protein chimeras, namely full length BiP69-C2, BiP60-C2 (BiP69 devoid of the C-terminus), 
N-terminal ATPD-C2, C-terminal PBD-C2 and C-term-C2, were expressed as insoluble 
proteins retained in inclusion bodies. The C-terminus of T. congolense BiP has been shown to 
be highly immunogenic, with specific epitopes not found in other organisms, including 
trypanosonomal species (Bangs et al., 1993; Boulangé et al., 2002). The role played by the 
immunogenic 10 kDa C-terminal extension was also investigated, firstly by linking it to C2 
alone and secondly by excluding it from the BiP60-C2 and PBD-C2 constructs. Full length 
BiP69 and its truncated forms have been expressed as recombinant MBP fusion proteins in a 
pMAL bacterial system (Boulangé et al., 2002). Although truncated forms of BiP expressed 
predominantly as soluble proteins, full length BiP was expressed mostly as insoluble protein. 
This is consistent with studies reporting expression of other kinetoplastids BiP homologs in T. 
b. brucei and L. donovani, as insoluble proteins in E. coli (Bangs et al., 1993; Jensen et al., 
2002).  
Attempts to express and purify MBP fusion protein chimeras of full length BiP69 and its 
truncated form BiP60, genetically linked to C2, were unsuccessful (Ndlovu, 2009). This was 
attributed to the expression of chimeras as insoluble inclusion bodies, and difficulty in 
purification using amylose affinity chromatography, as higher and lower molecular mass 
bacterial proteins co-purified (Boulangé et al., 2002; Ndlovu, 2009). This expression as 
insoluble protein was thought to be the result of poor solubility of MBP fusion protein 
chimeras in a pMAL vector. Therefore, a vector with a small carrier protein was proposed, 
which would not interfere with immunisation studies, and would allow easy purification. An 
expression vector coding for polyhistidines is the preferred choice of carrier protein in protein 
purification (Arnau et al., 2006a; Arnau et al., 2006b). A small His-tag on fusion proteins 
often does not interfere with enzymatic characterisation of proteases (Morty et al., 2005).  
This is confirmed by studies on recombinant hamster BiP expressed in E. coli with six His-
residues on the N-terminus, which showed no interference with ATPase activity (Wei and 
Hendershot, 1995).  
All His-tagged BiP-C2 chimeras were expressed as insoluble inclusion bodies in E. coli. 
Protein aggregation can be due to a number of factors including specific DNA sequences 




structural protein synthesis, over-loading of the chaperone or refolding capacity of the 
expression host (Sijwali et al., 2001) and a change in primary protein structure, resulting from 
mutations (Baneyx, 1999; Ho et al., 2003; Jhamb et al., 2008).  
This meant that, a difficult purification procedure would be necessary, requiring solubilisation 
and refolding of each protein to its native state. His-tagged C2 and BiP69 fusion proteins were 
expressed at their respective expected sizes and with the exception of the His-tagged ATPD-
C2 fusion protein chimera, all other His-tagged BiP-C2 fusion protein chimeras were 
expressed at their expected sizes. Detection by western blotting using anti-BiP and anti-
congopain N-terminal peptide antibodies confirmed that all chimeras contained the required 
BiP domain and C2. The anti-BiP antibodies could not detect PBD-C2 and C-term-C2 
chimeras, as they appear to recognise only epitopes on the N-terminus of the BiP69 molecule. 
The non-specific binding observed may be due to cross-reactivity of the chicken anti-BiP 
antibodies with bacterial proteins. The recombinant BiP protein used for antibody production 
was cut out from an SDS-PAGE gel and it is possible that some bacterial proteins were also 
cut out and injected together with BiP, resulting in antibodies that cross-react with bacterial 
proteins. The anti-congopain N-terminal peptide antibodies detected all His-tagged BiP-C2 
fusion protein chimeras expressed at their expected sizes. 
The His-tagged ATPD-C2 fusion protein chimera was expressed at an unexpected size of 88 
kDa, and the construct was thus sent for sequencing. Sequencing results revealed that a 
random DNA sequence had been incorporated into the construct, so it was re-amplified and re-
cloned. Following re-cloning, the His-tagged ATPD-C2 fusion protein chimera was expressed 
as a partially soluble fusion protein chimera at a size of 50 kDa, much lower than the 66 kDa 
expected. Expression of His-tagged ATPD-C2 as a smaller protein could not be explained, but 
after probing with antibodies in western blotting, it was shown that mouse anti-BiP antibodies 
detected the ATPase domain of the BiP molecule, in the 50 kDa protein. Probing with anti-
congopain N-terminal peptide antibodies, detected a 27 kDa protein band in the soluble 
fraction that was possibly C2. The behaviour of ATPD-C2 fusion protein could not be 
explained, so it was omitted from the vaccination experiment. Furthermore, the ATPase 
domain has been shown in previous studies not to play a role in adjuvanticity of HSPs (Wang 




It has been shown that protein aggregation in E. coli can be reduced by culturing at lower 
temperature since it slows down the rate of protein expression, and thereby improving folding 
and increasing yield of soluble protein (Baneyx, 1999; Joseph and Andreotti, 2008). Attempts 





unsuccessful except for BiP69 which expressed some soluble protein at 22
o
C. Formation of 
inclusion bodies could be attributed to the bacterial chaperone system (DnaK-DnaJ, 
GroEL/ES) being inactive at lower temperatures and thus unable to facilitate refolding of 
expressed proteins (Joseph and Andreotti, 2008). Competent cells like the ArticExpress
®
 
system (Stratagene) have a chaperone system that can maintain activity at much lower 
temperatures (Joseph and Andreotti, 2008), and this system could be evaluated in future for 
the expression of these His-tagged BiP-C2 fusion protein chimeras.  
BiP69 is an ER localised soluble protein shown by its localisation tetrapeptide MDDL, and is 
not secreted in the cytoplasm during normal non-stress conditions (Bangs et al., 1993; 
Boulangé and Authié, 1994; Bangs et al., 1996; Jensen et al., 2002; Ikadai et al., 2005). 
However, with increased stress levels e.g. a significant drop in temperature, it can be partially 
secreted into the cytoplasm to assist with folding and trafficking of misfolded proteins (Vogel 
et al., 1990; Kumar et al., 1991; Pidoux and Armstrong, 1993; Boulangé et al., 2002; Jensen et 
al., 2002). This was observed when full length BiP was expressed at 22
o
C, but it could not 
assist in refolding the whole chimera. 
In the present study the congopain catalytic domain was successfully cloned into a pTZ57RT 
vector and subsequently sub-cloned into the pET-28a expression vector. The various BiP 
fragments were successfully sub-cloned into the pET-28a-C2 recombinant vector. His-tagged 
full length BiP69-C2, BiP60-C2, PBD-C2, C-term-C2, full length BiP69 and C2 transformed 
in E. coli BL21DE3 were over-expressed in inclusion bodies in E. coli. Lowering culturing 
temperatures had no effect in attaining soluble proteins, but full length BiP was partially 
soluble at 22
o
C. Antibodies against BiP recognised N-terminal epitopes of recombinant BiP 
while antibodies directed against N-terminal peptide of congopain recognised all expressed 
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ABSTRACT 
Kinetoplastid cysteine peptidases have been a target for chemotherapy and vaccine 
development against parasitic diseases. Congopain, the cysteine peptidase of Trypanosoma 
congolense, is associated with trypanotolerance in N‘Dama cattle and is a target for an anti-
disease vaccine strategy. In order to improve the presentation of the catalytic domain of 
congopain (C2) to the immune system, it was linked to the proposed molecular adjuvant, BiP. 
A further aim was to localise the domain(s) of BiP where the adjuvant properties reside. 
Consequently recombinantly expressed peptide binding domain (PBD)-C2, C-terminus-C2, 
BiP69-C2 and BiP60-C2 chimeras as well as a BiP69 fusion protein were purified and 
refolded by a Ni-NTA based one-step on-column refolding method.  Bacterial proteins co-
purifying with BiP69-C2 and BiP60-C2 chimeras were removed by incubation with 5 mM 
ATP in the dissociation buffer. Immunisation of Balb/c mice with the BiP69-C2 fusion protein 
chimera induced a higher antibody response to C2 compared to control groups.  BiP69-C2 and 
PBD-C2 chimeras and a mixture of BiP69 and C2 induced a robust antibody response to 
BiP69. Mice immunised with BiP69-C2 and PBD-C2 chimeras showed a better booster effect 
upon infection with T. congolense compared to control groups. Mice immunised with a 
mixture of BiP69 and C2 and with the PBD-C2 chimera cleared parasites and maintained very 
low levels of parasites 10-15 days earlier than mice immunised with other BiP-C2 chimeras 
and control groups and showed no clinical symptoms of the disease. There was no significant 
difference in percentage survival between BiP-C2 chimera immunised mice and control 






Trypanosoma congolense is the most prevalent and detrimental trypanosome species causing 
African animal trypanosomiasis (Hide, 1999). The disease costs to African agriculture are 
estimated to be more than 4.5 billion US$ per annum (Kristjanson et al., 1999).  The clinical 
symptoms in livestock infected with the disease include anaemia, weight loss, high fever and 
increased foetal abortion rates (Murray et al., 1982; Büscher and Lejon, 2004; Taylor and 
Authié, 2004). 
Control strategies include vector control using insecticides, insect traps, trypanocidal 
therapeutic drugs, clearing of forests and the use of trypanotolerant cattle. These strategies are 
largely ineffective or cause huge environmental concerns (Kabayo, 2002; Vale and Torr, 2004; 
Van den Bossche and De Deken, 2004; Welburn et al., 2009). Chemotherapy is the only 
available method of controlling established disease, but is limited by drug resistance and the 
absence of new drugs (Barrett et al., 2004; Holmes et al., 2004; Barrett et al., 2007; Delespaux 
and de Koning, 2007; Mamoudou et al., 2008) . There is currently no effective vaccine against 
African trypanosomiasis, due to difficulties in its development (Welburn et al., 2009; 
Molyneux et al., 2010). This is largely due to the highly variable surface glycoproteins 
covering the surface of the parasite, which enables it to evade the host immune system (Barry 
et al., 1985; Barry and McCulloch, 2009; Morrison et al., 2009).  
An anti-disease vaccine strategy was a concept proposed for design of a malarial vaccine, 
which aimed to control the disease rather than the parasite (Playfair et al., 1990). The strategy 
targets invariant antigens implicated in pathogenesis, and immunisation with these antigens is 
thought to protect animals by inducing a protective immune response (Playfair, 1991; Authié 
et al., 1993a; Authié, 1994; Authié et al., 2001). Partial protection has been achieved when 
immunising with a T. b. rhodesiense flagellar pocket antigen fraction (Mkunza et al., 1995), T. 
b. brucei  and T. evansi tubulin (Lubega et al., 2002; Li et al., 2007b), microtubule associated 
proteins (Rasooly and Balaban, 2004) and congopain of T. congolense  (Authié et al., 2001).   
Congopain, a major cysteine peptidase of T. congolense, is a target for an anti-disease vaccine, 
as it has been implicated in natural trypanotolerance of West African N‘Dama cattle. 




cattle, by mounting an antibody response that inhibited congopain activity (Authié et al., 
2001). Failure of congopain to fully protect the host against T. congolense infection has been 
attributed to its poor immunogenicity and insufficient presentation and delivery of its 
protective epitopes by conventional adjuvants (Authié et al., 2001; Lalmanach et al., 2002; 
Boulangé et al., 2011). Sera from trypanotolerant cattle consistently recognised the dimeric 
form of congopain, found at physiological pH (Serveau et al., 2003; Boulangé et al., 2011) 
and thought to contain the protective epitopes. In order to improve the immunogenicity of 
congopain, chimeras were produced with the molecular adjuvant, BiP, an ER localised HSP70 
of T. congolense. 
Heat shock proteins are members of the ―stress protein‖ superfamily (Pockley et al., 2008) and 
are chaperones involved in folding of newly synthesised and misfolded proteins, protein 
trafficking and degradation (Lindquist and Craig, 1988; Hartl, 1996; Hartl and Hayer-Hartl, 
2002; Bukau et al., 2006). Heat Shock Protein 70 (HSP70) is believed to play a vital role in 
regulation of the immune response, showing potential as an adjuvant in subunit vaccine 
development (MacAry et al., 2004; Tobian et al., 2005; Su et al., 2007; Li et al., 2009). This 
potential is exhibited by the HSP70 chaperoning of exogenous complexed peptides and 
internalisation by antigen presenting cells, through a receptor mediated endocytosis pathway 
(Lehner et al., 2004; Javid et al., 2007; Karyampudi and Ghosh, 2008; Nishikawa et al., 
2008). The internalised antigens are presented to MHC class I and II molecules eliciting T 
lymphocyte mediated immunity (Blachere et al., 1997; Ge et al., 2006; Li et al., 2006; Li et 
al., 2007a; Nishikawa et al., 2008).  
The structure of HSP70 comprises a 44 kDa N-terminal ATPase domain, an 18 kDa C-
terminal peptide binding domain and a 10 kDa C-terminal extension (Bukau and Horwich, 
1998; Hartl and Hayer-Hartl, 2002; Wang et al., 2002; Lehner et al., 2004; Javid et al., 2007). 
The ATPase and peptide binding domains are highly conserved across all species with 
sequence identity ranging from 45-70%. The C-terminal domain is highly variable and differs 
between species (Boulangé and Authié, 1994; Ikadai et al., 2005). It has been shown that 
mycobacterial HSP70 has adjuvant effects when linked to the major antigenic segment of 
Japanese encephalitis virus, antigenic epitopes of foot and mouth diseases virus, hantaviral 




resulting in significantly enhanced humoral and cellular responses (Ge et al., 2006; Li et al., 
2006; Li et al., 2007a; Su et al., 2007). 
Wang et al. (2002), did a study where either mycobacterial HSP70 or the C-terminal peptide 
binding domain (HSP70 359-610) was covalently linked to synthetic peptides, and the resulting 
HSP-peptide complexes were used for the immunisation of rhesus macaques primates and 
Balb/c mice. This induced maturation of dendritic cells and stimulation of  Th1 type polarised 
cytokines shown by higher serum IgG2a and IgG3 antibodies, as well as significantly higher 
induction of IL-12, TNF-α and NO and reduced autoantibody responses. It was also shown 
that removal of the ATPase domain of mycobacterial HSP70 was necessary for effective 
stimulation of monocytes to produce IL-12, TNF-α, NO and C-C chemokine.  
In this chapter humoral immune response of Balb/c mice when immunised with BiP-C2 fusion 
protein chimeras is reported. Different BiP-C2 fusion protein chimeras were previously 
constructed and recombinantly expressed (Chapter 2). Here the purification and refolding of 
His-tagged BiP69-C2, BiP60-C2, PBD-C2, and C-term-C2 fusion protein chimeras and BiP69 
from inclusion bodies is described. Balb/c mice were immunised with each purified BiP-C2 
chimera, C2 alone, or mixed with BiP69 or conventional adjuvants and the antibody response 
followed by ELISA. Mice were challenged by T. congolense infection and a possible booster 
effect of infection on antibody levels, parasitemia and disease progression monitored to 
evaluate the adjuvant potential of the different BiP domains.  
3.2 MATERIALS AND METHODS 
Materials 
Buffer salts and other common chemicals were obtained from Saarchem (South Africa), 
Merck (Germany) and Sigma-Aldrich (Germany) and were of the highest purity available.  
His-select™ Nickel affinity resin (Ni-NTA), His select™ Cobalt affinity resin (Co-NTA), 
Guanidine-HCl and Sephacryl S-300HR resin were obtained from Sigma (Munich, Germany). 
Chicken anti-congopain N-terminal peptide IgY antibodies (Mkhize, 2003) and chicken anti-
BiP IgY antibodies were in-house antibodies. Mouse anti-BiP N-terminal monoclonal 




from Dr A Boulangé. Horse anti-mouse IgG-HPRO conjugate and HPRO conjugated goat 
anti-mouse IgG antibodies were obtained from Jackson Immunochemicals (USA), and rabbit 
anti-chicken IgY-HPRO conjugate from Sigma (Steinhem, Germany). Nitrocellulose 
membrane was purchased from GE Healthcare (Frieburg, Germany) and Vacutainer
TM
 tubes 
from BD Vacutainer Systems (UK). Nunc-Immuno
TM
 96-well plates were from Nunc 
Intermed (Denmark). EndoTrap
®
 columns were obtained from Profos AG (Regensburg, 
Germany). 2,2-azino-di-[3-ethylbenzthiazoline sulfonate] (ABTS) was obtained from Roche 
(Germany). Procedures using animals received ethical approval from the University of 
KwaZulu-Natal animal ethics committee (reference number 069/2010/Animal). Pathogen free 
Balb/c mice were obtained from National Health Laboratory Services (Johannesburg, South 
Africa). Adjuphos
®
 and Quil A
®
 adjuvants were a gift from Erik Lindlad, Brenntag Biosector, 
Frederikssund, (Denmark).  
Methods 
3.2.1 Washing of insoluble inclusion bodies of His-tagged fusion proteins 
The pellet obtained from separating insoluble and soluble recombinantly expressed His-tagged 
fusion protein (Section 2.2.6.5) after lysis with lysis buffer was resuspended in PBS and 
centrifuged (10 000 x g, 15 min, RT). The resulting pellet was washed twice with 1% (v/v) 
Triton X-100, twice with water and twice with 1 M urea with centrifugation (10 000 x g, 5 
min, RT) after each wash. The supernatants were kept for SDS-PAGE analysis (Section 3.2.8). 
The resulting insoluble inclusion bodies were purified and solubilised following a method by 
Sijwali et al. (2001). The cell pellet was resuspended and washed twice with wash buffer 1 [2 
M urea, 20 mM Tris-Cl, 2.5% (v/v) Triton X-100, pH 8.0] and centrifuged (12 000 x g, 30 
min, 4
o
C) between each wash. The resulting pellet was washed twice with wash buffer 2 [20% 
(w/v) sucrose, 20 mM Tris-Cl, pH 8.0] and centrifuged (12 000 x g, 30 min, 4
o
C) between 
each wash. Finally the pellet was solubilised with solubilisation buffer (6 M guanidine-Cl, 20 
mM Tris-Cl, 500 mM NaCl, 10 mM imidizole, pH 8.0) overnight at RT. Solubilised sample 
was centrifuged (27 000 x g, 30 min, 4
o
C) and the resulting supernatant loaded onto a 1  ml 




3.2.2 Purification of His-tagged fusion proteins  
Insoluble His-tagged fusion proteins were first purified under denaturing conditions using a 
His-select™ Nickel affinity column. Small protein amounts and poor protein refolding limited 
this method and a one-step on-column refolding method was pursued which allows easy 
purification and refolding of bound proteins (Glynou et al., 2003; Lemercier et al., 2003). 
Partially soluble His-tagged BiP69 fusion protein was purified under native conditions using a 
His-select™ Nickel affinity column.  
3.2.2.1 Purification of insoluble His-tagged fusion proteins under denaturing conditions 
The insoluble fusion protein chimeras were purified under denaturation conditions on a His-
select™ Nickel affinity column according to the manufacturer‘s protocol (Sigma) with minor 
modifications involving washing with 20 mM imidazole to wash off non-specifically bound 
proteins and elution with 250 mM imidazole in a lower pH (6.3) buffer, followed by a further 
decrease in pH of the elution buffer to 4.6 with the omission of imidazole to elute strongly 
bound His-tagged proteins. Prior to use the column was equilibrated with 3 column volumes 
of Buffer A (100 mM NaH2PO4, 10 mM Tris-Cl, 8 M urea, pH 8.0). The solubilised sample 
was circulated over the column for an hour at RT or overnight at 4
o
C, and the unbound 
fraction kept. The Ni-NTA column was washed with 3 column volumes of Buffer A and 
washes collected in 1.5 ml aliquots. The column was washed with 20 mM imidazole in Buffer 
A, followed by washing with 3 column volumes of Buffer B (100 mM NaH2PO4, 10 mM Tris-
Cl, 8 M urea, pH 6.3). The fusion protein was eluted with 250 mM imidazole in Buffer B 
followed by a final elution with Buffer C (100 mM NaH2PO4, 10 mM Tris-Cl, 8 M urea, pH 
4.6). 
3.2.2.2 Purification of His-tagged fusion proteins by an on-column refolding method 
The His-select™ Nickel affinity column (1 ml) was washed with distilled water, recharged 
with 0.1 M NiCl, further washed with 5 ml distilled water before equilibrating with 5 ml 
solubilisation buffer (6 M guanidine-Cl, 500 mM NaCl, 20 mM Tris-Cl, 10 mM imidazole, 2 
mM β-mercaptoethanol, pH 8.0). The solubilised protein (5 ml) was mixed with resin in a 15 
ml conical tube and allowed to bind for 1 hour at RT or overnight at 4
o
C with rotation. The 
resin-protein mixture was packed into 2 ml Pierce
®




collected. The column was washed with 5 ml solubilisation buffer followed by a wash with 5 
ml Wash buffer (6 M urea, 500 mM NaCl, 20 mM Tris-Cl, 20 mM imidazole, 2 mM β-
mercaptoethanol, pH 8.0). The bound protein was refolded while absorbed on the column 
using a linear gradient of 6-0 M urea (30 ml, flow rate, 0.7 ml/min). The bound protein was 
further washed with 5 ml of Wash buffer without urea. The refolded protein was eluted using a 
linear gradient of 20 to 500 mM imidazole in elution buffer (500 mM NaCl, 50 mM Tris-Cl, 1 
mM β-mercaptoethanol, pH 8.0) in a total volume of 20 ml. The washes and eluted fractions 
were kept for analysis by reducing SDS-PAGE (Section 3.2.8).  
3.2.2.3 Purification of soluble His-tagged fusion proteins under native conditions 
The manufacturer‘s protocol (Sigma) was used for purification of soluble protein using a Ni-
NTA resin. His-tagged BiP69 soluble protein (5  ml) was mixed with 1  ml of His select™ 
Nickel affinity resin in a 15  ml conical tube, and binding effected overnight at 4
o
C by end-
over-end rotation or rotation for 1 hour at RT. The mixture was packed into a column (2 ml). 
The flow-through was collected and the column washed twice with 4 ml wash buffer (50 mM 
NaH2PO4, 300 mM NaCl, 20 mM imidizole, pH 8.0) and 1.5 ml samples collected. The 
column was finally eluted with four column volumes of elution buffer (50 mM NaH2PO4, 300 
mM NaCl, 250 mM imidazole, pH 8.0). All collected samples were analysed by SDS-PAGE 
(Section 3.2.8). 
3.2.3 Purification of His-tagged fusion proteins by molecular exclusion chromatography 
(MEC) 
A Sephacryl S-300 HR column (1.25 x 83 cm) was equilibrated with 50 mM Tris-Cl buffer, 
pH 7.5 and calibrated with a mixture of 2 mg/ml blue dextran (> 2 000 kDa) and 5 mg/ml each 
of bovine serum albumin (66 kDa), ovalbumin (45 kDa), carbonic anhydrase (34.3 kDa), soy 
bean trypsin inhibitor (21 kDa), and lysozyme (14 kDa). The fractions were eluted with 50 
mM Tris-Cl buffer and 2 ml fractions collected. The absorbance values at 280 nm (A280nm) 
were taken for each sample to construct a standard curve (Fig. 3.1). The calibration curve was 
constructed by determining the Kav of each standard protein. The void volume (Vo) of the 
column was determined using the elution volume (Ve) of blue dextran. The availability 
constant (Kav) was calculated based on the following equation: Kav = Ve –Vo/Vt - Vo, where 




volume (Dennison, 1999). The Kav-values were used to plot a standard curve of Kav vs log Mr. 
The protein sample (BiP69-C2 or BiP60-C2) was concentrated by dialysis against PEG 20 000 
to a volume equivalent to 2.5% of the column volume and loaded onto the column. Fractions 
of 2 ml each were collected, their A280nm monitored, and samples corresponding to the peaks 
of absorption at 280 nm analysed by reducing SDS-PAGE. 
 
 
Figure 3.1: Fischer’s plot of availability constant (Kav) of each standard protein against log Mr used to 
estimate Mr of proteins. The calibration mixture was applied to a Sephacryl S-300 HR column (1.25 × 83 cm) 
and eluted with 50 mM Tris-Cl buffer, pH 7.5 (25 ml.h
-1
, 4ºC). The availability constant (Kav) was determined for 
each protein standard. The equation of the slope is y = -0.9567x + 2.2222 with correlation co-efficient of 0.9656. 
3.2.4 Refolding of His-tagged fusion protein chimeras by stepwise dilution 
The denatured samples of each chimera eluted from the Ni-NTA column were pooled, the 
resulting sample reduced by addition of 10 mM DTT. The reduced protein was dialysed in a 
10 kDa cut-off dialysis tube against 1 L of renaturation buffer (50 mM L-arginine, 20 mM 
Tris-Cl buffer, pH 8.5, 20% (v/v) glycerol, 4 M urea, 0.05 mM reduced glutathione, 0.1 mM 
oxidized glutathione, 1 mM EDTA, 1 μM E-64, 1 μΜ leupeptin, 1 μM AEBSF) for 16 h at 
4
o
C. The urea concentration in the renaturation buffer was changed to 2 M and finally omitted 
in each successive dialysis step. The refolded protein was concentrated using ultrafiltration 
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3.2.5 Removal of co-purifying bacterial proteins by washing with dissociation buffer 
Removal of co-purifying bacterial proteins from His-tagged BiP69-C2 and BiP60-C2 fusion 
protein chimeras was achieved by a minor modification of the on-column refolding method 
using Ni-NTA affinity resin. Denatured His-tagged BiP-C2 fusion protein chimera was mixed 
with 2 ml of the Ni-NTA affinity resin and allowed to bind by mixing at 250 rpm either for 1 h 
at RT or overnight at 4
o
C. The on-column refolding protocol (Amersham) was followed using 
a 50 mM phosphate buffer, pH 8.0 containing (150 mM NaCl, 20 mM imidazole and 2 mM β-
mercaptoethanol). The column was incubated with dissociation buffer (20 mM HEPES, 10 
mM MgCl2, 150 mM NaCl, 50 mM KH2PO4, 5 mM ATP, pH 7.0) for 2 h at 4
o
C and further 
washed with phosphate buffer before elution with 500 mM imidazole in elution buffer (50 mM 
Tris-Cl, pH 7.4, 0.5 M NaCl, 1 mM β-mercaptoethanol). 
3.2.6 Expression of the catalytic domain of congopain (C2) in Pichia pastoris 
A glycerol stock of P. pastoris GS115 containing pPic9-C2 was streaked on a YPD plate [1% 
(w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) dextrose and 15 g/L bacteriological agar] 
containing ampicillin (50 µg/ ml) and incubated for two days at 30
o
C.  A single colony was 
picked and grown in 100 ml of YPD medium [1% (w/v) yeast extract, 2% (w/v) peptone, 2% 
(w/v) dextrose] with 50 µg/ml of ampicillin to prevent contamination. The culture was 
allowed to grow for 2-3 days at 30
o
C in an orbital shaking incubator.  These cells were 
transferred to 1 L of buffered glycerol BMGY medium [1% (w/v) yeast extract, 2% (w/v) 
peptone, 100 mM potassium phosphate buffer, pH 6.5 and 1.34% (w/v) yeast nitrogen base 
(YNB)] in a baffled flask. The culture was allowed to grow for a further 2 days at 30
o
C in a 
shaking incubator to increase biomass. The cells were harvested by centrifugation (5 000 x g, 
10 min, 4
o
C) and resuspended in 500 ml of buffered minimal medium (BMM) [100 mM 
potassium phosphate buffer, pH 6.5, 1.34% (w/v) YNB, 0.00004% (w/v) biotin and 0.5% (v/v) 
methanol]. The culture was grown in a baffled 2 L flask for a further 4-6 days in a 30
o
C 
shaking incubator to allow expression of C2. Methanol [0.5% (v/v)] was added daily during 
the expression period to induce continuous expression of C2 in P. pastoris. Cells were pelleted 
by centrifugation (5000 x g, 10 min, RT) and the supernatant kept at -20
o
C, as P. pastoris 




3.2.7 Purification of C2  
3.2.7.1 Three Phase Partitioning (TPP) 
The recombinantly expressed C2 containing supernatant (500 ml) was thawed and filtered 
through Whatman No 1 filter paper. Three phase partitioning (Pike and Dennison, 1989) was 
used as an initial method for concentrating and purification of recombinant C2. The pH of the 
supernatant was lowered to pH 4.2 with phosphoric acid to effect autocatalytical maturation of 
C2 to the active form of the peptidase. Tertiary butanol [30% (v/v), 250 ml] was added to 500 
ml of supernatant and C2 was precipitated out into the third phase by adding ammonium 
sulfate [40% (w/v), 300 g)]. The salt was completely dissolved by stirring and the mixture was 
centrifuged (6 000 x g, 10 min, 4
o
C) using a pre-chilled swing out rotor. The precipitated 
protein containing layer was collected at the interface between the aqueous and tertiary 
butanol layers and redissolved in phosphate buffered saline (PBS) [100 mM Na2HPO4, 2 mM 
KH2PHO4, 2.7 mM KCl and 137 mM NaCl, pH 7.2]. The protein was dialysed against several 
changes of PBS for 48 h at 4
o
C using 10 kDa cut-off snake Skin
®
 dialysis tubing (Rockford, 
USA), to remove any residual traces of tertiary butanol and salts. Reducing SDS-PAGE 
analysis of a C2 sample purified by TPP revealed that a further purification step was required 
to remove higher molecular weight proteins. 
3.2.7.2 Ion exchange chromatography 
A column (0.75 x 10 cm) was packed with Sephadex C-25 resin (Sigma) and equilibrated with 




C). The dialysed C2 protein sample (5 ml) 
was loaded and circulated through the column overnight at 4
o
C. The column was further 
washed with sodium acetate buffer until the A280 reached baseline. Five column volumes of a 
0 - 1 M NaCl gradient in sodium acetate buffer was used to elute bound protein and elution 
was monitored by measuring A280. The samples representing peak absorbance values were 
analysed by reducing 12% SDS-PAGE. Fractions containing purified C2 were pooled and 
concentrated using ultrafiltration (10 kDa cut-off Centricon YM-10, Rockford, USA). 
3.2.8 SDS-PAGE for analysis of proteins 
Analysis of protein samples was carried out in a 10% SDS-PAGE gel using a discontinuous 




gives the protein a negative charge. When negatively charged protein-SDS complexes are 
subjected to electrophoresis, they experience the same current and are separated based solely 
on molecular weight (Dennison, 1999). Proteins were separated through a large pore stacking 
gel, pH 6.8, and a small pore running gel at pH 8.8, allowing clear separation of proteins of 
different sizes. A mini-PROTEAN 3
® 
gel system (BioRad) was used to separate proteins. His-
tagged BiP-C2 fusion protein chimeras, BiP69 or C2 protein samples were mixed with an 
equal volume of reducing treatment buffer [125 mM Tris-Cl buffer, pH 6.8, 4% (w/v) SDS, 
20% (v/v) glycerol, 10% (v/v) β-mercaptoethanol] and boiled for 5 min before loading.  Low 
molecular weight markers (Amersham) comprising phosphorylase b (97 kDa), bovine serum 
albumin (66 kDa), ovalbumin (45 kDa), carbonic anhydrase (34.3 kDa), soy bean trypsin 
inhibitor (21 kDa) and lysozyme (14 kDa) were used to construct a calibration curve and 
included on all gels as a Mr reference. Electrophoresis was conducted in Tank buffer [250 mM 
Tris-Cl buffer, 192 mM glycine, 0.1% (w/v) SDS, pH 8.3] at 20 mA per gel. The proteins 
were stained with Coomassie brilliant blue R-250 [0.125 g (w/v) Coomassie blue R-250, 50% 
(v/v) methanol, 10% (v/v) glacial acetic acid]. The molecular size of protein bands were 
determined using a calibration curve prepared by plotting the relative mobility of protein 
molecular weight standards against the log of their molecular weight (Fig. 3.2) (Dennison, 
1999).  
 
Figure 3.2: Calibration curve of relative mobility of standard proteins against their log Mr used to 
determine Mr of proteins of unknown size. Biosciences low molecular weight markers (Amersham) contains: 
phosphorylase b (97 kDa), BSA (66 kDa), ovalbumin (45 kDa), carbonic anhydrase (34.3 kDa), soybean trypsin 
inhibitor (21 kDa) and lysozyme (14 kDa). The equation of the slope is y = -0.9203x + 1.9394 with a correlation 



























The detection limit for Coomassie blue is approximately 50-100 ng of protein. When more 
sensitive protein detection was required, a silver stain method with a detection limit of 1-10 ng 
described by Blum et al. (1987) was employed. Proteins with low concentration for detection 
were concentrated with a SDS/KCl precipitation method before loading. 
Silver staining 
Briefly, the gel was soaked in fixing solution [50% (v/v) methanol, 12% (v/v) acetic acid, 
0.05% (v/v) 37% formaldehyde] in a clean glass Petri dish overnight followed by washing in 
washing solution 1 [50% (v/v) ethanol] (3 x 20 min). The gel was then soaked in pretreatment 
solution [0.02% (w/v) Na2S2O3.5H2O] for 1 min, rinsed in dH2O (3 x 20 s), and soaked in 
impregnation solution [0.2% (w/v) AgNO3, 0.075% (v/v) 37% formaldehyde] (20 min). The 
gel was rinsed in dH2O (3 x 20 s) and immersed in developing solution [6% (w/v) Na2CO3, 
0.0004% (w/v) Na2S2O3.5H2O, 0.05% (v/v) 37% formaldehyde] until the protein bands 
became visible. The gel was washed in dH2O (2 x 2 min) and development stopped by 
immersing in stopping solution [50% (v/v) methanol, 12% (v/v) acetic acid] (10 min) before 
being washed in washing solution 2 [50% (v/v) methanol] for 20 min. 
3.2.9 Protein quantification assay 
Protein concentration was determined using two methods, namely BCA™ Protein Assay kit 
(Pierce, Rockford, IL, USA) and direct visualisation of protein bands on an SDS-PAGE gel 
and comparing with BSA protein standards of known concentration also separated on SDS-
PAGE under reducing conditions. For the BCA protein assay, reagent A was mixed with 
reagent B, in a 50:1 ratio to prepare the working reagent. Bovine serum albumin protein 
standards (25 – 2 000 µg/ml) were each mixed with working reagent (200 µl) in a Nunc
® 
96 
microtiter plate and incubated at 37
o
C for 30 min. The bicinchoninic acid in the working 
reagent interacts with proteins producing a purple coloured product which is measured at 595 
nm. A standard curve was constructed plotting absorbance at 595 nm vs standard BSA 





Figure 3.3: Calibration curve to quantify protein samples unknown concentration. The BCA protein assay 
was used to determine the absorbance of BSA standard protein samples (25 - 2 000 µg/ml) and a standard curve 
constructed. The equation of the slope is y = 0.0005x + 0.0119 with a correlation co-efficient of 0.9968.  
Quantification of proteins by direct visualisation was achieved by separating standard amounts 
of BSA (25 - 2000 µg/ml) on a 10% SDS-PAGE gel under reducing conditions followed by 
staining with Coomassie blue R-250. The concentration of proteins of unknown concentration 
was estimated by comparing protein band intensity against known protein standards (Fig. 3.4). 
 
 
Figure 3.4: Determination of BSA protein concentration by direct visualisation on a SDS-PAGE gel. The 
BSA protein standards (2 000 -  25 µg/ml) were mixed with an equal volume of reducing treatment buffer and 
boiled for 5 min before separation on a reducing 10% SDS-PAGE gel. Lane 1, Biosciences Low molecular 
weight marker (Amersham); lane 2, 2000 µg/ml; lane 3, 1500 µg/ml; lane 4, 1000 µg/ml; lane 5, 750 µg/ml; lane 
6,  500 µg/ml; lane 7, 250 µg/ml; lane 8, 125 µg/ml and lane 9, 25 µg/ml. After electrophoresis the gel was 
































3.2.10 Western blot using either anti-BiP, anti-congopain N-terminal peptide or anti-His-
tag antibodies 
Proteins separated by SDS-PAGE were transferred to a nitrocellulose membrane (Amersham 
Biosciences) as described by Towbin et al. (1979) for 1 h using a dry blotter (BioRad, 
Hercules, CA, USA) at 17 V, maximum current. The nitrocellulose membrane was transiently 
stained with Ponceau S [0.1% (w/v) Ponceau S in 1% (v/v) glacial acetic acid] to mark the 
positions of molecular mass standards and destained by adding a drop of 1 M NaOH to the 
distilled H2O used for rinsing the membrane. The unoccupied sites on the nitrocellulose 
membrane were blocked for 1 h with low fat milk powder in Tris Buffered Saline [5% (w/v) 
low fat milk powder, 20 mM Tris-Cl, 200 mM NaCl, pH 7.4], followed by washes (3 x 5 min) 
with TBS. This was followed by incubation for 2 h with primary antibody (affinity purified 
chicken anti-congopain N-terminal peptide antibodies (1 µg/ml) for C2 and mouse anti-BiP 
M1D4 or M1B2 monoclonal antibodies (1: 2000) or chicken anti-BiP antibodies (1 µg/ml) for 
BiP or HPRO-conjugated mouse anti-His-tag monoclonal antibodies (1: 500), diluted in 0.5% 
(w/v) BSA in TBS. This was followed by washes of the nitrocellulose membrane with TBS (3 
x 5 min) before it was incubated for 1 h with HRPO-conjugated secondary antibody diluted in 
0.5% (w/v) BSA in TBS (rabbit anti-IgY-HPRO conjugate or horse/goat anti-mouse IgG-
HPRO conjugate). The membrane was washed again in TBS (3 x 5 min) before being 
developed in substrate solution [0.06% (w/v) 4-chloro-1-naphthol, 0.1% (v/v) methanol, 
0.0015% (v/v) hydrogen peroxide (H2O2) in TBS]. This was left to develop in the dark until 
protein bands were visible.  
3.2.11 Endotoxin removal by EndoTrap® 
In the present study, endotoxins were removed from recombinantly expressed bacterial proteins 
before immunisation of mice using a polymaxin B based endotoxin affinity resin, EndoTrap
®
 
(Profos AG, Germany), according to the manufacturer‘s specifications. 
3.2.12 Immunisation of mice 
Mice were kept under pathogen free conditions in the Animal House in the School of 
Biological and Conservation Sciences, Pietermaritzburg campus, University of KwaZulu-
Natal. Six to eight weeks old female Balb/c mice (40) were put in 8 cages of 5 mice each. All 




was injected sub-cutenously. Insulin syringes (1 ml) with 27 guage needles (Terumo™) were 
used to inject mice on days 0, 7 and 14 at two sites in the abdomen or on the back under the 
skin. Mice were immunised either with PBS, C2 alone, C2 mixed with adjuvant mixture [Quil 
A (30 µg) and Adjuphos (1:1 ratio in volume)] in PBS, C2 mixed with BiP69 protein, PBD-
C2, C-term-C2, BiP69-C2 or BiP60-C2. All mice were immunised with 0.87 µmole of protein 
per mouse in a final volume of 100 µl. PBS was injected in a final volume of 100 µl. The mice 
were boosted with the same dose of each immunogen and were bled through the tail once per 
week and blood collected into heparinised capillary tubes. Capillaries were centrifuged in a 
micro-centrifuge for 5 min. The capillaries were broken at the interface between blood cells 
and plasma, and the plasma collected in microfuge tubes. 
3.2.13 Measuring antibody production by Enzyme Linked Immunosorbent Assay 
(ELISA) 
To follow antibody production in mice, 96-well microtitre plates (Nunc Intermed, Denmark) 
were coated with 150 µl per well of either of either recombinant C2 (1 µg/ml) or recombinant 
BiP69 (1 µg/ml) diluted in PBS overnight at 4
o
C. The unoccupied spaces of coated wells were 
blocked with 0.5% (w/v) BSA-PBS (200 µl per well) at 37
o
C for 1 h followed by washing 3 
times with 0.1% (v/v) PBS-Tween. Mouse plasma from each group was diluted 1:100 with 
0.5% (w/v) BSA-PBS and incubated in the wells (100 µl per well) for 2 h at 37
o
C. This was 
followed by washing 3 times with 0.1% (v/v) PBS-Tween before incubation with 120 µl per 
well of HPRO-conjugated goat anti-mouse IgG antibodies [diluted 1 in 10 000 in 0.5% (w/v) 
BSA-PBS] at 37
o
C for 1 h. Following 3 times washing with 0.1% (v/v) PBS-Tween, the plate 
was incubated in the dark with 150 µl per well of ABTS/ H2O2 substrate solution [0.05% (w/v) 
ABTS and 0.0015% (v/v) H2O2 in 0.15 M citrate-phosphate buffer, pH 5.0] for 15 min at RT. 
Once the green colour had developed sufficiently, the absorbance was read at 405 nm using a 
FLUORStar Optima Spectrophotometer (BMG Labtech, Offenburg, Germany). 
3.2.14 Infection of immunised mice with T. congolense parasites 
To determine protection efficacy of immunised mice, they were challenged by infection with 
blood stream forms of a chronic T. congolense IL1180 strain. Firstly, blood of Balb/c mice 
infected with T. congolense IL1180 strain was collected at high parasitemia levels by cardiac 




saline glucose [57 mM Na2HPO4, 3 mM NaH2PO4, 42 mM NaCl, 50 mM glucose and 1 mM 
hypoxanthine] in 50% (v/v) glycerol and live parasites counted using a Neubauer 
haemocytometer or counts per field of view using light microscopy at 20 x magnification 
(Paris et al., 1982). Immunised mice were infected with 10
3 
parasites per ml, 8 weeks after the 
last booster injection. Blood was collected every week from the tail and centrifuged (2 000 x 
g, 5 min). Parasites were counted using a Neubauer haemocytometer once every 3 days for the 
first 30 days and thereafter once every 4 days to estimate parasitemia burden. When necessary 
plasma was diluted with PSG to aid parasite counts. Packed cell volume (PCV) percentage 
was monitored to assess anaemia and disease progression, by measuring the proportion of 
blood volume that is occupied by red blood cells using capillary microhaematocrit 
centrifugation. The survival time and disease clinical symptoms after challenge were also 
monitored. Anti-C2 antibody levels were monitored over an 8 week period after the last boost 
to determine when antibody levels decreased sufficiently to perform the challenge with 
parasites. This was done to ensure that a possible booster effect of infection could be 
observed. 
3.2.15 Statistical analysis 
A two-way ANOVA test was used to determine wether there was a significant difference in 
the number of parasites over time post-infection between the experimental and control groups. 
Log Rank Student‘s t-test was used to determine if there was a significant difference in the 
percentage of mice survival between experimental and control groups. A p value of 0.05 or 






3.3.1 Washing of inclusion bodies from insoluble protein 
The BiP-C2 chimeras were expressed as insoluble proteins in inclusion bodies (shown in Fig. 
2.15). A washing step was required to remove bacterial proteins expressed along with the 
target His-tagged BiP-C2 fusion protein chimeras (Fig. 3.5).  
Upon washing with detergents all His-tagged BiP-C2 fusion protein chimeras seemed to be 
partially solubilised especially BiP69-C2 (96 kDa), BiP60-C2 (88 kDa) and BiP69 (73 kDa) 
(Fig. 3.5, Panels A, B and E, lanes 5-9). Some of the BiP-C2 inclusion bodies in the final 
pellet were also lost as a result of the washes (Fig. 3.5, Panels A-E, lanes 5-16). Most of BiP69 
was completely solubilised when washed with 1 M urea (Fig. 3.5, Panel E, lane 12) showing 
that it is partially soluble. Washes with buffers 1 (containing urea and Triton X-100) and 2 
(containing sucrose) significantly reduced the amount of bacterial proteins especially in the 
case of the PBD-C2 (47 kDa) and C-term-C2 (34 kDa) chimeras (Fig. 3.5, Panels C and D, 
lanes 5-16).  All BiP-C2 chimeras were completely solubilised by 8 M urea (Fig. 3.5, Panels 
A-E, lane 17). 
3.3.2 Purification of His-tagged BiP-C2 fusion protein chimeras using Ni-NTA affinity 
chromatography under denaturing conditions 
Purification of solubilised His-tagged BiP69-C2 and BiP60-C2 fusion protein chimeras, by 
Nickel affinity chromatography under denaturing conditions, resulted in co-purification of 
bacterial proteins (Fig. 3.6, Panels A and B, lanes 7-14). In contrast, co-purifying bacterial 
proteins were successfully removed from His-tagged PBD-C2 and His-tagged C-term-C2 
fusion protein chimeras by washes in buffers of decreasing pH and increasing imidazole 
concentration (Fig. 3.6, Panel C, lanes 12-14 and Panel D, lanes 9 and 10). Most His-tagged 
BiP-C2 fusion protein chimeras seemed to bind poorly to the nickel resin. Most of the protein 
either did not bind (Fig. 3.6, Panels A-D, lane 2) or was removed during washing steps, with 
20 mM imidazole (Fig. 3.6, Panel A, lanes 3-10, Panel B, lanes 3-9 and Panel C, lanes 3-10). 
Small amounts of the His-tagged BiP69-C2 fusion protein chimera were obtained and it co-
eluted with bacterial proteins. The His-tagged BiP60-C2 fusion protein chimera also co-eluted 




tagged PBD-C2 and His-tagged C-term-C2 fusion protein chimeras were eluted as pure 
proteins (Panel C, lanes 10, 12-14 and Panel D, lanes 9 and 10) and only required refolding.  
3.3.3 Refolding of denatured His-tagged BiP-C2 fusion protein chimeras by step-wise 
dialysis method against refolding buffers 
Since His-tagged PBD-C2 and C-term-C2 were successfully purified under denaturing 
conditions these proteins were refolded by step-wise dilution against refolding buffers with 
different urea concentrations, chaotrophic detergents and salts which promote refolding. 
Refolding of His-tagged BiP69-C2 and BiP60-C2 containing co-purifying bacterial proteins 
was also attempted to assess whether co-purifying bacterial proteins were associated with their 
denatured form.  
Upon refolding by dialysis, aggregated proteins were observed when samples were reduced 
and boiled before SDS-PAGE analysis as shown by protein bands above 97 kDa (Fig. 3.7, 
Panel A-C, lanes 3-5). However, this was not observed when protein samples were not 
reduced or boiled (Fig. 3.7, Panel A-C, lanes 6-9). Refolding of BiP-C2 fusion protein 
chimeras by dialysis in refolding buffer resulted in significant losses in protein and did not 
diminish co-purifying bacterial proteins shown by major bands at 90 kDa, 75 kDa, 50 kDa an 
some minor bands between 30 and 90 kDa (Fig. 3.7, Panels A-C, lanes 2-9). Refolding by 
step-wise dialysis required big vessels, large amounts of refolding buffer which requires 
expensive reagents i.e. L-arginine and glutathione (reduced and oxidized) and a further 
concentration step by ultrafitration, which escalated protein refolding and purification costs. 
Purified denatured His-tagged BiP69 and PBD-C2 chimera were not refolded by this method 
due to these reasons. Other purification and refolding methods were pursued which were less 
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kDa Figure 3.5: Washing and solubilisation of His-tagged BiP-C2 fusion 
protein chimeras and His-tagged BiP69 inclusion bodies. Insoluble 
His-tagged BiP-C2 fusion protein chimeras were washed with Triton X-
100, urea and sucrose to remove bacterial proteins and then solubilised. 
A, BiP69-C2; B, BiP60-C2; C, PBD-C2; D, C-term-C2; E, BiP69. 
Lanes 1 and 11, Amersham Biosciences molecular weight markers; 
lane 2, insoluble protein (pellet) in PBS; lane 3, soluble protein 
(supernatant); lane 4, supernatant of pellet resuspended in PBS after 
centrifugation; lanes 5 and  6, 1% (v/v) Triton X-100 wash 1 and  2; 
lanes 7 and  8, water wash 1 and  2; lane 9, 1 M urea wash 1; lane 10, 
inclusion bodies re-suspended in 1 M urea; lane 12, 1 M urea 
supernatant; lanes 13 and 14, wash buffer 1; lanes 15 and 16, wash 
buffer 2; lane 17, inclusion bodies solubilised with 6 M guanidine-Cl. 
The protein samples were mixed with an equal volume of reducing 
treatment buffer and boiled before being analysed by reducing 10% 
SDS-PAGE and stained with Coomassie blue R-250. The arrows show 







Figure 3.6: Purification of His-tagged BiP-C2 chimeras using Ni-NTA affinity column under denaturing conditions. Solubilised His–tagged protein: A, 
BiP69-C2; B, BiP60-C2; C, PBD-C2; D, C-term-C2 was adsorbed to the Ni-affinity resin. Following washes with buffer of progressively decreasing pH, 
containing 20 mM imidazole, protein was eluted with 250 mM imidazole. Lanes 1 and 11, Amersham Biosciences molecular weight marker; lane 2, unbound 
fraction; lanes 3 and 4, pH 8 buffer wash; lanes 5 and 6, 20 mM imidazole in pH 8 buffer wash; lanes 7 and 8, pH 6.3 buffer wash; lanes 9 and 10, elution with 
250 mM imidazole in pH 6.3 buffer; lanes 12, 13 and 14, pH 4.6 buffer elutions. The protein samples were mixed with an equal volume of reducing treatment 
buffer boiled, and analysed by 10% SDS-PAGE and stained with Coomassie blue R-250. The arrows show the respective proteins of interest. 
























































Figure 3.7: Refolding of BiP-C2 chimeras by step-wise dialysis method in refolding buffer with different 
concentrations of urea. Protein fractions eluted from Ni-chelate affinity columns (A, BiP69-C2; B, BiP60-C2; 
C, C-term-C2) were pooled, reduced with 10 mM DTT and subsequently dialysed against refolding buffer with 
decreasing urea concentrations. Lane 1, Amersham Biosciences molecular weight marker; lanes 2 and 6, sample 
in 4 M urea; lanes 3 and 7, sample in 2 M urea; lanes 4 and 8, sample in 1 M urea; lanes 5 and 9, sample in 0 M 
urea. Protein samples in lanes 2 - 5 were reduced and boiled and protein samples in lanes 6 - 9 were not boiled 
and not reduced and all samples were analysed by 10% SDS-PAGE under reducing conditions and stained with 
Coomassie blue R-250. The arrows show the respective proteins of interest. 
3.3.4 On-column refolding and purification of His-tagged BiP-C2 fusion protein 
chimeras using urea and imidazole gradients 
Each solubilised His-tagged BiP-C2 fusion protein chimera was adsorbed to a Ni-affinity 
resin. The bound protein was then washed and refolded using a decreasing urea gradient, and 
eluted using an increasing imidazole gradient (Fig. 3.8). On-column refolding and purification 
did not reduce the number of co-purifying bacterial proteins in samples containing His-tagged 
BiP69-C2 and BiP60-C2 fusion protein chimeras (Fig. 3.8, Panel A, lanes 10, 12-14; Panel B, 
lanes 13-16). On-column refolding and purification of His-tagged PBD-C2, His-tagged C-
term-C2 and His-tagged BiP69 fusion proteins using Nickel affinity chromatography was 
successful, resulting in the complete removal of co-purifying bacterial proteins (Fig. 3.8, Panel 
























His-tagged C-term-C2 fusion protein chimeras were eluted before elution with the imidazole 
gradient, they were washed off as pure proteins with 20 mM imidazole (Fig. 3.8, Panels C and 
D, lanes 3-5). Although the His-tagged BiP69 fusion protein was eluted at low concentration 
with 20 mM imidazole, it was refolded and purified to homogeneity (Fig. 3.8, Panel E, lane 
12). 
3.3.5 Purification of His-tagged fusion protein chimeras by molecular exclusion 
chromatography 




-affinity resins was 
unsuccessful as bacterial proteins were co-purifying with the target His-tagged fusion protein. 
To circumvent this, Sephacryl S-300 HR MEC, that separates proteins based on molecular 
weight, was attempted to remove the co-purifying lower molecular weight bacterial proteins. 
Proteins eluted as two peaks of 97 kDa and 66 kDa (Fig. 3.9, Panel A). Fractions 
corresponding to the absorbance peaks were analysed by reducing 10% SDS-PAGE (Fig. 3.9, 
Panel B). Separation of His-tagged BiP60-C2 fusion protein (97 kDa, arrow in Fig. 3.9) on 
molecular exclusion chromatography failed to remove bacterial co-purifying proteins at 66 
kDa, 45 kDa and 30 kDa (Fig. 3.9, Panel B, lanes 2-15). Bacterial proteins co-eluting with the 

































































kDa1 2 3 4 5 6 7 8 10 11 12 13 14 159 Figure 3.8: On-column refolding and purification of His-
tagged BiP-C2 fusion protein chimeras.  Solubilised His–
tagged protein: A, BiP69-C2; B, BiP60-C2; C, PBD-C2; D, 
C-term-C2; E, BiP69 was adsorbed to the Ni-affinity resin 
washed with 6 M guanidine-Cl, further washed with a urea 
gradient and eluted with an imidazole gradient: Lanes 1 and 
11, Amersham Biosciences molecular weight marker; lane 2, 
unbound fraction; lane 3, 6 M guanidine wash; lane 4, 8 M 
urea wash; lane 5, 6 M urea wash; lanes 6 - 9, urea gradient 
from 6 - 0 M; lane 10, 0 M urea wash; lanes 12-16, imidazole 
elution gradient from 20-500 mM. The arrows show the 






Figure 3.9: Purification of the His-tagged BiP60-C2 fusion protein chimera by molecular exclusion 
chromatography. A: Elution profile of BiP60-C2 on the Sephacryl S-300HR column (1.25 x 83 cm) equilibrated 
with 50 mM Tris-Cl buffer, pH 7.5. A total of 74 fractions (2 mL each) were collected at a flow rate (2.4 ml/min) 
and absorbance readings taken at 280 nm. B: Fractions 36-50 corresponding to 72 - 100 ml were further analysed 
by 10% reducing SDS-PAGE and silver stained. Samples were concentrated using SDS/KCl precipitation 
method, mixed with an equal volume of reducing treatment buffer and boiled before loading. Lanes 1 and 11, 
Biosciences low molecular weight marker (Amersham); lanes 2-16, peak fractions from Sephacryl S-300 HR (see 











































































3.3.6 Removal of co-purifying bacterial proteins by washing with dissociation buffer 
Removal of co-purifying bacterial proteins was achieved when denatured His-tagged BiP69-
C2 (Fig. 3.10, Panel A) and BiP60-C2 (Fig. 3.10, Panel B) fusion protein chimeras were 
allowed to bind for a longer time period to the Ni-NTA resin, incubated in dissociation buffer 
[20 mM HEPES, 5 mM ATP, 10 mM MgCl2, 150 mM KCl, pH 7.0] for 2 h at 4
o
C (Fig. 3.10, 
Panels A and B, lane 10) and refolded by a urea gradient in phosphate buffer (Panels A and B, 
lanes 5-9). These co-purifying bacterial proteins were suspected to be bacterial chaperones and 
co-chaperones which tend to bind target proteins especially proteins with similar properties 
e.g. BiP (Joseph and Andreotti, 2008). Protein yields were too small, but were relatively pure 
compared to other methods (Panel A, lanes 12-14 and Panel B, lane 13). Attempts to improve 
protein yields by binding protein to Ni-NTA for longer and using different buffers was 
unsuccessful.   
 
 
Figure 3.10: On-column refolding and purification of His-tagged BiP-C2 fusion protein chimeras using a 
Nickel affinity resin, with removal of co-purifying bacterial proteins by 5 mM ATP wash.  The Nickel-NTA 
resin was mixed with 4 M urea solubilised BiP69-C2 (A) or BiP60-C2 (B) protein (4 mL), and left to bind. The 
bound protein in the column was refolded with refolding buffer using a urea gradient from 4 - 0 M, before elution 
with imidazole and analysis on a 10% SDS-PAGE gel followed by staining with Coomassie R-250. Lanes 1 and 
11, Amersham Biosciences Low molecular weight marker; lane 2, unbound fraction; lane 3, 4 M urea wash; lanes 
4-9, urea gradient from 4-0 M; lane 10, dissociation buffer wash; lane 12, phosphate buffer wash; lanes 13 and 



























3.3.7 Purification of His-tagged BiP69 fusion protein under native conditions. 
Most of the His-tagged BiP69 fusion protein was solubilised by washing the pellet with 1 M 
urea buffer (Fig. 3.5, Panel E, lane 12). The solubilised protein was refolded by dialysis 
against PBS and purified on a Ni-NTA affinity resin. Soluble His-tagged BiP69 fusion protein 
was purified successfully under native conditions with relatively pure and high protein yields 
(Fig. 3.11, lanes 6 and 7). Most of bacterial co-purifying proteins were removed by washes 
before dialysis and also during purification on the column. Purification of soluble His-tagged 
BiP69 directly from expressed culture mediums was ineffective as significant amounts of 
bacterial proteins were co-purifying with BiP69 (results not shown).  
 
Figure 3.11: Purification of His-tagged BiP69 fusion protein under native conditions. Soluble His-tagged 
BiP69 fusion protein was allowed to bind with the Ni
2+
 affinity resin overnight at 4
o
C. The flow through was 
collected and the column washed twice with Tris-Cl buffer and eluted with 250 mM Imidazole. Lane 1, 
Bioscience Low molecular weight marker (Amersham); lane 2, BiP69 dialysed protein; lane 3, unbound material; 
lane 4, wash buffer 1; lane 5, wash buffer 2; lane 6, elution 1 with 250 mM imidazole in elution buffer; lane 7, 
elution 2 with 250 mM imidazole in elution buffer. The samples were mixed with an equal volume of reducing 
treatment buffer, boiled and analysed on a 10% SDS-PAGE gel before staining in Coomassie blue R-250. The 









3.3.8 Purification of C2 by three phase partitioning and ion exchange chromatography  
C2 expressed in large volumes of P. pastoris supernatant, was concentrated using three phase 
partitioning (TPP). This step was also suppose to serve as a purifying step to remove some 
expressed extracellular yeast proteins, but was unsuccessful as yeast proteins at 22 kDa and 38 
kDa were observed after concentration (Fig. 3.12, lane 3). C2 was further purified by 
removing contaminating yeast proteins using Sephadex C-25 ion exchange chromatography 
(Fig. 3.13, Panel A). Purification of C2 was successful as contaminating higher molecular 
weight yeast proteins were successfully removed by low salt concentrations, followed by C2 
elution at about 0.3 M NaCl (Fig. 3.12, Panel A). Analysis on reducing 12% SDS-PAGE gel 
showed C2 migrating at 27 kDa as expected (Panel B, lanes 3-10), but a further lower 
molecular weight band was observed at 20 kDa and is due to the autocatalytic activity of the 
peptidase that results in the production of the mature 23 kDa peptidase.  
 
 
Figure 3.12: Analysis of expression of C2 in Pichia pastoris and subsequent precipitation by TPP from 
culture supernatants. C2 supernatants were precipitated by TPP using 40% (w/v) NH2SO4 and 30% (v/v) t-
butanol. Lane 1, Biosciences low molecular weight marker; lane 2, C2 supernatant from culture (10 µl); lane 3, 
C2 precipitated sample after TPP, dialysed and re-suspended in PBS (10 µl). Samples were mixed with an equal 
volume of reducing treatment buffer, boiled before loading and analysed by 12% SDS-PAGE before staining in 















Figure 3.13: Purification of C2 by ion exchange chromatography on a Sephadex C-25 column. A: Elution of 
C2 on a Sephadex C-25 column (0.75 x 10 cm, 0.41 ml/min) with a 0-1 M NaCl gradient in 50 mM Na-acetate 
buffer pH 4.2. The protein elution profile was constructed by measuring absorbance at 280 nm for each fraction.  
The purity of proteins (20-42 ml) was assessed by 12% reducing SDS-PAGE and staining with Coomassie blue 
R-250. B:  Lane 1, Biosciences low molecular weight marker (Amersham); lane 2, unbound fraction; lanes 3-10, 
fractions from elution peak at 22-42 ml. 
3.3.9 Western blotting to detect purified proteins 
The identity of His-tagged BiP-C2 fusion protein chimeras, His-tagged BiP69 and C2 purified 
from P. pastoris was confirmed by western blotting using chicken anti-congopain N-terminal 
peptide antibodies that detected all BiP-C2 chimeras (Fig. 3.14, Panel A), mouse anti-BiP 
monoclonal antibodies (M1D4 and M1B2) that detected all N-terminal and C-terminal 






























































































antibodies that detected all His-tagged fusion proteins (Fig. 3.14, Panel C).  Purified His-
tagged BiP69-C2, 96 kDa (Panel A, lane 1), His-tagged BiP60-C2, 88 kDa (Panel A, lane 2), 
His-tagged PBD-C2, 47 kDa (Panel A, lane 3), and His-tagged C-term-C2, 34 kDa (Panel A, 
lane 4) and C2 (Panel A, lane 5) were detected at the expected sizes using anti-congopain 
antibodies. The same fusion proteins were detected at the expected sizes using anti-BiP 
monoclonal antibodies (Panel B, lanes 1-4 and lane 5, BiP69) with non-specific binding or 
degraded fusion protein chimeras observed in BiP69-C2 and BiP60-C2 fusion protein 
chimeras at 45 kDa, 66 kDa, 80 kDa (Panel A and B, lanes 1 and 2), and in PBD-C2 fusion 
protein chimera at 35 and 30 kDa (Panel A, lane 4). All chimeras were confirmed to have their 
His-tag intact, after purification at 96 kDa (BiP69-C2, lane 1), 88 kDa (BiP60-C2, lane 2), 47 
kDa (PBD-C2, lane 3) and 34 kDa (C-term-C2, lane 4). 
 
Figure 3.14: Western blot analysis of purified of BiP-C2, BiP69 and C2 fusion proteins using chicken anti-
congopain peptide, mouse anti-BiP monoclonal antibodies (M1B2 and M1D4) and mouse anti-His-tag 
monoclonal antibodies. Purified His tagged BiP-C2 fusion protein chimeras and C2 protein were probed with 
anti-congopain peptide (A), anti-BiP (B) and anti-His-tag (C) antibodies and either HPRO linked rabbit anti-
chicken antibodies (1:10 000) or HPRO-conjugated horse anti-mouse antibodies used as a secondary antibody. 
M, Biosciences molecular weight marker; lane 1, BiP69-C2; lane 2, BiP60-C2; lane 3, PBD-C2; lane 4, C-term-
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3.3.10 Determination of antibody response against C2 using an ELISA 
Eight groups of Balb/c mice were immunised with C2 alone, a mixture of C2 with Adjuphos/ 
Quil A, BiP69-C2, BiP60-C2, PBD-C2, C-term-C2 or a mixture of BiP69 and C2. The C2 
specific antibody response was followed by ELISA using pooled mouse plasma collected 
every week from each group of mice (Fig. 3.15). All groups of mice produced C2-specific 
antibodies after the first boost (week 1), except those immunised with PBS or C-term-C2. 
BiP69-C2 produced higher levels of C2-specific antibodies compared to the other responding 
groups, followed by groups immunised with C2 in Adjuphos/Quil A, BiP69/C2 mixture, PBD-
C2 and C2 alone. Upon infection with T. congolense at week 12, all mice showed a short-lived 
booster effect on antibody levels 7-14 days post infection, matching the observation of 
circulating parasites in the blood 6-12 days after infection as observed by microscopy. Mice 
immunised with BiP69-C2 and PBD-C2 showed the highest booster effect upon infection, 
suggesting better activation of memory B cells. Antibody response was only followed until 




















Figure 3.15: ELISA showing the anti-C2 antibody response of Balb/c mice when C2 was immunised with 
BiP-C2 chimeras and C2 with adjuvant.  Antibody response was monitored for BiP69-C2 ( ), BiP60-C2 (
), PBD-C2 ( ), C-term-C2 ( ), BiP69/C2 mixture ( ), C2 in Adjuphos/Quil A mix ( ), C2 alone (
) and PBS ( ) immunised mice. Microtitre plates were coated with C2 and incubated with pooled mouse 
plasma samples collected weekly. Goat anti-mouse IgG conjugated to HRPO followed by ABTS/H2O2 substrate 
solution were used in the detection of mouse antibodies. Absorbance was read at 405 nm and represents the 





















Mice immunised with BiP69-C2 gave a higher antibody response compared to those 
immunised with C2 alone and C2 administered with a mixture of Adjuphos/Quil A. Mice 
started producing anti-C2 antibodies by week 2, just after the first booster injection in all 
groups. Antibody production seems to peak at week 8 in most cases. Mice injected with PBS 
or immunised with C-term-C2 produced no antibodies against C2, while mice immunised with 
the BiP69/C2 mixture, C2 in Adjuphos/Quil A mixture and PBD-C2 showed relatively similar 
antibody responses. Mice immunised with BiP60-C2 had a low specific antibody response 
against C2 compared to those immunised with C2 alone, C2 in Adjuphos/Quil A or the 
BiP69/C2 mixture.  
Mice immunised with BiP69-C2, and PBD-C2 chimeras and as well as the BiP69/C2 mixture 
produced higher BiP69-specific antibody responses (Fig. 3.16). Mice immunised with BiP60-
C2 produced a significantly lower anti-BiP69 antibody response. All mice immunised with C2 
in the absence of BiP69 (C2 alone, C2 with Adjuphos/Quil A, C-term-C2 or PBS) produced 
no specific antibody response to BiP69 (Fig. 3.16). All groups showed a short-lived ‗booster 
effect of infection‘ on antibody levels 7-14 days post infection, matching the observation of 
circulating parasites in the blood 6-12 days after infection as observed by microscopy. Mice 
immunised with BiP60-C2 died at week 14 corresponding to 7-14 days post infection.  
 
Figure 3.16: ELISA showing anti-BiP69 antibody response of Balb/c mice immunised with BiP-C2 
chimeras.  Antibody response was monitored for BiP69-C2 ( ), BiP60-C2 ( ), PBD-C2 ( ), C-term-C2 
( ), BiP69/C2 mixture ( ), C2 in Adjuphos/Quil A ( ), C2 alone ( ) and PBS ( ) immunised 
mice. Microtitre plates were coated with BiP69 and incubated with pooled mouse plasma samples collected 
weekly. Horse anti-mouse IgG conjugated to HRPO followed by ABTS/H2O2 substrate solution were used in the 
detection of mouse antibodies. Absorbance was read at 405nm and represents the average of three replicates. 



















3.3.11 Infection and mice survival  
Immunised mice were infected with T. congolense IL1180, which causes a mild chronic 
infection, 8 weeks after the last booster injection and parasitaemia monitored. In all groups of 
mice parasites were only detected at day 5 post infection (Fig. 3.17, Panels A-E). Parasitaemia 
peaked at day 10 post infection and thereafter all groups seemed to control infection as 
parasites were cleared from the blood stream with successive waves of parasitaemia observed 
throughout the infection period in all groups. Mice immunised with PBD-C2 cleared 
circulating parasites in the bloodstream 10 days earlier compared to PBS and C2 groups (Panel 
C). Mice immunised with the BiP69/C2 mixture controlled parasitaemia levels 16 days earlier 
compared to PBS and C2 groups (Panel E). Control (PBS), C2, C2 in Adjuphos/Quil A, 
BiP69-C2 (Panel A), BiP60-C2 (Panel B) and C-term-C2 (Panel D) immunised groups failed 
to keep low parasitaemia levels throughout the infection period. Mice immunised with BiP60-
C2 showed a delayed infection, but did not survive the first peak of parasitaemia. The ability 
of mice to control parasitaemia after the first wave of parasitaemia correlated with their ability 












Figure 3.17: Parasitaemia levels of infected, immunised Balb/c mice.  All groups were infected with T. 
congolense IL1180 at week 12. Parasitaemia of immunised mice A, BiP69-C2 (green); B, BiP60-C2 (red); C, 
PBD-C2 (dark blue); D, C-term-C2 (black); E, BiP69/C2 mixture (purple) compared to control groups PBS (
), C2 ( ) and C2 in Adjuphos/Quil A ( ) was monitored by counting the number of parasites circulating in 
the bloodstream using a haemocytometer. Parasites were first counted once every two days, and then twice a 
week.  Statistical evaluation on number of parasites days post infection between PBS and experimental groups 
revealed p-values > 0.05 (two-way ANOVA test) and were considered not significant. 
Mice controlled infection by also controlling anaemia which was measured as the volume 































































































































had the lowest volume of red blood cells, and the levels recovered after parasite clearance 
from the blood stream (Fig. 3.18). Most groups consistently maintained lower anaemia levels, 
but did not a make full recovery. The BiP60-C2 group did not recover from anaemia with a 
PCV less than 30% at day 15 post infection. As a result all mice in this group died at day 16 
and 17 post-infection. 
 
Figure 3.18: Disease progression of immunised mice after infection shown by percentage of packed cell 
volume (PCV). Immunised mice were infected with T. congolense IL1180 at week 12 and anaemia levels 
monitored by measuring PCV.  Percentage PCV of BiP69-C2 ( ), BiP60-C2 ( ), PBD-C2 ( ), C-term-
C2 ( ), BiP69 and C2 mixture ( ), C2 in Adjuphos/Quil A ( ), C2 alone ( ) and PBS ( ) immunised 
mice was monitored by centrifuging pooled blood from each group of mice followed by measuring volume 
occupied by red blood cells in capillary tubes. Measurements were done in triplicate.  
There was no difference in mice survival when comparing the PBS control group and the BiP-
C2 chimera immunised mice (Fig. 3.19 and Table 3.1). In the group immunised with C2 alone 
60% of the mice died at days 36 and 37 post-infection, while 60% of those immunised with C2 
co-administered with Adjuphos/Quil A died at days 9, 36 and 41 post infection. In the group 
immunised with BiP69-C2 40% of mice died at day 11 and 17 post infection (Fig. 3.19, Panel 
A). In the group immunised with PBD-C2 only 20% of the mice died at day 10. No mice died 
in the C-term-C2 and BiP69/C2 mixture immunised groups (Panel D and E). All surviving 























Table 3.1: Number of immunised mice surviving in days post infection following T. congolense IL1180 
infection.   
Groups Death (dpi) Survival number % Survival 
PBS 11 4 80 
C2 36, 37 3 60 
C2+Adjuv 9, 36, 41 2 40 
BiP69+C2 nd 5 100 
PBD-C2 23 4 80 
C-term-C2 nd 5 100 
BiP69-C2 11, 17 3 60 
BiP60-C2 17, 18 9 0 
nd- no death 
dpi- days post infection 
 









































































































        
Figure 3.19: Kaplan-Meier curve showing survival of immunised mice after challenge with T. congolense 
IL1180. Comparison of survival of Balb/c mice immunised with A, BiP69-C2 (green); B, BiP60-C2 (red); C, 
PBD-C2 (dark blue); D, C-term-C2 (black); E, BiP69 and C2 mixture (purple) with control groups: PBS ( ), 
C2 ( ) and C2 in Adjuphos/Quil A ( ). Number of mice per group were expressed as percentage each group 
had five mice, with each mouse representing 20%. Percentage survival was recorded after intraperitoneal 
infection with 1000 living parasites. Statistical evaluation on median survival times of PBS and experimental 
groups revealed p-values > 0.05 (Log rank, student‘s t-test) and were considered not significant. 
3.4 DISCUSSION  
Kinetoplastid cysteine peptidases have been a target for both vaccine development and 
chemotherapy (Caffrey and Steverding, 2009). Vaccination of rodents with DNA coding for 
cysteine peptidases or with recombinant cysteine peptidases co-administered with or without 
adjuvants has shown partial or full protection of the host upon infection (Authié et al., 2001; 
Cazorla et al., 2008b; Fedeli et al., 2010). Vaccination with cysteine peptidases I, II and III of 
L. infantum, L. dovonani and L. braziliense respectively confer protection to susceptible mice 
against cutaneous and visceral leishmaniasis displaying high IgG2a and IgG1 antibody 
response, reduced parasite load and tissue damage (Rafati et al., 2006; Khoshgoo et al., 2008; 
Rafati et al., 2008). Vaccine development using cruzipain, a major cysteine peptidase in T. 
cruzi, displayed protective immunity when a prime-boosting immunisation was used inducing 
strong specific IgG  titres, reduced tissue damage and lower levels of parasitaemia when 
compared to controls (Cazorla et al., 2008a; Cazorla et al., 2008b). 
Congopain, a major cysteine peptidase in T. congolense, induces antibody production in 
N‘Dama cattle and is thought to be involved in trypanotolerance mitigating disease pathology 





























never been achieved when vaccinating with congopain or its catalytic domain (Authié et al., 
2001; Bizaaré, 2008). It is still not clear as to why congopain fails to give complete protection 
like other kinetoplastid cysteine peptidases and it is suspected that it is poorly presented to the 
immune system by the conventional adjuvants used in previous vaccination studies (Alain 
Boulangé pers. comm.). In order to improve the delivery of the catalytic domain of congopain 
to the immune system it was linked to BiP69, an ER localised HSP70 thought to have 
molecular adjuvant effects. A construct was prepared for the recombinant expression of fusion 
protein comprising the individual BiP domains linked to C2 in a His-tagged pET-28a vector. 
His-tagged fusion protein chimeras were over-expressed in a bacterial system as insoluble 
inclusion bodies. This part of the study was concerned with solubilising, refolding and 
purification of the BiP-C2 chimera fusion proteins and evaluating them in a mouse vaccination 
and challenge experiment.  
Inclusion body formation might have been promoted by the high number of cysteine residues 
in the BiP-C2 fusion protein chimera sequences as was suggested by Jungbauer and Kaar 
(2007). Inclusion bodies are less likely to be degraded and are easier to separate from soluble 
bacterial proteins by centrifugation (Katoh and Katoh, 2000; Singh and Panda, 2005).  
Washing of His-tagged fusion protein chimeras with chaotrophic detergents removed some 
bacterial proteins, although some target protein loss also occurred, thereby decreasing final 
yields. Some membrane-bound contaminating bacterial proteins are known to be difficult to 
remove even with stronger detergents and increased concentrations of detergents (Clark, 
2001). 
His-select Nickel affinity resins are commonly used in purification of His-tagged proteins, 
although relatively poor binding and low yields has been reported (Lichty et al., 2005). In the 
present study most protein was eluted by washes with low concentrations of imidazole and 
buffers of slightly deceasing pH. Changing the time allowed for adsorption to the resin, 
concentration of denatured protein loaded on the column and/or temperature at which these 
steps were conducted, did not improve binding capacity of His-tagged fusion proteins. 
Purification under denaturing conditions resulted in purification of PBD-C2 and C-term-C2 
chimeras to homogeneity but with poor yields, while BiP69-C2 and BiP60-C2 chimeras co-




Refolding of denatured fusion proteins, purified under denaturing conditions, was first 
attempted by a stepwise dialysis method. Low yields of refolded inclusion bodies by batch 
dialysis were obtained for all four chimeras attempted. The method was too lengthy requiring 
at least four days, it required expensive reagents and a further purification and concentration 
steps to remove co-purifying bacterial proteins thereby escalating refolding costs as is often is 
the case for inclusion bodies (Li et al., 2004; Jungbauer and Kaar, 2007). The co-purifying 
bacterial proteins in BiP69-C2 and BiP60-C2 chimeras could have promoted protein 
aggregation during the refolding step, thereby reducing folding yields as suggested by Singh 
and Panda (2005).  
The one-step, on-column refolding method is based on immobilised nickel affinity 
chromatography and allows simultaneous purification and refolding of His-tagged fusion 
protein by a gradual decrease in denaturant concentration (Glynou et al., 2003; Lemercier et 
al., 2003). High yields of pure refolded C-term-C2 and PBD-C2 chimeras were obtained using 
this approach. However, bacterial proteins co-eluted with BiP69-C2 and BiP60-C2 chimeras. 
His-tagged BiP69 fusion protein was successfully purified, but with poor yield. A one-step on-
column purification and refolding method was shown to give better recovery of folded protein 
compared to the dilution and dialysis methods. This method resulted in improved protein 
refolding, in a shorter time and with reduced cost of protein purification and refolding. Protein  
recovery was comparable to yields obtained in folding of a His-tagged T. brucei 
exopolyphosphatase (Lemercier et al., 2003), Toc75 (Rogl et al., 1998) and apoaequorin 
(Glynou et al., 2003) using one-step immobilised metal affinity chromatography.  
Attempts to remove co-purifying bacterial proteins by gel filtration and ion exchange 
chromatography were unsuccessful. It was then suspected that the co-eluting bacterial host 
proteins might be attached to target proteins by non-covalent interactions requiring a different 
purification approach. Host-encoded proteins, e.g. metal binding protein (WHP) (Wulfing et 
al., 1994) and apoaequorin (Sly D) (Inouye et al., 1989) are histidine rich and have a high 
affinity for divalent cations and tend to bind to Ni-NTA resins becoming difficult to remove 
(Glynou et al., 2003). It is possible that some of the co-purifying bacterial proteins could be 
WHP and Sly D proteins, observed at 27 and 29 kDa respectively, however the presence of 




that some of the co-purifying bacterial proteins were host co-chaperones like DnaK and DnaJ 
binding to target proteins as suggested by Rial and Ceccarelli (2002). Removal of co-purifying 
bacterial proteins has been achieved when fusion proteins were incubated with dissociation 
buffer with varying ATP concentrations (Rohman and Harrison-Lavoie, 2000; Rial and 
Ceccarelli, 2002; Joseph and Andreotti, 2008). Incubation of nickel bound His-tagged BiP60-
C2 and His-tagged BiP69-C2 fusion protein chimeras with dissociation buffer containing 5 
mM ATP, removed bacterial co-purifying proteins. However, poor adsorption of the His-
tagged fusion protein to the immobilised nickel affinity resin was observed, resulting in 
reduced recovery. Changing various parameters in an attempt to improve adsorption of His-
tagged fusion proteins to the nickel affinity resin was not successful and did not improve 
protein yields. His-tagged BiP69-C2 and His-tagged BiP60-C2 fusion protein chimeras were 
purified and refolded using an on-column refolding method, but were used as non-pure 
proteins for immunisation due to co-purifying bacterial proteins.  
Cysteine peptidases have been expressed as active enzyme in both bacterial (Eakin et al., 
1992; McGrath et al., 1995; Sanderson et al., 2000) and yeast systems (Aoki et al., 2003; 
Aloulou et al., 2006; Pillay et al., 2010; Boulangé et al., 2011). The catalytic domain of 
congopain, C2, was expressed in P. pastoris and purified by three phase partitioning and ion 
exchange chromatography to homogeneity for the vaccination study. The His-tagged BiP69 
fusion protein was purified successfully under native conditions using nickel affinity resin to 
homogeneity for the vaccination study. 
The identity of the purified PBD-C2 and C-term-C2 chimeras, BiP69 and C2 fusion proteins 
and the non-purified BiP69-C2 and BiP60-C2 chimeras were confirmed by western blotting 
using anti-BiP and anti-congopain N-terminal peptide antibodies. Non-specific interactions 
observed in the western blots of non-purified BiP69-C2, BiP60-C2 chimeras and purified 
PBD-C2 chimera are suspected to be degradation products from the unstable chimeras.  This 
may especially be the case for bands smaller than 30 kDa which are thought to be products of 
C2 hydrolysis. It is also possible that these chimeras were cleaved by the maturing C2 
peptidase which is part of the chimera, resulting in degradation products as C2 has been shown 




After removal of endotoxins, purified PBD-C2 and C-term-C2 chimeras, BiP69 and C2 and 
the non-purified BiP69-C2 and BiP60-C2 chimeras were used to immunise Balb/c mice. 
Inbred, susceptible Balb/c mice are widely used and provide an economical alternative model 
for research, especially when studying direct effects of trypanosomal specific antibodies and 
their role in parasite clearance and anaemia control (Taylor, 1998; Taylor and Authié, 2004; 
Naessens, 2006; Antoine-Moussiaux et al., 2008). 
Since African trypanosomes are extracellular haemoparasites, the humoral immune response 
of the host is the most dominant upon infection. Host antibodies can be protective: mediating 
parasite clearance, neutralising toxic products released by parasites and clearing immune 
complexes formed by the complement system (Taylor and Authié, 2004). Trypanotolerant 
N‘Dama cattle produce long-lived IgG responses to VSG, congopain and BiP69, implicating 
these antigens in trypanotolerance (Authié et al., 1993b; Lutje et al., 1995b; Taylor, 1998). 
This is confirmed by the secretion of IgM antibodies and proliferative T-cell response to VSG, 
congopain and BiP69, by activated spleen cells from susceptible cattle in vitro (Lutje et al., 
1996; Taylor et al., 1996; Taylor, 1998).   
In the present study, immunisation of T. congolense susceptible Balb/c mice with a BiP69-C2 
chimera produced a higher level of specific anti-C2 antibodies compared to immunisation with 
C2 mixed with BiP69 or conventional adjuvants. These results are comparable to those 
reported for vaccination of rodents using recombinant Hepatitis B virus surface protein and 
major antigenic segment of Japanese encephalitis virus E-protein linked to mycobacterial 
HSP70 and its C-terminal peptide binding domain, where they induced higher antibody titres 
compared to HSP70 mixed with antigens. The C-terminal peptide binding domain has been 
thus suggested as possible domain with adjuvant effect (Wang et al., 2002; Ge et al., 2006; Li 
et al., 2006). In the present study PBD-C2 induced moderate levels of anti-C2 antibodies, 
slightly lower levels than with BiP69-C2, but better in controlling parasitaemia burden and 
reducing disease induced pathology. This group also showed a better booster effect of T. 
congolense infection shown by much higher anti-C2 antibody stimulation. Booster effect of T. 
congolense infection have been shown in trypanotolerant N‘Dama cattle three years post 
infection producing specific anti-congopain and BiP69 antibodies (Lutje et al., 1995b; Lutje et 




most groups showing a similar pattern of infection and blood parameter to what was shown in 
a previous study (Kateregga et al. In preparation). It is possible that the removal of the C-
terminal domain reduced adjuvant potency of the peptide binding domain, suggesting a 
prominent role in the adjuvant effect of the BiP molecule. This has not been shown in other 
studies, however the epitopes binding to antigen presenting cells have been localised on the C-
terminal peptide binding domain (Zitzler et al., 2008). It would be necessary to find the exact 
role of the C-terminal domain in adjuvant effect by comparing peptide binding domain with or 
without the C-terminal domain. 
In leishmaniasis the prime-boost vaccination with cysteine peptidase type I, II and III of L. 
infatum co-administered with either CpG-deoxyoligonucleotide (ODN) or Montanide 720 
induced a strong antibody response and gave significant protection shown by reduced footpad 
lesions and liver parasite load (Rafati et al., 2006; Khoshgoo et al., 2008).  In Chagas‘ disease, 
vaccination with cruzipain mixed with either macrophage activating lipopeptide-2 (MALP-2) 
or CpG- ODN induced a strong cruzipain specific IgG antibody response that was adequate in 
controlling T. cruzi infection shown by reduced parasite load and tissue damage (Cazorla et 
al., 2008a; Cazorla et al., 2008b). Furthermore, there was a significant percentage mice 
survival in groups prime-boosted with recombinant cruzipain protein admixed with MALP-2 
(Cazorla et al., 2008b).  In the present study no significant differences in percentage mice 
survival could be deduced as only 20% of the mice in the PBS control group died upon 
infection, suggesting that the T. congolense strain IL1180 used is not particularly pathogenic 
in mice. 
Leishmania major HSP70 and its peptide binding domain induced a strong humoral immune 
response in Balb/c mice, however, this failed to reduce lymph node parasitaemia burden and 
dermal pathology (Rafati et al., 2007). These observations suggested that HSP70 is not 
involved in control of cutaneous leishmaniaisis in rodents. In contrast earlier findings on L. 
donovani showed that ER-localised BiP co-administered with Freund‘s adjuvant played a role 
in controlling parasitaemia burden in lymph nodes and foot pad dermal pathology leading to 
control of cutaneous leishmaniasis (Jensen et al., 2002). In the present study mice immunised 
with BiP69-C2, and PBD-C2 chimeras as well as a BiP69/C2 mixture induced a robust 




of parasitaemia levels and reduced disease pathology as the BiP69-C2 chimera immunised 
group succumbed to severe clinical disease pathology on day 27 after T. congolense challenge. 
Survival is an imprecise parameter to assess vaccine induced protective antibody mediated 
immunity in mice challenged with T. brucei or T. congolense (Antoine-Moussiaux et al., 
2008). Susceptible Balb/c mice do not necessarily die from uncontrolled anaemia or high 
parasitaemia, but they can die from systemic inflammatory response syndrome, renal failure, 
central nervous system invasion and opportunistic infections as a result of immuno-depression 
(Stijlemans et al., 2007; Antoine-Moussiaux et al., 2008; Radwanska et al., 2008; Noyes et al., 
2009). In addition, death can also be dependent on mouse strain, trypanosome species and 
strain and diseases stage (Antoine-Moussiaux et al., 2008; Noyes et al., 2009).  
Mechanisms underlying control of trypanosomal infections in rodents and cattle are not well 
understood with few authors suggesting immune cytokines such as INF-γ, TNF-α, NO and B-
cells secreting IgG1, IgG2a and IgG3a as being crucial factors in phagocytosis, parasite 
clearance, long lasting immunity and control of infection (Lutje et al., 1995b; Taylor, 1998; 
Magez et al., 2006). In the present study it was shown that the anti-C2 antibodies produced by 
immunisation with PBD-C2 were likely to be involved in clearing of parasitaemia and disease 
induced pathology, showing similar observations to trypanotolerant cattle. 
In conclusion, these results showed that vaccination of Balb/c mice with a BiP69-C2 chimera 
induces an increased IgG antibody response compared to vaccination with C2 alone, or with 
C2 mixed with Adjuphos/Quil A, BiP69 mixed with C2 and the PBD-C2 chimera. Mice 
immunised with BiP69-C2 and PBD-C2 chimeras showed a better booster effect upon 
infection with T. congolense compared to control groups. There was no significant difference 
in the percentage mice surviving between controls and BiP69-C2 chimera immunised mice. 
Mice immunised with a BiP69/C2 mixture and with a PBD-C2 chimera cleared parasites and 
maintained very low levels of parasites 10-15 days earlier and showed no clinical symptoms of 
the disease. The role of the C-terminus on the adjuvant effect of HSP70 still needs to be 
further investigated. Now that its has been established that BiP69 has adjuvant effects and that 
its PBD region acts as an adjuvant alone, it would be interesting to repeat this study in 




4 GENERAL DISCUSSION 
African animal trypanosomiasis (nagana) is a devastating disease which remains a major 
constraint to livestock based agriculture and significantly impacts on millions of people in 
sub-Saharan Africa (Büscher and Lejon, 2004; Hide and Tait, 2009; Welburn et al., 2009; 
Salifu et al., 2010). The disease cost in this region is estimated to be more than $ 5 billion US 
per annum (Kristjanson et al., 1999; Shaw, 2004). The disease is caused by parasites of the 
genus Trypanosoma and transmitted via tsetse flies of the Glossina species from one host to 
another (Akoda et al., 2008; Roditi and Lehane, 2008; Schofield and Kabayo, 2008; Masumu 
et al., 2010). In cattle, trypanosomiasis has characteristic symptoms of high fever, chronic 
anaemia, enlarged liver and spleen, loss of appetite and subsequent weight-loss, reduced 
fertility, foetal abortion(s), and immunosupression that results in susceptibility to opportunistic 
infections (Murray et al., 1982; Taylor and Authié, 2004). 
Current control strategies include trypanocidal drugs, tsetse control and trypanotolerant cattle, 
none of which is entirely satisfactory. This is due to increasing drug resistance, the deleterious 
environmental impact of the insecticides and the small size of trypanotolerant cattle make their 
use not economically viable (Kgori et al., 2006; Delespaux and de Koning, 2007; Torr et al., 
2007; Schofield and Kabayo, 2008).  Hence, there is an urgent need for the development of 
new, effective control strategies. Variable surface glycoproteins (VSGs) covering the parasite 
is subject to antigenic variation, hindering vaccine development (Barry and McCulloch, 2009; 
Morrison et al., 2009).  Vaccine development targeting parasite invariant antigens such as T. 
b. rhodeisiense flagellar pocket antigens (Mkunza et al., 1995) and T. b. brucei and T. evansi 
tubulin (Lubega et al., 2002; Li et al., 2007b) have been shown to give partial protection, 
although attempts to reproduce these results in other trypanosomal species were unsuccessful. 
A concept called ‗anti-disease vaccine‘ was developed which aims at targeting the disease 
pathology rather than the parasitic infection itself (Playfair et al., 1990; Schofield, 2007). 
Invariant antigens released by parasites during infection or upon parasite death have been 
implicated in pathogenesis, and their inhibition is thought to have potential in inducing host 
protection (Playfair, 1991; Authié, 1994; Authié et al., 2001; Antoine-Moussiaux et al., 2009).  
Cysteine peptidases of kinetoplastids are targeted for vaccine development and chemotherapy. 




proteins, with or without co-administered adjuvants, has been shown to provide significant 
protection of mammalian hosts from disease upon infection (Authié et al., 2001; Cazorla et al., 
2008a; Fedeli et al., 2010; Kedzierski, 2010). The prime-boost vaccination with cysteine 
peptidase type I, II and III of L. infatum admixed with either CpG- deoxyoligonucleotide 
(ODN) or Montanide 720 induced strong antibody response and gave significant protection of 
mice against cutaneous leishmaniasis, as shown by reduced footpad lesions and liver parasite 
burden (Rafati et al., 2006; Khoshgoo et al., 2008).  Vaccination with cruzipain in either 
macrophage activating lipopeptide-2 (MALP-2) or CpG-ODN induced a strong cruzipain 
specific IgG antibody response capable of reducing parasite load and tissue damage in 
Chaga‘s disease (Cazorla et al., 2008a; Cazorla et al., 2008b). There was a significant 
percentage mice survival in groups prime-boosted with recombinant cruzipain protein 
admixed with MALP-2 (Cazorla et al., 2008b).   
Trypanotolerant N‘Dama cattle produce prominent IgG responses against congopain (Authié, 
1994; Taylor, 1998). This suggests that trypanotolerant cattle control the disease by antibody 
mediated neutralisation of congopain, and that immunisation of trypanosusceptible cattle with 
congopain may induce an immune response mimicking natural trypanotolerance, resulting in 
minimised disease pathology (Authié, 1994). Trypanosusceptible cattle immunised with the 
recombinant catalytic domain of congopain (C2) co-administered with the RWL proprietary 
adjuvant from SmithKline-Beecham mounted a high C2-specific IgG response that inhibited 
congopain activity. Immunisation had no effect on the establishment of T. congolense 
infection and acute anaemia development, but immunised animals showed faster recovery and 
high blood parameter during the chronic phase (Authié et al., 2001).  Immunisation of rabbits 
with C2 complexed to bovine or rabbit α2-macroglobulin (Huson et al., 2009), and mice with 
C2 co-administered with Adjuphos and Quil A (Bizaaré, 2008; Kateregga et al. In 
preparation), raised antibodies capable of inhibiting between 65 and 100% of C2 activity. 
Immunised mice were partially protected when challenged with T. congolense developing less 
severe chronic anaemia and reduced parasitemia burden compared to controls (Kateregga et 
al. In preparation). C2-immunised animals showed a better control of the disease and 
eventually of infection during chronic phase of the disease, but the effect remains limited. This 




conventional adjuvants. There is a need to improve C2 presentation to attain better immune 
responses mimicking that in trypanotolerant cattle. 
The objective of this study was first to improve the presentation of the native form of the 
catalytic domain of congopain (C2), by using the chaperone BiP (an ER localised HSP70) as a 
molecular adjuvant. Secondly, it was aimed to identify the specific domain of BiP where the 
adjuvant effect resides through analysing anti-C2 immune response in mice. Thirdly, it was 
aimed to compare anti-C2 antibody response raised by conventional adjuvants (Adjuphos/Quil 
A mixture) with that raised by the molecular adjuvant BiP, and lastly to compare BiP69 fused 
to C2 with C2 co-administered with BiP69.  BiP-C2 chimeras were first constructed by 
cloning C2 in a pET-28a expression vector before inserting BiP fragments namely BiP69, 
BiP60, PBD and C-term into the same recombinant plasmid. The various BiP-C2 fusion 
protein chimeras were expressed as insoluble proteins in inclusion bodies, purified and 
refolded using an on-column refolding method. Co-purifying bacterial proteins were removed 
by washing BiP69-C2 and BiP60-C2 chimeras with 5 mM ATP. However, low yields limited 
immunisation with pure protein. Purified recombinant proteins were used to immunise Balb/c 
mice in the hope of raising a robust antibody response to C2, capable of reducing its activity.  
The heat shock protein 70 has been shown to display adjuvant effects, inducing both humoral 
and cell-mediated immunity to complexed antigens. The immune response induced by HSP70 
is of type 1 cytokine polarised, although type 2 favoured cytokine responses are observed with 
some antigens. The type 1 cytokines are predominantly INF-γ, IL-2, TNF, as well as IgG2a 
and IgG2b, which all play key roles in pro-inflammatory and/or anti-inflammatory immune 
responses, that result in enhanced immunity to various disease pathogens (Planelles et al., 
2001; Wang et al., 2002; Lehner et al., 2004; Ge et al., 2006; Wang et al., 2006b; Karyampudi 
and Ghosh, 2008).  
The immunogenic potential of HSP70 in a vaccine strategy has been explored in L. major and 
L. donovani (Jensen et al., 2002; Rafati et al., 2007). Jensen et al., (2002) previously showed 
that BiP, an ER localised HSP70 of L. donovani, when used in prime-boosting experiments in 
murine models enhanced the healing of lesions when compared to controls, suggesting that 




response. In contrast, L. major HSP70 and its truncated forms were used in a prime-boost 
vaccination experiment and failed to reduce necrotic foot-pad lesions and lymph node 
parasitaemia burden. However, truncated C-terminus peptide binding domain and full length 
HSP70-immunised mice did induce a strong humoral IgG1 and IgG2 immune response before 
and after infection (Rafati et al., 2007). This work suggested that L. major HSP70 is not 
involved in inducing immune protection against cutaneous leishmaniasis. 
Host immune responses are crucial in controlling parasite load, parasite responses disease 
pathology and cell/host/parasite death (Stijlemans et al., 2007; Antoine-Moussiaux et al., 
2009; Baral, 2010). Host antibodies have been shown to play a major role in parasite control 
during trypanosome infection by interaction with surface proteins of parasites (Namangala et 
al., 2000; Magez et al., 2006; Naessens, 2006; Pays, 2006; Magez et al., 2008; Radwanska et 
al., 2008).  The key role of IgG in T. congolense and T. brucei parasite clearance has been 
confirmed in knock-out mouse studies (Namangala et al., 2000; Magez et al., 2006; Stijlemans 
et al., 2007; Magez et al., 2008). IgM was found not to have a role in parasite clearance in 
both T. congolense and T. brucei (Magez et al., 2006; Magez et al., 2008), but was found to 
play a role in T. evansi parasite clearance (Baral et al., 2007). In T. congolense clearance, the 
mechanism is thought to be IgG-mediated phagocytosis of opsonised parasites by 
macrophages and Kupffer cells (Shi et al., 2004).  
In the present study, most of immunised mice groups controlled the first wave of parasitaemia 
effectively, indicating better opsonisation of parasites by anti-C2 antibodies. Most groups 
including those immunised with PBS, C2 alone, C-term-C2 and BiP69-C2, developed severe 
pathology demonstrated by hair loss, and increased morbidity by day 25 post infection. The 
experiment had to be terminated due to increasing adverse pathology, clinical symptoms and 
immune suppression, common symptoms observed in cattle suffering from the disease at the 
later stages (Murray et al., 1982). Mice immunised with PBD-C2 and the BiP69/C2 mixture 
showed no clinical symptoms of the disease upon T. congolense infection, suggesting that 
anti-C2 antibodies produced were involved in controlling disease induced clinical symptoms. 
Significant differences in the percentage of mice surviving could not be deduced between 




with T. congolense IL1180 strain infection, as suggested in previous studies (Antoine-
Moussiaux et al., 2008; Noyes et al., 2009). 
In the present study, immunisation with BiP69-C2, and PBD-C2 chimeras as well as the 
BiP69/C2 mixture produced a robust antibody response to BiP69, but no correlation could be 
made on its contribution to control of parasitaemia levels or reduction of disease pathology, as 
the BiP69-C2 group succumbed to severe clinical disease pathology. This suggests that it is 
possible that BiP and its fragments may have played some role in controlling parasitaemia, 
however its involvement was in the capacity of an adjuvant rather than acting as an antigen 
itself.  
Radwanska et al., (2008) showed that T. brucei infections cause a rapid loss of splenic 
marginal zone B cells, hindering plasma cell differentiation and their specific protective 
antibody secretion induced by vaccination. These findings are worrying for the development 
of an anti-disease vaccine, which relies on raising a robust humoral antibody response to 
inhibit circulating parasite invariant antigens and the production, and later activation, of viable 
memory B cells for controlling disease upon secondary infections. In this study a significant 
booster effect of infection with T. congolense was observed when immunising with PBD-C2 
and BiP69-C2 suggesting activation of memory B cells secreting anti-C2 antibodies. This is 
promising as memory B cells secreting specific antibodies involved in disease control are 
crucial in attaining a successful anti-disease vaccination. 
Mice experimentally infected with T. congolense IL1180, do not necessarily die from 
uncontrolled anaemia or high parasitaemia, they rather develop chronic infection lasting for 
months (Noyes et al., 2009). During the chronic phase of the disease mice seem to eventually 
die from systemic inflammatory response syndrome, renal failure, central nervous system 
(CNS) invasion and opportunistic infections as a result of immune-depression (Stijlemans et 
al., 2007; Antoine-Moussiaux et al., 2008; Noyes et al., 2009). Mortality generally depends on 
mouse strain, trypanosome species and strain and the disease stage (Antoine-Moussiaux et al., 
2008; Noyes et al., 2009). Thus, survival is not an accurate parameter to evaluate the efficacy 




The role of mouse models in studying trypanotolerance and vaccine development against 
trypanosomiasis has been questioned (Naessens, 2006; Antoine-Moussiaux et al., 2008; Noyes 
et al., 2009). The susceptibility and tolerance of certain strains of mice to particular strains of 
trypanosomes complicates this model and its use in studying trypanosomiasis and mechanisms 
invoking trypanotolerance (Antoine-Moussiaux et al., 2008; Noyes et al., 2009; Baral, 2010). 
Nevertheless, mouse models are convenient to use, as they provide an economical alternative 
model for research, especially when studying the direct effects of specific antibodies and their 
role in parasite clearance and anaemia control. A major obstacle with the use of murine 
models is the lack of physiological correlation with N‘Dama cattle, in their development of 
trypanotolerance, making it hard to draw conclusions based on mouse models for use in cattle. 
Genetic crossbred mouse strains are promising for finding suitable murine models mimicking 
trypanotolerant West African N‘Dama cattle (Antoine-Moussiaux et al., 2008; Namangala et 
al., 2009).  
Some authors speculate that cysteine peptidases may be involved in facilitating trypanosomes‘ 
entry into the CNS in T. brucei species. Down regulation of brucipain by RNAi showed a 
reduced permeability of the blood brain barrier to parasite penetration (Nikolskaia et al., 2006; 
Abdulla et al., 2008). The recent identification of multi-copy genes of cathepsin L-like and B-
like cysteine peptidase variants which possess slightly differing catalytic triads and kinetic 
constants (Mendoza-Palomares et al., 2008; Pillay et al., 2010), suggests that these variants 
might also play essential but different roles in pathogenesis and parasite survival inside host, 
and that immunisation with one variant may not be sufficient in attaining complete inhibition 
of other circulating variants upon infection with T. congolense. Gene disruption technology of 
the cysteine peptidases has not been possible, due to difficulties with in vitro culturing of the 
parasite bloodstream forms where these peptidases are up-regulated (Mottram et al., 1996). 
Recently, a completed T. congolense in vitro life cycle culture provides new prospects for 
gene knockout and -down regulation technology of genes in blood stream forms that should 
contribute to identifying possible functions of cysteine peptidases, and provide a safe in vitro 
testing environment for possible chemotherapeutic agents against T. congolense (Coustou et 




In addition to the targeting of cysteine peptidases in vaccine development, they have also been 
targets of chemotherapy. Drugs currently available on the market are either no longer effective 
due to drug resistant parasites or they are too toxic for use e.g. first line therapy in human 
infection with severe T. b. rhodeisiense, with the arsenic based compound Melarsoprol, carries 
a 5% mortality rate from severe encephalitis which is entirely treatment (not disease) related. 
Cysteine peptidase inhibitors are being screened as possible chemotherapeutic agents for the 
treatment of trypanosomiasis and some are showing good pharmacokinetic and safety profiles 
in rodents, canines and primates (McKerrow et al., 2008; Kerr et al., 2009a; Mott et al., 2009). 
The anti-parasitic effects of cysteine peptidase inhibitors e.g. micromolar concentrations of 
irreversible vinyl sulfones, peptidyl methylketones fluoromethylketones its derivatives and 
small inhibitory molecules (Z-Phe-Ala-CNH2) are capable of killing parasites or inhibiting 
specific active cysteine peptidase enzymes in vivo and/or in vitro. Mice treated with these 
inhibitors cleared parasitaemia, altered trypanosomal cell division and morphology, with less 
degradation of host proteins and longer host survival (Scory et al., 2007; Abdulla et al., 2008; 
O'Brien et al., 2008). The advancement in obtaining crystal structures of T. brucei cathepsin B 
and of rhodesain, P. falcipurum falcipain-2 and falcipain-3 (Kerr et al., 2009b; Kerr et al., 
2010), L. major oligopeptidase B (McLuskey et al., 2010) and congopain of T. congolense in 
progress (Prof. T. Coetzer pers. comm.) are promising avenues in designing new 
peptidomimotopes which could potentially be used as chemotherapeutic agents.  
 
In summary, in this study it was shown that BiP/HSP70 of T. congolense has an adjuvant 
effect and that its peptide binding domain acts as an adjuvant alone, though with reduced 
effectiveness as compared to whole BiP. This study also showed that BiP linked to C2 gives 
better antibody response compared to simply mixing C2 with BiP or with conventional 
adjuvants (Adjuphos/Quil A). In addition, immunisation with PBD-C2 chimera raised an anti-
C2 antibody response able to clear circulating parasites. Immunisation did not affect 
establishment of T. congolense infection, but mice immunised with the PBD-C2 chimera and a 
mixture of BiP69 and C2 did not develop clinical symptoms of the disease upon infection with 
T. congolense, thereby mimicking trypanotolerant cattle. It is possible that the removal of the 
C-terminal domain reduced adjuvant potency of the peptide binding domain suggesting an 




domain in the adjuvant effect of BiP would involve comparing anti-C2 antibody response 
produced by immunisation with C2 linked to the peptide binding domain with or without the 
C-terminal domain. Ultimately, it would be of utmost interest to repeat this study in 
trypanosusceptible cattle to confirm these findings. This could then allow PBD or BiP69 to be 
used as general adjuvants to fuse with various pathogenic factors, in order to achieve full 
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Tabular results of statistical analysis using 2way ANOVA test comparing number of parasites days post infection between 
PBS group and experimental groups. The statistics were done using GraphPad Prism software.  
 
Source of Variation % of total variation P value     
Parasites 13.55 0.0003     
Days 43.05 < 0.0001     
          
Source of Variation P value summary Significant?     
Parasites *** Yes     
Days **** Yes     
          
Source of Variation Df Sum-of-squares Mean square F 
Parasites 7 4.185e+015 5.979e+014 4.370 
Days 14 1.330e+016 9.500e+014 6.944 
Residual 98 1.341e+016 1.368e+014   
          
Number of missing values 0       
          
Bonferroni multiple 
comparisons 
Number of comparisons: 
105 






PBS vs C2         
    Days PBS C2 Difference 95% CI of diff. Difference t P value Summary 
0 0.0 0.0 0.0 -5.980e+007 to 5.980e+007 0.0 0.0 P > 0.05 ns 
5 500000 0.0 -500000 -6.030e+007 to 5.930e+007 -500000 0.03023 P > 0.05 ns 
6 4.000e+006 1000000 -3.000e+006 -6.280e+007 to 5.680e+007 -3.000e+006 0.1814 P > 0.05 ns 
8 3.000e+007 1.000e+007 -2.000e+007 -7.980e+007 to 3.980e+007 -2.000e+007 1.209 P > 0.05 ns 
10 4.000e+007 4.000e+007 0.0 -5.980e+007 to 5.980e+007 0.0 0.0 P > 0.05 ns 
12 9.000e+006 1.000e+007 1000000 -5.880e+007 to 6.080e+007 1000000 0.06045 P > 0.05 ns 
15 5.500e+006 1.550e+007 1.000e+007 -4.980e+007 to 6.980e+007 1.000e+007 0.6045 P > 0.05 ns 
18 2.480e+007 4.400e+007 1.920e+007 -4.060e+007 to 7.900e+007 1.920e+007 1.161 P > 0.05 ns 
21 1.130e+007 1.530e+007 4.000e+006 -5.580e+007 to 6.380e+007 4.000e+006 0.2418 P > 0.05 ns 
24 1.550e+007 2.850e+007 1.300e+007 -4.680e+007 to 7.280e+007 1.300e+007 0.7859 P > 0.05 ns 
27 1.050e+007 1.600e+007 5.500e+006 -5.430e+007 to 6.530e+007 5.500e+006 0.3325 P > 0.05 ns 
30 1.750e+007 1.450e+007 -3.000e+006 -6.280e+007 to 5.680e+007 -3.000e+006 0.1814 P > 0.05 ns 
34 8.500e+006 6.250e+006 -2.250e+006 -6.205e+007 to 5.755e+007 -2.250e+006 0.1360 P > 0.05 ns 
38 2.600e+007 7.000e+006 -1.900e+007 -7.880e+007 to 4.080e+007 -1.900e+007 1.149 P > 0.05 ns 






PBS vs C2+Adjuv         
    Days PBS C2+Adjuv Difference 95% CI of diff. Difference t P value Summary 
0 0.0 0.0 0.0 -5.980e+007 to 5.980e+007 0.0 0.0 P > 0.05 ns 
5 500000 2.200e+006 1.700e+006 -5.810e+007 to 6.150e+007 1.700e+006 0.1028 P > 0.05 ns 
6 4.000e+006 2.500e+006 -1.500e+006 -6.130e+007 to 5.830e+007 -1.500e+006 0.09068 P > 0.05 ns 
8 3.000e+007 5.000e+007 2.000e+007 -3.980e+007 to 7.980e+007 2.000e+007 1.209 P > 0.05 ns 
10 4.000e+007 1.000e+008 6.000e+007 200122 to 1.198e+008 6.000e+007 3.627 P < 0.05 * 
12 9.000e+006 1.000e+007 1000000 -5.880e+007 to 6.080e+007 1000000 0.06045 P > 0.05 ns 
15 5.500e+006 4.000e+007 3.450e+007 -2.530e+007 to 9.430e+007 3.450e+007 2.086 P > 0.05 ns 
18 2.480e+007 3.000e+007 5.200e+006 -5.460e+007 to 6.500e+007 5.200e+006 0.3144 P > 0.05 ns 
21 1.130e+007 1.000e+007 -1.300e+006 -6.110e+007 to 5.850e+007 -1.300e+006 0.07859 P > 0.05 ns 
24 1.550e+007 2.000e+007 4.500e+006 -5.530e+007 to 6.430e+007 4.500e+006 0.2720 P > 0.05 ns 
27 1.050e+007 2.000e+007 9.500e+006 -5.030e+007 to 6.930e+007 9.500e+006 0.5743 P > 0.05 ns 
30 1.750e+007 1.000e+007 -7.500e+006 -6.730e+007 to 5.230e+007 -7.500e+006 0.4534 P > 0.05 ns 
34 8.500e+006 3.000e+006 -5.500e+006 -6.530e+007 to 5.430e+007 -5.500e+006 0.3325 P > 0.05 ns 
38 2.600e+007 2.000e+007 -6.000e+006 -6.580e+007 to 5.380e+007 -6.000e+006 0.3627 P > 0.05 ns 





PBS vs BiP69+C2         
    Days PBS BiP69+C2 Difference 95% CI of diff. Difference t P value Summary 
0 0.0 0.0 0.0 -5.980e+007 to 5.980e+007 0.0 0.0 P > 0.05 ns 
5 500000 50000 -450000 -6.025e+007 to 5.935e+007 -450000 0.02720 P > 0.05 ns 
6 4.000e+006 1000000 -3.000e+006 -6.280e+007 to 5.680e+007 -3.000e+006 0.1814 P > 0.05 ns 
8 3.000e+007 9.000e+006 -2.100e+007 -8.080e+007 to 3.880e+007 -2.100e+007 1.270 P > 0.05 ns 
10 4.000e+007 2.000e+007 -2.000e+007 -7.980e+007 to 3.980e+007 -2.000e+007 1.209 P > 0.05 ns 
12 9.000e+006 8.000e+006 -1000000 -6.080e+007 to 5.880e+007 -1000000 0.06045 P > 0.05 ns 
15 5.500e+006 3.000e+006 -2.500e+006 -6.230e+007 to 5.730e+007 -2.500e+006 0.1511 P > 0.05 ns 
18 2.480e+007 2.100e+007 -3.800e+006 -6.360e+007 to 5.600e+007 -3.800e+006 0.2297 P > 0.05 ns 
21 1.130e+007 2.520e+007 1.390e+007 -4.590e+007 to 7.370e+007 1.390e+007 0.8403 P > 0.05 ns 
24 1.550e+007 9.500e+006 -6.000e+006 -6.580e+007 to 5.380e+007 -6.000e+006 0.3627 P > 0.05 ns 
27 1.050e+007 7.400e+006 -3.100e+006 -6.290e+007 to 5.670e+007 -3.100e+006 0.1874 P > 0.05 ns 
30 1.750e+007 2.050e+006 -1.545e+007 -7.525e+007 to 4.435e+007 -1.545e+007 0.9340 P > 0.05 ns 
34 8.500e+006 3.000e+006 -5.500e+006 -6.530e+007 to 5.430e+007 -5.500e+006 0.3325 P > 0.05 ns 
38 2.600e+007 2.500e+006 -2.350e+007 -8.330e+007 to 3.630e+007 -2.350e+007 1.421 P > 0.05 ns 





PBS vs PBD-C2                 
Days PBS PBD-C2 Difference 95% CI of diff. Difference t P value Summary 
0 0.0 0.0 0.0 -5.980e+007 to 5.980e+007 0.0 0.0 P > 0.05 ns 
5 500000 50000 -450000 -6.025e+007 to 5.935e+007 -450000 0.02720 P > 0.05 ns 
6 4.000e+006 3.000e+006 -1000000 -6.080e+007 to 5.880e+007 -1000000 0.06045 P > 0.05 ns 
8 3.000e+007 3.000e+007 0.0 -5.980e+007 to 5.980e+007 0.0 0.0 P > 0.05 ns 
10 4.000e+007 3.000e+007 -1.000e+007 -6.980e+007 to 4.980e+007 -1.000e+007 0.6045 P > 0.05 ns 
12 9.000e+006 1.000e+007 1000000 -5.880e+007 to 6.080e+007 1000000 0.06045 P > 0.05 ns 
15 5.500e+006 2.010e+007 1.460e+007 -4.520e+007 to 7.440e+007 1.460e+007 0.8826 P > 0.05 ns 
18 2.480e+007 1.600e+007 -8.800e+006 -6.860e+007 to 5.100e+007 -8.800e+006 0.5320 P > 0.05 ns 
21 1.130e+007 1.000e+007 -1.300e+006 -6.110e+007 to 5.850e+007 -1.300e+006 0.07859 P > 0.05 ns 
24 1.550e+007 2.450e+006 -1.305e+007 -7.285e+007 to 4.675e+007 -1.305e+007 0.7889 P > 0.05 ns 
27 1.050e+007 1.250e+006 -9.250e+006 -6.905e+007 to 5.055e+007 -9.250e+006 0.5592 P > 0.05 ns 
30 1.750e+007 2.000e+006 -1.550e+007 -7.530e+007 to 4.430e+007 -1.550e+007 0.9370 P > 0.05 ns 
34 8.500e+006 1.150e+006 -7.350e+006 -6.715e+007 to 5.245e+007 -7.350e+006 0.4443 P > 0.05 ns 
38 2.600e+007 1.450e+006 -2.455e+007 -8.435e+007 to 3.525e+007 -2.455e+007 1.484 P > 0.05 ns 





PBS vs C-term-C2         
    Days PBS C-term-C2 Difference 95% CI of diff. Difference t P value Summary 
0 0.0 0.0 0.0 -5.980e+007 to 5.980e+007 0.0 0.0 P > 0.05 ns 
5 500000 50000 -450000 -6.025e+007 to 5.935e+007 -450000 0.02720 P > 0.05 ns 
6 4.000e+006 2.000e+006 -2.000e+006 -6.180e+007 to 5.780e+007 -2.000e+006 0.1209 P > 0.05 ns 
8 3.000e+007 2.000e+007 -1.000e+007 -6.980e+007 to 4.980e+007 -1.000e+007 0.6045 P > 0.05 ns 
10 4.000e+007 4.000e+007 0.0 -5.980e+007 to 5.980e+007 0.0 0.0 P > 0.05 ns 
12 9.000e+006 9.000e+006 0.0 -5.980e+007 to 5.980e+007 0.0 0.0 P > 0.05 ns 
15 5.500e+006 7.000e+006 1.500e+006 -5.830e+007 to 6.130e+007 1.500e+006 0.09068 P > 0.05 ns 
18 2.480e+007 4.900e+007 2.420e+007 -3.560e+007 to 8.400e+007 2.420e+007 1.463 P > 0.05 ns 
21 1.130e+007 1.860e+007 7.300e+006 -5.250e+007 to 6.710e+007 7.300e+006 0.4413 P > 0.05 ns 
24 1.550e+007 5.000e+007 3.450e+007 -2.530e+007 to 9.430e+007 3.450e+007 2.086 P > 0.05 ns 
27 1.050e+007 1.650e+007 6.000e+006 -5.380e+007 to 6.580e+007 6.000e+006 0.3627 P > 0.05 ns 
30 1.750e+007 1.550e+007 -2.000e+006 -6.180e+007 to 5.780e+007 -2.000e+006 0.1209 P > 0.05 ns 
34 8.500e+006 1.050e+007 2.000e+006 -5.780e+007 to 6.180e+007 2.000e+006 0.1209 P > 0.05 ns 
38 2.600e+007 4.200e+006 -2.180e+007 -8.160e+007 to 3.800e+007 -2.180e+007 1.318 P > 0.05 ns 





PBS vs BiP69-C2         
    Days PBS BiP69-C2 Difference 95% CI of diff. Difference t P value Summary 
0 0.0 0.0 0.0 -5.980e+007 to 5.980e+007 0.0 0.0 P > 0.05 ns 
5 500000 0.0 -500000 -6.030e+007 to 5.930e+007 -500000 0.03023 P > 0.05 ns 
6 4.000e+006 1000 -3.999e+006 -6.380e+007 to 5.580e+007 -3.999e+006 0.2418 P > 0.05 ns 
8 3.000e+007 3.000e+006 -2.700e+007 -8.680e+007 to 3.280e+007 -2.700e+007 1.632 P > 0.05 ns 
10 4.000e+007 5.000e+007 1.000e+007 -4.980e+007 to 6.980e+007 1.000e+007 0.6045 P > 0.05 ns 
12 9.000e+006 8.000e+006 -1000000 -6.080e+007 to 5.880e+007 -1000000 0.06045 P > 0.05 ns 
15 5.500e+006 2.000e+006 -3.500e+006 -6.330e+007 to 5.630e+007 -3.500e+006 0.2116 P > 0.05 ns 
18 2.480e+007 1.000e+007 -1.480e+007 -7.460e+007 to 4.500e+007 -1.480e+007 0.8947 P > 0.05 ns 
21 1.130e+007 7.000e+007 5.870e+007 -1.100e+006 to 1.185e+008 5.870e+007 3.549 P > 0.05 ns 
24 1.550e+007 3.000e+007 1.450e+007 -4.530e+007 to 7.430e+007 1.450e+007 0.8766 P > 0.05 ns 
27 1.050e+007 2.000e+007 9.500e+006 -5.030e+007 to 6.930e+007 9.500e+006 0.5743 P > 0.05 ns 
30 1.750e+007 2.000e+007 2.500e+006 -5.730e+007 to 6.230e+007 2.500e+006 0.1511 P > 0.05 ns 
34 8.500e+006 6.000e+006 -2.500e+006 -6.230e+007 to 5.730e+007 -2.500e+006 0.1511 P > 0.05 ns 
38 2.600e+007 7.000e+006 -1.900e+007 -7.880e+007 to 4.080e+007 -1.900e+007 1.149 P > 0.05 ns 





PBS vs BiP60-C2         
    Days PBS BiP60-C2 Difference 95% CI of diff. Difference t P value Summary 
0 0.0 0.0 0.0 -5.980e+007 to 5.980e+007 0.0 0.0 P > 0.05 ns 
5 500000 0.0 -500000 -6.030e+007 to 5.930e+007 -500000 0.03023 P > 0.05 ns 
6 4.000e+006 0.0 -4.000e+006 -6.380e+007 to 5.580e+007 -4.000e+006 0.2418 P > 0.05 ns 
8 3.000e+007 1000 -3.000e+007 -8.980e+007 to 2.980e+007 -3.000e+007 1.814 P > 0.05 ns 
10 4.000e+007 6.000e+006 -3.400e+007 -9.380e+007 to 2.580e+007 -3.400e+007 2.055 P > 0.05 ns 
12 9.000e+006 1000000 -8.000e+006 -6.780e+007 to 5.180e+007 -8.000e+006 0.4836 P > 0.05 ns 
15 5.500e+006 1.000e+007 4.500e+006 -5.530e+007 to 6.430e+007 4.500e+006 0.2720 P > 0.05 ns 
18 2.480e+007 0.0 -2.480e+007 -8.460e+007 to 3.500e+007 -2.480e+007 1.499 P > 0.05 ns 
21 1.130e+007 0.0 -1.130e+007 -7.110e+007 to 4.850e+007 -1.130e+007 0.6831 P > 0.05 ns 
24 1.550e+007 0.0 -1.550e+007 -7.530e+007 to 4.430e+007 -1.550e+007 0.9370 P > 0.05 ns 
27 1.050e+007 0.0 -1.050e+007 -7.030e+007 to 4.930e+007 -1.050e+007 0.6348 P > 0.05 ns 
30 1.750e+007 0.0 -1.750e+007 -7.730e+007 to 4.230e+007 -1.750e+007 1.058 P > 0.05 ns 
34 8.500e+006 0.0 -8.500e+006 -6.830e+007 to 5.130e+007 -8.500e+006 0.5139 P > 0.05 ns 
38 2.600e+007 0.0 -2.600e+007 -8.580e+007 to 3.380e+007 -2.600e+007 1.572 P > 0.05 ns 







Tabular results of statistical analysis using Log rank test comparing median survival days post infection between PBS 
group and experimental groups. The statistics were done using GraphPad Prism software.  
 
    
Survival of PBS vs C2Adj:Curve comparison 
  Days     PBS     C2+Adj   
 
    Data Set-A   
0 100 100 
 
Comparison of Survival Curves   
9   80 
 
    
11 80   
 
Log-rank (Mantel-Cox) Test   
36   60 
 
Chi square 0.4132 
42 80 60 
 
df 1 
    
P value 0.5203 
Survival of PBS vs C2Adj:# of subjects at risk 
 
P value summary ns 
  Days     PBS     C2+Adj   
 
Are the survival curves sig different? No 
0 5 5 
 
    
9   5 
 
Gehan-Breslow-Wilcoxon Test   
11 5   
 
Chi square 0.4098 
36   4 
 
df 1 
42 4 3 
 
P value 0.5221 
    
P value summary ns 
Survival of PBS vs C2Adj:Data summary 
 
Are the survival curves sig different? No 
    PBS     C2+Adj   
 
    
Number of rows 10 10 
 
Median survival   
# of blank lines 5 5 
 
PBS Undefined 
# rows with impossible data 0 0 
 
C2+Adj Undefined 
# censored subjects 4 3 
 
    
# deaths/events 1 2 
 
Hazard Ratio   
      
 
Ratio 0.4753 
Median survival Undefined Undefined 
 
95% CI of ratio 0.04921 to 4.591 
      
      Survival of PBS vs C2:Survival proportions 
 




  Days     PBS     C2   
 
    Data Set-A   
0 100 100 
 
Comparison of Survival Curves   
11 80   
 
    
36   80 
 
Log-rank (Mantel-Cox) Test   
37   60 
 
Chi square 0.2645 
42 80 60 
 
df 1 
    
P value 0.6071 
Survival of PBS vs C2:# of subjects at risk 
 
P value summary ns 
  Days     PBS     C2   
 
Are the survival curves sig different? No 
0 5 5 
 
    
11 5   
 
Gehan-Breslow-Wilcoxon Test   
36   5 
 
Chi square 0.1475 
37   4 
 
df 1 
42 4 3 
 
P value 0.7009 
    
P value summary ns 
Survival of PBS vs C2:Data summary 
  
Are the survival curves sig different? No 
    PBS     C2   
 
    
Number of rows 10 10 
 
Median survival   
# of blank lines 5 5 
 
PBS Undefined 
# rows with impossible data 0 0 
 
C2 Undefined 
# censored subjects 4 3 
 
    
# deaths/events 1 2 
 
Hazard Ratio   
      
 
Ratio 0.5515 
Median survival Undefined Undefined 
 





Survival of PBS vs BiP69+C2:Survival proportions 
 
Survival of PBS vs BiP69+C2:Curve comparison 
  Days     PBS     C2   
 
    Data Set-A   
0 100 100 
 
Comparison of Survival Curves   
11 80   
 
    
42 80 100 
 
Log-rank (Mantel-Cox) Test   
    
Chi square 1 
Survival of PBS vs BiP69+C2:# of subjects at risk 
 
df 1 
  Days     PBS     C2   
 
P value 0.3173 
0 5 5 
 
P value summary ns 
11 5   
 
Are the survival curves sig different? No 
42 4 5 
 
    
    
Gehan-Breslow-Wilcoxon Test   
    
Chi square 1 
Survival of PBS vs BiP69+C2:Data summary
 
df 1 
    PBS     C2   
 
P value 0.3173 
Number of rows 10 10 
 
P value summary ns 
# of blank lines 5 5 
 
Are the survival curves sig different? No 
# rows with impossible data 0 0 
 
    
# censored subjects 4 5 
 
Median survival   
# deaths/events 1 0 
 
PBS Undefined 
      
 
C2 Undefined 
Median survival Undefined Undefined 
 
    
    
Hazard Ratio   
    
Ratio 7.389 
    





Survival of PBS vs PBD-C2:Survival proportions 
 
Survival of PBS vs PBD+C2:Curve comparison 
  Days     PBS     C2   
 
    Data Set-A   
0 100 100 
 
Comparison of Survival Curves   
11 80   
 
    
23   80 
 
Log-rank (Mantel-Cox) Test   
42 80 80 
 
Chi square 0.006211 
    
df 1 
Survival of PBS vs PBD+C2:# of subjects at risk 
 
P value 0.9372 
  Days     PBS     C2   
 
P value summary ns 
0 5 5 
 
Are the survival curves sig different? No 
11 5   
 
    
23   5 
 
Gehan-Breslow-Wilcoxon Test   
42 4 4 
 
Chi square 0.02222 
    
df 1 
    
P value 0.8815 
Survival of PBS vs PBD+C2:Data summary 
 
P value summary ns 
    PBS     C2   
 
Are the survival curves sig different? No 
Number of rows 10 10 
 
    
# of blank lines 5 5 
 
Median survival   
# rows with impossible data 0 0 
 
PBS Undefined 
# censored subjects 4 4 
 
C2 Undefined 
# deaths/events 1 1 
 
    
      
 
Hazard Ratio   
Median survival Undefined Undefined 
 
Ratio 1.118 
    
95% CI of ratio 0.06935 to 18.03 
      
      




Survival of PBS vs C-term-C2:Survival proportions 
 
Survival of PBS vs Cterm-C2:Curve comparison 
  Days     PBS     C2   
 
    Data Set-A   
0 100 100 
 
Comparison of Survival Curves   
11 80   
 
    
42 80 100 
 
Log-rank (Mantel-Cox) Test   
    
Chi square 1 
    
df 1 
Survival of PBS vs C-term-C2:# of subjects at risk 
 
P value 0.3173 
  Days     PBS     C2   
 
P value summary ns 
0 5 5 
 
Are the survival curves sig different? No 
11 5   
 
    
42 4 5 
 
Gehan-Breslow-Wilcoxon Test   
    
Chi square 1 
    
df 1 
    
P value 0.3173 
Survival of PBS vs Cterm-C2:Data summary 
 
P value summary ns 
    PBS     C2   
 
Are the survival curves sig different? No 
Number of rows 10 10 
 
    
# of blank lines 5 5 
 
Median survival   
# rows with impossible data 0 0 
 
PBS Undefined 
# censored subjects 4 5 
 
C2 Undefined 
# deaths/events 1 0 
 
    
      
 
Hazard Ratio   
Median survival Undefined Undefined 
 
Ratio 7.389 
    
95% CI of ratio 0.1466 to 372.4 
      
      




Survival of PBS vs BiP69-C2:Survival proportions 
 
Survival of PBS vs BiP69-C2:Curve comparison 
  Days     PBS     BiP69-C2   
 
    Data Set-A   
0 100 100 
 
Comparison of Survival Curves   
11 80 80 
 
    
17   60 
 
Log-rank (Mantel-Cox) Test   
42 80 60 
 
Chi square 0.36 
    
df 1 
    
P value 0.5485 
Survival of PBS vs BiP69-C2:# of subjects at risk 
 
P value summary ns 
  Days     PBS     BiP69-C2   
 
Are the survival curves sig different? No 
0 5 5 
 
    
11 5 5 
 
Gehan-Breslow-Wilcoxon Test   
17   4 
 
Chi square 0.2647 
42 4 3 
 
df 1 
    
P value 0.6069 
    
P value summary ns 
Survival of PBS vs BiP69-C2:Data summary 
 
Are the survival curves sig different? No 
    PBS     BiP69-C2   
 
    
Number of rows 10 10 
 
Median survival   
# of blank lines 5 5 
 
PBS Undefined 
# rows with impossible data 0 0 
 
BiP69-C2 Undefined 
# censored subjects 4 3 
 
    
# deaths/events 1 2 
 
Hazard Ratio   
      
 
Ratio 0.4868 
Median survival Undefined Undefined 
 
95% CI of ratio 0.04633 to 5.114 




Survival of PBS vs BiP60-C2:Survival proportions 
 
Survival of PBS vs BiP60C2:Curve comparison 
  Days     PBS     BiP60-C2   
 
    Data Set-A   
0 100 100 
 
Comparison of Survival Curves   
11 80 80 
 
    
17   60 
 
Log-rank (Mantel-Cox) Test   
18   60 
 
Chi square 0.36 
42 80   
 
df 1 
    
P value 0.5485 
Survival of PBS vs BiP60-C2:# of subjects at risk 
 
P value summary ns 
  Days     PBS     BiP60-C2   
 
Are the survival curves sig different? No 
0 5 5 
 
    
11 5 5 
 
Gehan-Breslow-Wilcoxon Test   
17   4 
 
Chi square 0.2647 
18   2 
 
df 1 
42 4   
 
P value 0.6069 
    
P value summary ns 
Survival of PBS vs BiP60C2:Data summary 
 
Are the survival curves sig different? No 
    PBS     BiP60-C2   
 
    
Number of rows 10 10 
 
Median survival   
# of blank lines 5 5 
 
PBS Undefined 
# rows with impossible data 0 0 
 
BiP60-C2 Undefined 
# censored subjects 4 3 
 
    
# deaths/events 1 2 
 
Hazard Ratio   
      
 
Ratio 0.4868 
Median survival Undefined Undefined 
 
95% CI of ratio 0.04633 to 5.114 
 
